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This PhD thesis reports on (1) factors and processes influencing  
(non-)adherence and (non-)persistence to oral anticancer drugs (OACD), (2) 
healthcare professionals’ perceptions about managing OACD adherence and 
shared decision making (SDM) and beliefs towards OACD, and (3) usual care in 
supporting adherence to OACD. The introductory chapter provides a 
background on (non-)adherence and (non-)persistence in cancer patients 
treated with OACD. An overview of the conceptual approaches to define 
patients’ medication taking behavior, methods used to assess medication 
adherence and persistence, prevalence and consequences of non-adherence 
and non-persistence to OACD, research on factors influencing (non-)adherence 
and (non-)persistence in patients taking OACD, current knowledge about 
healthcare professionals’ related factors influencing OACD adherence and usual 
care in supporting adherence to OACD, and OACD adherence enhancing 
interventions is given. Finally, the outline of this PhD thesis is presented. 
 
ORAL ANTICANCER DRUGS 
The use and number of OACD have increased steadily within the last decade 
(Banna et al., 2010). Almost half of the targeted anticancer drugs developed 
since 2000 are exclusively administered orally (Ozols et al., 2006; Gralow et al., 
2007; Winer et al., 2008). Twenty-five percent of the anticancer drugs can be 
taken orally (Banna et al., 2010). The shift from intravenous to oral delivery will 
most likely continue to evolve. 
Currently, more than 30 OACD are used for different types of cancer. Most of 
them are primarily cytostatic in nature and most effective over long periods of 
time (Foulon et al., 2011). Three major categories of OACD addressed in this 
PhD thesis are Tyrosine Kinase Inhibitors (TKIs), Selective Estrogen Receptor 
Modulators (SERMs), and Aromatase Inhibitors (AIs). These categories of 
OACD were selected because until now, little was known about factors 
influencing (non-)adherence and (non-)persistence and/or no clear 
understanding of the complex patterns and dynamics of (non-)adherence and 
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(non-)persistence existed in patients taking those OACD. Table 1 provides an 
overview of the substance and brand names of most of the three categories of 
OACD and the indications they are used for. 
Most patients prefer OACD over intravenous anticancer therapy (Liu et al., 1997; 
Paley et al., 2005; Fallowfield et al., 2006). Reasons are: the convenience of a 
home-based therapy, the avoidance of an insertion of a central venous catheter, 
less frequent hospital visits, the feeling of a greater sense of ‘control’ over their 
treatment, and previous negative experiences with intravenous therapy (Liu et 
al., 1997; Paley et al., 2005; Fallowfield et al., 2006). However, the preference 
for OACD over intravenous anticancer therapy is conditioned by efficacy and 
toxicity of the treatment (Liu et al., 1997). Only when OACD is no less effective 
than intravenous anticancer therapy, and toxicity is not worse than expected 
from intravenous anticancer therapy, patients prefer OACD (Liu et al., 1997; 
Fallowfield et al., 2006; Pfeiffer et al., 2006). The preference for OACD can also 
change over time as patients experience more side effects from OACD than 
expected (Pfeiffer et al., 2006). 
Treatment with OACD also poses important challenges for both patients and 
healthcare professionals. Patients on OACD have to manage their medication 
more autonomously than intravenous anticancer therapy, time and dosing 
schedules are often complex, and OACD have to be taken over a long period of 
time. Many patients believe that OACD are less toxic than intravenous 
anticancer therapy (Moody et al., 2012). However, patients treated with OACD 
may also be confronted with severe side effects because chemotherapy 
medication (both oral and intravenous) often has a narrow therapeutic index (i.e. 
there is little difference between toxic and therapeutic doses), which increases 
the risk for harmful side effects (Griffin, 2003; Bartel, 2007; Weingart et al., 
2008).  
Healthcare professionals are challenged with optimal dose finding, drug 
interactions, specific education of patients and family, and - above all - the 
management of toxicity and adherence issues. 
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Table 1 Tyrosine Kinase Inhibitors, Selective Estrogen Receptor Modulators, and  
Aromatase Inhibitors and indications for use  
Drug classification Substance name Brand name Indication 
Tyrosine Kinase 
Inhibitors (TKIs) 
dasatinib Sprycel® (Bristol-
Myers-Squibb) 
Chronic Myelogenous Leukaemia 
(CML) 
 erlotinib Tarceva® (Roche) Non-small cell lung cancer, 
pancreatic cancer 
 gefitinib Iressa® (AstraZeneca) Non-small cell lung cancer 
 imatinib Glivec® (Novartis 
Pharma) 
Chronic Myelogenous Leukaemia 
(CML), Gastrointestinal stromal tumor 
(GIST) 
 lapatinib Tyverb® 
(GlaxoSmithKline) 
Breast cancer 
 nilotinib Tasigna® (Novartis 
Pharma) 
Chronic Myelogenous Leukaemia 
(CML) 
 pazopanib Votrient® 
(GlaxoSmithKline) 
Renal Cell Cancer (RCC) 
 sorafenib Nexavar® (Bayer) Renal Cell Cancer (RCC), 
Hepatocellular carcinoma (HCC) 
 sunitinib Sutent® (Pfizer) Gastrointestinal stromal tumor 
(GIST), Renal cell cancer (RCC) 
Selective Estrogen 
Receptor Modulators 
(SERMs) 
tamoxifen Nolvadex® 
(AstraZeneca, 
Impexeco, PI-Pharma) 
Breast cancer 
  Tamizam® (Mithra)  
  Tamoplex® (Teva)  
  Tamoxifen-Mylan 
(Mylan) 
 
  Tamoxifen EG® 
(Eurogenerics) 
 
  Tamoxifen Sandoz® 
(Sandoz) 
 
 fulvestrant Faslodex® 
(AstraZeneca) 
Breast cancer 
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TERMINOLOGY AND MEASUREMENT 
Different conceptual approaches have been described to define patients’ 
medication taking behavior. The terminology reflects the changing views on 
medication taking behavior and the changing relationships between patients and 
healthcare professionals. The terms ‘patient compliance’, ‘medication 
Drug classification Substance name Brand name Indication 
Aromatase Inhibitors 
(AIs) 
anastrozol Anastratom® (Mithra) Breast cancer 
  Anastrozole EG® 
(Eurogenerics) 
 
  Anastrozole Mylan® 
(Mylan) 
 
  Anastrozole Teva® 
(Teva) 
 
  Anastrozol Sandoz® 
(Sandoz) 
 
  Arimidex® 
(AstraZeneca) 
 
 exemestan Aromasin® (Pfizer) Breast cancer 
  Exemarom® (Mithra)  
  Exemestane Mylan® 
(Mylan) 
 
  Exemestane Teva® 
(Teva) 
 
  Exemestan Sandoz® 
(Sandoz) 
 
 letrozol Femara® (Novartis 
Pharma) 
Breast cancer 
  Femara® (PI-Pharma)  
  Letrozarom® (Mithra)  
  Letrozole Mylan® 
(Mylan) 
 
    Letrozole Teva® (Teva)   
Based on: Foulon et al.  (2011), BCFI (2013) 
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adherence’, ‘concordance’, ‘persistence’, and ‘self-management’ will be 
discussed below. 
Haynes and colleagues (1979) defined ‘patient compliance’ as “the extent to 
which the behavior of a patient – with regard to taking medication, following a 
diet and/or the execution of behavioral changes in lifestyle – is consistent with 
the recommendations of a specialist”. This definition shows a clear distinction of 
roles in which the healthcare professional imposes the therapy and in which the 
patient follows the imposed therapy. Within this definition, the role of the 
healthcare professional is a paternalistic one rather than a collaborative one. 
In 2003, the World Health Organization (WHO) introduced the term ‘adherence’ 
as “the extent to which a person’s behavior – taking medication, following a diet, 
and/or executing lifestyle changes, corresponds with agreed recommendations 
from a healthcare provider” (WHO, 2003). To date, the term ‘medication 
adherence’ is more frequently used than ‘patient compliance’ because this term 
includes more diverse reasons for patients not following treatment instructions 
partially or fully (Ngoh, 2009). Other than ‘patient compliance’, the term 
‘medication adherence’ includes active, voluntary, and collaborative patient 
involvement (Delamater, 2006). Medication non-adherence is generally believed 
to have a less judgemental connotation than ‘patient non-compliance’ (Banna et 
al., 2010; Foulon et al., 2011) and is more seen as a failure of the health system 
that has not recognized the patients’ needs (EBMT, 2011).  
To date, multiple definitions for ‘medication adherence’ exist (Cramer et al., 
2008; Ruddy et al., 2009), but there is still no universally accepted definition 
(Gebbia et al., 2011). A patient is considered to be fully adherent (100%) when 
no doses are missed, no more doses are taken than prescribed, and no doses 
are taken at the wrong time or in the wrong quantity (Cramer et al., 2008; Ruddy 
et al., 2009; Staddon, 2011). Adherence is mostly measured over a period of 
time and expressed as a percentage (Cramer et al., 2008). To date, different 
cut-off rates are used to define medication non-adherence: being ≤80%, ≤90%, 
≤100%, or ≥110% adherent over a period of time (Lebovits et al., 1990; 
Partridge et al., 2003; Kirk and Hudis, 2008; Eliasson et al., 2011; Gebbia et al., 
Chapter 1 
20 
2011). The cut-off rate of ≤80% is frequently cited in the literature as acceptable 
or achievable (Sikka et al., 2005; Hess et al., 2006; Simpson et al., 2006). 
However, until now, little is known about how much adherence to OACD is 
necessary for optimal treatment effectiveness. Future research is needed to 
explore more clinically significant and meaningful cut-off rates for the different 
types of OACD and the different methods to assess non-adherence. 
The term ‘concordance’ was introduced in 1995 by the Royal Pharmaceutical 
Society of Great Britain. Concordance is about “an agreement reached after 
negotiation between a patient in determining whether, when and how medicines 
are to be taken” (Horne, 2006). The term ‘concordance’ highlights more the 
relationship between healthcare professionals and patients in which both are 
equal (Horne, 2006; Bissonnette, 2008). 
Bailey and colleagues (2013) introduced a new conceptual model in order to 
rethink medication adherence: ‘medication self-management’. The conceptual 
model deconstructs the tasks associated with taking prescription drugs; such as 
knowledge, skills, and behaviors necessary to take medication correctly. No 
single clear definition of ‘self-management’ exists. Barlow and colleagues (2002) 
define self-management in chronic conditions as “the individual’s ability to 
manage the symptoms, treatment, physical and psychosocial consequences and 
life style changes inherent in living with a chronic condition”. Grypdonck (1999) 
describes self-management in a broad way with attention to the empowerment 
of patients and the existential dimension of living with a disease. Grypdonck 
(1999) defines self-management as the efforts patients make in order to find the 
best possible compromise between the demands of the disease and the 
demands of life. From the patient’s perspective, self-management is adequate or 
successful when it leads to goals improving quality of life (Grypdonck in van den 
Brink et al., 2013). Consequently, choices patients make could be different from 
those of healthcare professionals.  
In the conceptual model introduced by Bailey and colleagues (2013), a series of 
steps are identified which a patient has to follow to take medication in a safe and 
effective way within an ambulatory care setting (see figure 1). The conceptual 
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model particularly attends to the health literacy of patients, or “the degree to 
which individuals have the capacity to obtain, process, and understand basic 
health information and services needed to make appropriate health decisions” 
(Institute of Medicine, 2004; Kutner et al., 2006). This perspective emphasizes 
the role of health systems and the way in which information is provided to 
patients (Parker and Ratzan, 2010). 
 
 
Figure 1. Model of medication self-management (Bailey et al., 2013) 
The term ‘medication persistence’ describes the duration of time from treatment 
initiation to discontinuation (Cramer et al., 2008). Medication persistence is 
considered as being optimal when medication is taken as long as prescribed by 
the treating physician. The terms ‘non-persistence’ and ‘early discontinuation’ 
are used interchangeably in literature. Medication persistence may be reported 
as a continuous variable (i.e. number of days therapy), or as a dichotomous 
variable (i.e. persistent or non-persistent at a predefined period of time) (Cramer 
et al., 2008; Foulon et al., 2011). To define non-persistence as a dichotomous 
variable, several different cut-offs in number of days without subsequent refill of 
pills are used: ≥30, ≥45, ≥60, and ≥180 days (Barron et al., 2007; Darkow et al., 
2007; Owusu et al., 2008; Hershman et al., 2010a; Neugut et al., 2011; 
Nekhlyudov et al., 2011; Streeter et al., 2011). 
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In sum, an evolution over time can be noticed in conceptualizing patients’ 
medication taking behavior. The term ‘compliance’ was found to be too 
paternalistic: patients were expected to take their medication as prescribed by 
healthcare professionals without participation. To highlight the importance of 
collaboration between healthcare professionals and patients in decision making 
processes, the term ‘compliance’ was replaced by the term ‘adherence’. The 
term ‘self-management’, which is a further development in thinking about 
handling prescribed regimens and medication, emphasizes the daily activities a 
patient has to deal with in order to realize the therapeutic regimen. This way, 
thinking about medication taking behavior has changed from a paternalistic to an 
empowering approach in which patients’ quality of life plays an important part.  
 
METHODS USED TO ASSESS MEDICATION ADHERENCE AND PERSISTENCE 
Different methods are used to assess medication adherence and persistence. 
No gold standard exists as each method has advantages and limitations 
(Wagner et al., 2001). The available methods can be divided into direct and 
indirect methods of measurement (Osterberg and Blaschke, 2005).  
Direct methods to assess medication adherence include direct observation, 
measurement of the level of medicine or metabolite in the blood, and 
measurement of the biologic blood marker (Foulon et al., 2011). Despite the 
accuracy of these methods, they are mostly not appropriate to use in routine 
practice. Direct observation is not feasible to use in an ambulatory setting, and 
measurement of the level of the medicine or biological marker in the blood is 
often expensive. Furthermore, for most OACD, measurements of the level of 
medicine or metabolite in blood is not possible because available markers are 
not sensitive and reliable enough or not fully validated to assess adherence 
(Foulon et al., 2011). 
Indirect methods to assess medication adherence include pill counts, self-report, 
electronic medication monitors such as the Medication Event Monitoring System 
(MEMS©, Aardex), and patient diaries. Pill counts, prescription refills, and self-
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report are the most commonly used methods (Ho et al., 2009). Pill counts are 
easy to perform, however, data can easily be altered by the patient (e.g., pill 
dumping). Prescription refill rates based on retrospective databases are often 
used in studies to measure medication adherence (Partridge et al., 2003; Barron 
et al., 2007; Darkow et al., 2007; Owusu et al., 2008; Kimmick et al., 2009; 
Nekhlyudov et al., 2011; Neugut et al., 2011; Sedjo and Devine, 2011; Streeter 
et al., 2011). By using refill data, a Hawthorne effect could be avoided because 
patients are generally not aware that their refill rates are reviewed (Ruddy et al., 
2009). Furthermore, by using refill data, adherence of a large population over a 
long period of time could be quantified (Ruddy et al., 2009). However, a 
prescription refill is not equivalent to ingestion of medication, and refill data do 
not provide information regarding the timing of doses (Osterberg and Blaschke, 
2005; Ruddy et al., 2009). Patient self-report is simple, inexpensive, and the 
more useful method for the clinical setting (Osterberg and Blaschke, 2005). 
However, measuring adherence by self-report is subject to response bias, with 
patients often over-reporting adherence rates because of e.g. the desire to 
please healthcare professionals (Jasti et al., 2006). Numerous self-report 
adherence scales are available. In a systematic review conducted by Nguyen 
and colleagues (2014), 43 adherence scales were identified. These scales 
measure both medication-taking behavior, and/or identify barriers and beliefs 
associated with adherence (Nguyen et al., 2014). In selecting the ‘right’ self-
report adherence scale, careful consideration is needed of what needs to be 
measured, and how and in whom the scale has been validated (Nguyen et al., 
2014). The Medication adherence report scale (MARS-5) (Horne et al., 2001), a 
5-item scale to assess various non-adherent behaviors, and the Morisky and 
Green test (Morisky et al., 1986), a 4-item test to evaluate attitudes regarding 
treatment, are two examples of scales used to assess adherence in patients 
taking OACD (Grunfeld et al., 2005; Marques and Pierin, 2008). A combination 
of MEMS and self-report questionnaires is found to be the most accurate in 
measuring medication adherence using indirect methods (Shi et al., 2010). 
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PREVALENCE AND CONSEQUENCES OF NON-ADHERENCE AND NON-PERSISTENCE TO 
ORAL ANTICANCER DRUGS 
As this PhD thesis mainly focuses on (non-)adherence and (non-)persistence in 
patients following oral TKI therapy or AHT (SERMs or AIs), only these will be 
discussed below.  
Oral tyrosine kinase inhibitors 
Studies on the prevalence of non-adherence and non-persistence with oral TKIs 
mainly focus on chronic myeloid leukemia (CML) patients. Adherence among 
CML patients taking oral TKIs vary between 64 and 96.7% (Feng et al., 2006; 
Tsang et al., 2006; Darkow et al., 2007; Doti et al., 2007; Halpern et al., 2007; 
Doti et al., 2008; Noens et al., 2009; StCharles et al., 2009; Marin et al., 2010; 
Wu et al., 2010). In the study by Noens and colleagues (2009), about one-third 
of the CML patients treated with imatinib were classified as non-adherent as 
assessed by a structured patient interview. Adherence assessed with pill counts 
over a 99 days period revealed an adherence rate of 90.9%. In the study by 
Noens and colleagues (2009), only 14.2% of the patients with CML were 100% 
adherent. In the study of Marin and colleagues (2010), 14% of the total sample 
of 87 patients were considered to be non-adherent when using MEMS and a cut-
off rate of ≤ 80%. Twenty-three patients (26.4%) were ≤ 90% adherent (Marin et 
al., 2010). Khandelwal and colleagues (2012) studied adherence in patients with 
solid tumors (breast, colon) following therapy with oral TKIs sunitinib, sorafenib 
and erlotinib. They found that 99% were adherent at 1 month, 64% at 3 months, 
and 43% at 6 months. Non-persistence in this study was 48.8% at 3 months and 
76.2% at 6 months. Gebbia and colleagues (2013) studied medication 
adherence in patients with non-small-cell lung cancer taking the oral TKI 
erlotinib. They found that 7% of the patients were <90% adherent when using a 
self-reported questionnaire and 17% when using pill count.  
The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcome) 
study evaluated the impact on outcomes of non-adherence in patients with CML 
(Noens et al., 2009). The study showed that patients taking 74.0-76.8% of the 
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prescribed dose had a less good response than patients taking 89.9-92.7% of 
the prescribed dose (Noens et al., 2009). In this study, suboptimal response was 
defined at three months as incomplete hematologic response, at six months as 
less than partial cytogenetic response, and at 18 months as less than major 
molecular response and, in case of loss of major molecular response, other 
limitations or other chromosomal abnormalities.1 Optimal response has been 
associated with overall and progression-free survival in patients with CML 
(Druker et al., 2006; Ganesan et al., 2011). 
Other studies confirmed that adherence to CML oral anticancer therapies is 
linked to the achievement of a complete cytogenetic response and a major 
molecular response (Bazeos et al., 2009; Marin et al., 2010; Ganesan et al., 
2011; Ibrahim et al., 2011). Ganesan and colleagues (2011) showed that the 
estimated 5-year event free survival2 in non-adherent patients with CML taking 
imatinib was 59.8% compared with 76.7% in those with no interruptions. In the 
study of Ibrahim and colleagues (2011) in CML patients on imatinib, 23 patients 
with an adherence rate ≤85% had a higher probability of losing their complete 
cytogenetic response at 2 years (26.8% vs. 1.5%) and a lower probability of 
remaining on imatinib (64.5% vs. 90.6%) compared with the 64 patients with an 
adherence rate >85%. 
  
                                                          
1 Patients with CML respond to treatment in different ways. These are general guidelines for CML 
drug therapy. Baseline results (test levels at the time of diagnosis) can influence response. The 
doctor generally work with the following time frame as a guideline to achieve the desired response: 
After 3-6 months of therapy: a complete hematologic response and some cytogenetic improvement, 
after 6-12 months of therapy: a partial cytogenetic response of two-thirds reduction in the number of 
Ph chromosomes in the marrow, after 12-18 months of therapy: a complete cytogenetic response 
and partial molecular response. 
2 Event free survival was calculated from the date of starting of Imatinib to the occurrence of any one 
of the following: non-achievement of complete hematological response (CHR) at 6 months, non-
achievement of complete cytogenetic response (CCR) at 2 years, loss of cytogenetic response 
and/or hematological response, progression to accelerated phase/ blast crisis at any point, or death 
due to any reason. 
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Antihormonal therapy  
Most studies on prevalence and consequences of non-adherence and non-
persistence to OACD focus on antihormonal therapy (AHT) in breast cancer 
(Foulon et al., 2011). Non-adherence and non-persistence rates vary among 
studies: between 11% and 51% (Güth et al., 2012), between 15% and 50% 
(Doggrell, 2011) or between 40% and 60% (Fontein et al., 2012). These varying 
results may be due to different methods used to measure adherence or different 
definitions used to define (non-)adherence and (non-)persistence (Güth et al., 
2012). Non-adherence and non-persistence rates are similar among patients 
treated with SERMs (tamoxifen), AIs, or with a combination of both (Hershman 
et al., 2010a; Fontein et al., 2012). In a study by Grunfeld and colleagues 
(2005), 12% of self-reported non-adherence was found in patients with early 
stage breast cancer taking tamoxifen. In the study by Waterhouse and 
colleagues (1993), a combination of methods was used to assess non-
adherence in patients taking tamoxifen. A high self-reported adherence was 
found (97.9%), while adherence was 92.1% assessed by pill counts, and 85.4% 
by MEMS. In the study conducted by Dezentjé and colleagues (2010), the mean 
adherence in the first year was 93%, and the mean adherence at the third year 
was 84%. Sedjo and Devine (2011) studied adherence in patients with breast 
cancer treated with AIs. Over a one year period, 23% of the patients were non-
adherent (<80% medication possession ratio – number of days supply of 
medication divided by the number of days patient should take the medication).  
Non-persistence rates vary between 31% and 34.4% for the five-year treatment 
(Lash et al., 2006; Güth et al., 2008; Hershman et al., 2010b). In a large study by 
Barron and colleagues (2007), 21.1% discontinued within the first year of 
treatment with tamoxifen, 35.2% discontinued within the 3.5 years of treatment. 
In the study by Henry et al. (2012), 32.6% of the women discontinued the 
treatment with AIs within the first two years. The median time to treatment 
discontinuation was 6.1 months (range 0.1-21.2). In the study by Fontein et al. 
(2012), overall early discontinuation in the treatment with AIs was 18.4%, of 
which 49.7% discontinued within the first six months of treatment. Non-
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adherence and non-persistence increases over time treated with AHT (Barron et 
al., 2007; Fontein et al., 2012; Huiart et al., 2012). The study by van Herk-Sukel 
and colleagues (2010) showed that the percentage of continuous users of 
tamoxifen at 1, 2, 3, 4, and 5 years treatment was 83, 70, 55, 50, and 40%, 
respectively. 
Both non-adherence and non-persistence are associated with an increased risk 
of recurrence and mortality (Hershman et al., 2010b). In the study by Hershman 
and colleagues (2010b), the estimated survival at 10 years was 80.7% and 
73.6% for women who continued and discontinued AHT, respectively (p<0.001). 
In participants who continued AHT, survival at 10 years was 81.7% in women 
who were adherent (≥80% medication possession ratio) and 77.8% in women 
who were non-adherent (p<0.001) (Hershman et al., 2010b). After adjusting for 
clinical and demographic variables, both non-adherence and early 
discontinuation among those who continued AHT, were independent mortality 
predictors (Hershman et al., 2010b). 
 
FACTORS INFLUENCING (NON-)ADHERENCE AND (NON-)PERSISTENCE TO ORAL 
ANTICANCER DRUGS 
Factors influencing (non-)adherence and (non-)persistence are complex and 
interrelated. A frequently used framework to describe the multidimensional 
phenomenon of adherence, is the WHO framework (WHO, 2003). This 
framework (figure 2) consists of five dimensions affecting medication adherence: 
social and economic factors (e.g. medication cost), healthcare team and system-
related factors (e.g. provider-patient relationship), condition-related factors (e.g. 
severity of symptoms), therapy-related factors (e.g. complexity of medication 
regimen), and patient-related factors (e.g. fear of possible adverse events).  
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Figure 2: Five dimensions affecting adherence (WHO, 2003) 
In patients taking OACD, several factors are found to influence (non-)adherence 
and (non-)persistence (Ruddy et al., 2009). In a review, Ruddy and colleagues 
(2009) summarized three interrelated main categories of factors influencing 
(non-)adherence and (non-)persistence to OACD: personal factors (e.g. 
emotional state, health beliefs, and social supports), treatment factors (e.g. side 
effects, and costs), and factors interacting with the system (e.g. satisfaction with 
care, and relationship with providers). 
Most studies determining factors influencing (non-)adherence and  
(non-)persistence to OACD are conducted in patients with breast cancer. The 
vast majority of research focusing on factors influencing (non-)adherence and 
(non-)persistence to OACD is quantitative. Less research is qualitative or mixed 
methods. Until now, no qualitative research described processes and factors 
influencing (non-)adherence and (non-)persistence in patients taking different 
types of oral TKIs. Only one mixed method study was conducted in patients with 
CML taking the OACD imatinib (Eliasson et al., 2011).  
In breast cancer patients taking OACD, only two qualitative studies were 
conducted focusing on (non-)adherence and (non-)persistence (Pellegrini et al., 
2010; Regnier Denois et al., 2011). In the study by Pellegrini and colleagues 
(2010), the focus was narrowed to the exploration of the relation between 
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adherence and perceptions of the treatment and experiences of side effects in 
breast cancer patients taking the SERM tamoxifen. In the qualitative study by 
Regnier Denois and colleagues (2011) the focus was on behavior and 
representations of breast cancer patients and oncologists about adherence with 
OACD. However, Regnier Denois and colleagues (2011) only focused on 
patients taking capecitabine, an antimetabolite. 
Qualitative research could give us insight into the complexity and 
interrelatedness of factors influencing (non-)adherence and (non-)persistence in 
patients taking OACD. Qualitative research is more appropriate for studying 
experiences in the context of an experiential process (Morse and Field, 1996). 
Furthermore, qualitative research could give us insight into the processes 
associated with medication (non-)adherence and (non-)persistence to OACD 
and the meaning of the OACD therapy from the patients’ perspective. This is of 
particular importance to inform patient-tailored interventions to support patients 
treated with OACD. Qualitative research to different types of OACD is important 
because OACD groups have different characteristics which influence the 
experience of the therapy in patients. Oral TKIs, for example, are mainly used in 
a metastatic setting, and often have a narrow therapeutic index which increases 
the risk for severe side effects. Qualitative research could also show us how to 
understand results of quantitative research (Black, 1994), by giving insight into 
the way several factors found to be associated with (non-)adherence and  
(non-)persistence contribute to (non-)adherence and (non-)persistence. 
 
HEALTHCARE PROFESSIONALS’ RELATED FACTORS INFLUENCING ORAL ANTICANCER 
DRUGS ADHERENCE AND USUAL CARE IN SUPPORTING ADHERENCE TO ORAL 
ANTICANCER DRUGS 
Healthcare professional-related factors influencing non-adherence in patients 
with breast cancer taking OACD are e.g. giving too much or too less support 
than needed by patients (Kahn et al., 2007) and physicians’ poor explanation of 
treatment effects (Kahn et al., 2007). Less participation in decision making than 
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wanted by patients about OACD therapy was found to be associated with lower 
adherence in patients with breast cancer (Kahn et al., 2007). The study of Kahn 
et al. (2007) showed that women with breast cancer who were satisfied about 
the role they received in the OACD decision-making process, were more likely to 
continue their therapy (81%) compared to patients receiving a more (73%) or 
less expanded role (59%) than wanted in the OACD decision-making process. 
Healthcare professional-related factors influencing adherence in patients with 
CML taking OACD are e.g. feedback from physicians that seems to reinforce the 
belief that ‘occasional’ non-adherence does not matter (Eliasson et al., 2011), 
and the degree of faith in the physician (Eliasson et al., 2011). In a study by 
Noens and colleagues (2009), physicians were asked to rate the various WHO 
categories of adherence influencing factors as contributing or not to non-
adherence to imatinib in patients with CML. Therapy-related factors were 
identified by most of the physicians as determinants of non-adherence (96.1%), 
followed by patient demographic, social and economic factors (92.1%), the 
patient-physician relationship (92.1%), disease-related factors (84.3%), 
physician-related factors (70.6%), and other patient-related variables (70.5%). 
Within the patient-physician relationship, the communication and interpersonal 
style of the physician as well as physicians’ continuity of care were identified as 
contributing factors by most of the respondents (both 96.1%), followed by the 
time physicians spend with patients (91.2%), physicians’ empathy and 
assistance (89.2%), and patient involvement in planning (88.3%). However, 
most studies researching healthcare professional-related factors are studied 
from the patient’s perspective (Osterberg and Blaschke, 2005). A recently 
published paper showed that 60% of the physicians did not react to side effects 
patients experienced (Wuensch et al., 2015). Patients who reported having 
received detailed answers to their questions were significantly more adherent 
(Wuensch et al., 2015). Little is known about healthcare professionals’ 
perceptions on OACD adherence and usual care in supporting adherence to 
OACD. Exploring healthcare professionals’ beliefs about OACD and perceptions 
of OACD adherence, and exploring the current practice of adherence supportive 
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care is important. Both can offer a point of departure for outlining the aspects of 
an intervention to support patients following OACD therapy.   
ORAL ANTICANCER DRUGS ADHERENCE ENHANCING INTERVENTIONS 
Mathes et al. (2014) recently conducted a systematic review on adherence 
enhancing interventions for OACD. In this systematic review, six studies were 
included (of which one was an RCT). The methodological quality of the studies 
was evaluated as moderate to low. Only one study revealed significant results in 
favor of an adherence intervention (Tschida et al., 2012). In the latter study, a 
pharmacy program (biweekly to monthly the first three months and then every 
three months thereafter) was used. The pharmacy program consisted of patient 
education about medication and comorbidities, a proactive adherence program 
including refill reminders, and adherence screening. In case of non-adherence, 
an intervention with the patient and physician was conducted including an 
oncology clinical management program of telephonic clinical counseling and, the 
availability of a specialty pharmacist available 24h/7 days a week for questions. 
In the review of Mathes et al. (2014), two studies showed a tendency in favor of 
the intervention groups (Simons et al., 2011; Khandelwal et al., 2012). The study 
of Simons et al. (2011) described a pharmaceutical care intervention including 
initial patient consultation (median 75 min) and follow-up consultation (at least 
once during each OACD cycle). In the initial patient consultation, the 
characteristics of the OACD were explained in detail, education about the 
importance of adherence was given, a written dosing schedule and a leaflet with 
information about the prevention and management of adverse effects were 
provided. The study of Khandelwal et al. (2012) used an oral chemotherapy 
follow-up management program by an oncology nurse or pharmacist. The 
program consisted of education, monitoring, and counseling by telephone (day 
10 and 20 of the first month of the therapy and monthly thereafter). Furthermore, 
therapy and side effects were assessed between follow-up visits. When side 
effects were graded moderate or severe, the prescribing physician was 
contacted to revise the oral chemotherapy regimen. The results of the 
systematic review of Mathes et al. (2014) revealed that interventions to improve 
Chapter 1 
32 
adherence to oral anticancer drugs have only shown limited effects. This finding 
was confirmed in a systematic review on interventions for adherence with OACD 
in hematological malignancies (Kavookjian and Wittayanukorn, 2014). Of the six 
studies included in this systematic review, four reported statistically significant 
improvements in adherence outcomes compared to the control group, only two 
resulted in improvement in treatment outcomes. The interventions consist of one 
or more of the following components: general patient education (Levine et al., 
1987; Richardson et al., 1990; Doti et al., 2007; Moon et al., 2012), tailored 
intervention (combinations of patient education and targeted behavior change 
intervention) (Levine et al., 1987; Richardson et al., 1990; Doti et al., 2007; 
Moon et al., 2012), and simplification of the dosage/regimen (Doti et al., 2007). 
However, comparing intervention studies is difficult because of the 
heterogeneous nature of the different studies (e.g. different content of the 
adherence enhancing intervention, and differences in adherence definition and 
measurement) (Kavookjian and Wittayanukorn, 2014; Mathes et al., 2014). 
Tailored interventions with education and counseling including patient-centered 
decision-making about treatment choice and adherence support seems to be 
promising in several studies (Kavookjian and Wittayanukorn, 2014; Mathes et 
al., 2014). It could be concluded that further high quality intervention studies are 
needed (Kavookjian and Wittayanukorn, 2014; Mathes et al., 2014). 
 
AIMS AND SCOPE OF THIS THESIS 
The general objectives of this PhD thesis are to explore factors and processes 
influencing (non-)adherence and (non-)persistence in patients taking OACD, 
explore healthcare professionals’ perceptions about managing OACD adherence 
and SDM and beliefs towards OACD, and usual care in supporting adherence to 
OACD. We mainly focused on two major categories of OACD: oral TKIs and 
AHT (both SERMs and aromatase inhibitors). Until now, little was known about 
factors influencing (non-)adherence and (non-) persistence in patients taking 
oral TKIs. Much more research was conducted on factors influencing  
(non-)adherence and (non-)persistence in patients taking AHT. However, in this 
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group, there was still no clear understanding of the complex patterns and 
dynamics of (non-)adherence and (non-) persistence. Qualitative research in 
both patients treated with oral TKIs and AHT was scarce.  
Studies exploring adherence issues have predominantly focused on the patient’s 
perspective (Osterberg and Blaschke, 2005). Only few studies focused on the 
physicians’ perspective (Regnier Denois et al., 2010; Kekäle et al., 2014). No 
studies were conducted including pharmacists, nurses, and physicians. Insight 
into healthcare professionals’ perceptions and beliefs about OACD adherence is 
important because perceptions and beliefs may influence healthcare 
professionals’ behavior and care (Ajzen, 1991; Valente Teixeira et al., 2012). In 
turn this may influence patients’ adherence behavior (Marteau and Johnston, 
1991; Eliasson et al., 2011). Insight into usual care allows to determine areas for 
improvement. 
Van Meijel et al. (2004) constructed a model for the development of evidence-
based complex nursing interventions. The model is similar to the ‘Framework for 
development and evaluation of randomized controlled trials for complex 
interventions to improve health’, as published by the Medical Research Council 
(MRC framework, 2008). The van Meijel model describes four phases: (1) 
problem definition, (2) building blocks needed for intervention design, (3) 
intervention design, and (4) intervention validation. The patient’s perspective 
holds a central position in the model. The building blocks needed for intervention 
design could be derived from this PhD thesis (see figure 1).
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Figure 1: Diagram of developing evidence-based complex  
nursing interventions (Van Meijel et al., 2004) 
 
Information about interventions and their effectiveness is an important part of a 
thorough literature review to inform intervention design (van Meijel et al., 2014). 
In this PhD thesis, we did not evaluate the effectiveness of adherence 
interventions in patients taking OACD because Mathes et al. (2014) recently 
conducted a systematic review on adherence enhancing interventions for OACD 
(see chapter oral anticancer drugs adherence enhancing interventions). 
Chapters 3, 4 & 5 
Chapter 6 
Chapter 2 
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First, a systematic review was conducted to provide an updated overview of 
determinants and associated factors of medication (non-)adherence and  
(non-)persistence in patients taking OACD. In the systematic review, all types of 
OACD were considered. 
Second, a qualitative research on factors influencing (non-)adherence in patients 
taking oral TKIs was conducted to explore processes and factors influencing 
(non-)adherence to oral TKIs, and to get insight into the interrelatedness of 
influencing factors.  
Third, a qualitative research on factors influencing (non-)adherence and  
(non-)persistence in breast cancer patients with adjuvant AHT was conducted to 
explore processes and factors influencing (non-)adherence and  
(non-)persistence to AHT, and to get insight into the interrelatedness of 
influencing factors. 
Fourth, a quantitative study was conducted to get insight into healthcare 
professionals' perceptions about managing OACD adherence, beliefs towards 
OACD, and perceptions towards SDM, which is known to be an adherence 
influencing factor from the patients’ perspective (Kahn et al., 2007). 
Fifth, a quantitative study was conducted to get insight into usual care in 
supporting adherence to OACD in (hemato-)oncology settings in Belgium and 
the Netherlands. 
The results of the studies conducted in the context of this PhD thesis could help 
healthcare professionals to understand why patients taking oral TKI’s or AHT do 
not adhere or persist to their therapy. Insight into the patients’ experiences could 
help to inform the development of patient tailored interventions to support 
patients following oral anticancer therapy. Insight into the attitudes and beliefs of 
healthcare professionals about medication (non-)adherence in patients taking 
OACD could help to develop interventions tailored to healthcare professionals’ 
perceived capacity to support patients taking OACD. Insight into usual care 
could give a point of departure for outlining aspects of an intervention to support 
patients taking OACD.  
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In summary, the outline of this PhD thesis is as follows: 
• Chapter 1: General introduction 
• Chapter 2:  Determinants and associated factors influencing medication 
adherence and persistence to oral anticancer drugs: a 
systematic review 
• Chapter 3: Factors influencing adherence in cancer patients taking oral 
tyrosine kinase inhibitors: a qualitative study 
• Chapter 4: Factors influencing the process of medication (non-)adherence 
and (non-)persistence in breast cancer patients with adjuvant 
antihormonal therapy: a qualitative study 
• Chapter 5: Adherence to oral anticancer agents: healthcare providers’ 
perceptions, beliefs and shared decision making in Belgium and 
the Netherlands 
• Chapter 6:  Adherence to oral anticancer agents: healthcare providers’ 
perceptions and usual care in Belgium and the Netherlands 
• Chapter 7:  General discussion 
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ABSTRACT 
Background and aims 
The use of oral anticancer drugs has increased in modern oncology treatment. 
The move from intravenous treatments towards oral anticancer drugs has 
increased the patients’ own responsibility to take oral anticancer drugs as being 
prescribed. High rates of non-adherence to oral anticancer drugs have been 
reported. A systematic literature review was conducted to gain insight into 
determinants and associated factors of non-adherence and non-persistence in 
patients taking oral anticancer drugs. 
 
Review methods 
PubMed, Cochrane, Web of Science and Cinahl were systematically searched 
for studies focusing on determinants and associated factors of medication non-
adherence and non-persistence to oral anticancer drugs. The methodological 
quality of the included studies was assessed by two independent reviewers. No 
studies were excluded based on the quality assessment.  
 
Results 
Twenty five studies were included and systematically reviewed. The quality of 
the studies was moderate. Associated factors influencing medication non-
adherence and non-persistence to oral anticancer drugs are multifactorial and 
interrelated. Older and younger age, and the influence of therapy related side 
effects were found to be predominant factors. 
 
Conclusion 
Non-adherence and non-persistence to oral anticancer drug therapy are 
complex phenomena. More qualitative research is needed to facilitate the 
development of patient tailored complex interventions by exploring patients’ 
needs and underlying processes influencing medication non-adherence and 
non-persistence to oral anticancer drugs. 
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INTRODUCTION 
The use and the number of different oral anticancer drugs (OACD) have 
increased in modern oncology (Banna et al., 2010). Currently, 25% of the cancer 
chemotherapy in development can be taken orally (Banna et al., 2010). Many of 
the available OACD are primarily cytostatic in nature and most effective when 
given over long-term periods (Foulon et al., 2011). OACD such as imatinib, has 
transformed chronic myeloid leukemia (CML) from a lethal to a chronic disease 
(Eliasson et al., 2011).  The use of OACD improves the quality of life of cancer 
patients by reducing hospital stay and give them a greater sense of control over 
their treatment while guaranteeing the treatment efficacy (Regnier Denois et al., 
2010), however, also poses important challenges such as managing side 
effects, the prolonged treatment period and adherence issues. 
Several studies show that most patients (range 54% to 89%) prefer to be on an 
oral therapy compared to intravenous therapy (Liu et al., 1997; Paley et al., 
2005; Fallowfield et al., 2006; Wojtacki et al., 2006); this mainly because 
medication can be taken at home and no needle has to be placed (Liu et al., 
1997; Fallowfield et al, 2006; Simchowitz et al., 2010). The shift from 
intravenous treatments towards OACD therapy increases patients’ responsibility 
to take their OACD rigorously as being prescribed by their physician (Foulon et 
al., 2011). Because of the association between adherence and treatment 
success, concerns about non-adherence to OACD therapy have become an 
increasingly important issue in oncology (Partridge et al., 2002; Foulon et al., 
2011; Gebbia et al., 2011).  
Until now, multiple definitions of medication (non-)adherence exist (Cramer et 
al., 2008; Ruddy et al., 2009) but there is no universally accepted definition 
(Gebbia et al., 2011). For this review, non-adherence has been operationalized 
based on the definition by Ruddy et al. (2009), who consider a patient to be non-
adherent if “doses are missed, extra doses are taken or doses are taken in the 
wrong quantity or at the wrong time”. This definition was chosen because of its 
concreteness. Non-persistence occurs when patients “do not take their 
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medication as long as prescribed” (Ruddy et al., 2009). The terms non-
persistence and early discontinuation are used interchangeably in the literature. 
A literature review by Foulon et al. (2011) reports on OACD therapy non-
adherence rates between 0% and 84%. The variation is mainly related to (1) 
differences in the type of OACD therapy (e.g. side effects, complexity of 
regimen), (2) differences in the definition of adherence being applied in the 
primary studies, and (3) differences in the assessment of medication adherence. 
OACD therapy non-adherence rate in breast cancer patients was found to be as 
high as 23% over a one year period (Sedjo and Devine, 2011). Treatment 
discontinuity was found in 17% of the patients after two years (Fink et al., 2004); 
and even in 31% after five years (Lash et al., 2006). Marin et al. (2010) reported 
that 26.4% of the CML patients was ≤ 90% adherent with their prescribed OACD 
therapy. Similar results have been found in a Belgian setting (Noens et al., 
2009). One third of the patients with CML appeared to be non-adherent with 
their treatment; only 14.2% was found to be completely adherent (Noens et al., 
2009). 
Non-adherence and non-persistence significantly reduce the efficacy of OACD 
therapies (Foulon et al., 2011). Non-adherent patients with CML, treated with the 
OACD imanitib, were less likely to achieve complete cytogenetic responses 
(CCyR), resulting in a reduced success rate (Marin et al., 2010; Ganesan et al., 
2011; Ibrahim et al., 2011). In the study by Noens et al. (2009), patients taking 
74.0% to 76.8% of the prescribed dose had a less good response than patients 
taking 89.9% to 92.7% of the prescribed dose. In breast cancer patients, lower 
survival rates were found for patients being < 80% adherent to the oral drug 
tamoxifen (McCowan et al., 2008). Non-adherence to OACD therapy was also 
related to higher healthcare costs due to the increased number of doctor visits, 
longer hospital stays and more frequent hospitalizations (Darkow et al., 2007; 
Wu et al., 2010).  
Given the magnitude and consequences of non-adherence in patients on an 
OACD therapy, an exploration of associated factors and underlying processes of 
medication non-adherence is needed. Factors influencing medication non-
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adherence and non-persistence are complex due to the multifactorial and 
interrelated character (WHO, 2003). Understanding the complexity of non-
adherence and non-persistence to OACD is important as it can inform the 
development of an intervention to enhance adherence and persistence with this 
type of medication. A literature review is therefore a crucial step in the 
development of such interventions (Van Meijel et al., 2004). 
Literature reviews on medication non-adherence or non-persistence with OACD 
therapy are often not conducted and/or reported in a rigorous systematic way 
(Ruddy et al., 2009; Moore, 2010; Foulon et al., 2011). To our knowledge, only 
one systematic review including literature up until 2002 on non-adherence and 
non-persistence in patients taking OACD, has been conducted (Partridge et al., 
2002). In the latter review different OACD have been considered. 
The aim of our review is to provide an updated overview of determinants and 
associated factors of medication (non-)adherence and (non-)persistence in 
patients taking different types of OACD. 
 
METHODS 
Search strategy 
Four electronic databases were searched: PubMed, the Cochrane database, 
Web of Science, and the Cumulative Index to Nursing and Allied Health 
Literature (CINAHL). The search strategy consisted of MeSH terms and free text 
words subsequently combined (see table 1).  
All titles and abstracts were screened independently by two reviewers (MV & 
KL). If the abstract did not provide enough information to decide upon 
inclusion/exclusion, the full paper was retrieved for further screening. 
Disagreements about inclusion or exclusion were discussed between the 
reviewers until consensus was reached. The reference lists of the included 
articles were reviewed and additional articles were considered if appropriate. 
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Selection criteria 
Articles were included if they addressed OACD therapy, focused on 
determinants and associated factors of medication adherence/compliance 
and/or medication persistence of patients aged 18 and older, and were 
evaluated as being of strong or moderate methodological quality. Factors 
considered to evaluate methodological quality for quantitative studies were: the 
presence of selection bias, allocation bias, confounders, study design, blinding, 
data collection methods, withdrawals and drop-outs, and the appropriateness of 
the analysis to the research question (Vyncke et al., 2013). For qualitative 
studies, methodological quality was evaluated considering clear statement of the 
aims, the relationship between researcher and participants, ethical issues, 
rigorousness of the data analysis, clear statements of the findings, value of the 
study, appropriate methodology, design, recruitment strategy and data collection 
(Public Health Resource Unit, 2006).  
The primary outcomes of the primary studies had to be (non-)adherence and 
(non-)persistence to OACD therapy to be eligible for inclusion. Only original 
research articles published between 1990 and April 2012 and written in English, 
French, German or Dutch were included.  Study design was not used as a 
selection criterion. Studies conducted in developing countries were excluded 
because of the different context and differences in healthcare delivery systems.  
Quality assessment 
The methodological quality of each study was independently evaluated by two 
reviewers (MV & KL) using (1) the Quality Assessment Tool developed by 
Vyncke et al. (2013) for quantitative studies, and (2) the Critical Appraisal Skills 
Programme (CASP) developed by the Public Health Resource Unit, National 
Health Service, England (2006) for qualitative studies. 
The Quality Assessment Tool of Vyncke et al. (2013) is based on a tool 
developed by the Effective Public Health Practice Project (Thomas et al., 2004) 
and used by Mirza et al. (2007). This tool was chosen because of (1) the 
extensiveness of the assessment of methodological quality and, (2) the usability 
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for quality assessment of different quantitative research designs. The tool 
considers presence of selection bias and confounders, study design, blinding, 
data collection methods, withdrawals and drop-outs, appropriateness of the 
analysis to the research question, and the integrity of the intervention.  The item 
on integrity of the intervention was not applicable for this review. For each item, 
two reviewers (MV & KL) assigned a rating of strong, moderate or weak based 
on the evaluation criteria of the quality assessment tool. Discrepancies in the 
reviewers’ evaluations were discussed until consensus was reached.  
The CASP includes 10 questions to assess (1) rigorousness, (2) credibility and, 
(3) relevance of the qualitative study by answering yes/no for each question. The 
first two questions are general screening questions considering whether the goal 
of the study is clear, and whether a qualitative methodology is appropriate for 
the study. When both questions are positively answered, it is worth proceeding 
to the remaining detailed questions to consider methodological quality (Public 
Health Resource Unit, 2006). 
Data abstraction and synthesis  
Two reviewers (MV and KL) independently extracted the data from each article. 
Findings were summarized using a data extraction sheet (table 2). This sheet 
included the following items: author(s) and publication date, research focus, 
design, the definition of medication non-adherence and non-persistence, 
measurement, participants (n), factors associated with medication non-
adherence or higher adherence, and factors associated with medication non-
persistence or higher persistence. Inconsistencies in data extraction were 
discussed until consensus was reached.  
 
RESULTS 
Selection of the articles 
The literature search resulted in 3351 articles. Duplicates (n=485) were 
excluded. Based on the selection criteria, 85 full texts were retrieved and 
reviewed; resulting in 25 articles for inclusion. No relevant articles were added 
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after reviewing the reference list of the included articles. A flow chart of the 
search strategy is presented in figure 1. 
Methodological quality of the included studies 
Details on the quality assessment of the included studies are presented in table 
3 for studies with a quantitative approach, and in table 4 for studies with a 
qualitative or mixed method approach. In general, the overall methodological 
quality of the quantitative studies was moderate. None of the studies mentioned 
the influence of confounders on the results. For all studies, the method for the 
assessment of medication adherence was clearly indicated. Few studies 
reported on power calculations (n=1) (Noens et al., 2009) and on how they 
handled missing data (n=1) (Lebovits et al., 1990) and drop-outs (n=2) (Güth et 
al., 2008; Kirk and Hudis, 2008). None of the studies with a qualitative design 
adequately described the relationship between researcher and participants. 
However, the methodology, design, and data collection were evaluated as being 
appropriate. Consequently, none of the studies were excluded after considering 
methodological quality. 
Study characteristics 
An overview of the study characteristics, determinants and factors associated 
with medication  (non-)adherence and (non-)persistence to OACD therapy is 
presented in Table 2.  
Different study designs were used: retrospective study designs (n=12), 
prospective study designs (n=6), cross-sectional study designs (n=5), a 
qualitative study design (n=1), and a mixed method design (n=1). Sample size 
ranged from small studies (n=21) to large studies (n=13593). The majority of the 
studies (n=17) were conducted in the United States of America. The remaining 
studies were conducted in Europe (n=7) and Brazil (n=1).  
Eleven studies focused on medication (non-)adherence, nine studies on 
medication (non-)persistence or early discontinuation and five studies on both 
(non-)adherence and (non-)persistence with OACD. Most of the studies (n=20) 
focused on patients with breast cancer and often included a secondary 
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characteristic (age, stage of the disease or a combination of both). The other 
studies focused on (non-)adherence and (non-)persistence in patients with CML 
(n=3), and in patients with different types of cancer (n=2).  
Definition and assessment of medication (non-)adherence and (non-)persistence 
A wide variation was found regarding the criteria for defining medication  
(non-)adherence and (non-)persistence and methods for assessment.   
Criteria used for defining medication non-adherence were taking less (< 80% 
[Partridge et al., 2003; Partridge et al., 2010], < 90% [Lebovits et al., 1990; 
Eliasson et al., 2011], < 100% [Kirk and Hudis, 2008])  or more of the prescribed 
dose (> 110% [Lebovits et al., 1990]), lower scores on the Medication 
Adherence Report Scale (MARS-5) (Grunfeld et al., 2005), having a Medication 
Possession Ratio (MPR) ≤ 80% (Kimmick et al., 2009; Hershman et al., 2010; 
Nekhlyudov et al., 2011; Neugut et al., 2011; Sedjo and Devine, 2011), having  
≤ 3 points on the Morisky and Green Test (Marques and Pierin, 2008), or  having 
≥ 1 positive answer on the Basel Assessment of Adherence Scale (Noens et al., 
2009). The definition of medication non-persistence included different cut-off 
rates in number of days with a discontinued intake of OACD (≥ 30 [Darkow et al., 
2007], ≥ 45 [Neugut et al., 2011], ≥ 60 days [Owusu et al., 2008; Nekhlyudov et 
al., 2011] and ≥ 180 days [Barron et al., 2007; Hershman et al., 2010). 
The methods used to assess medication adherence and persistence in patients 
taking OACD were pharmacy refill data extracted from pharmacy records and 
medical claims (n=11) (Partridge et al., 2003; Barron et al., 2007; Darkow et al., 
2007; Kirk and Hudis, 2008; Ma et al., 2008; Owusu et al., 2008; Kimmick et al., 
2009; Nekhlyudov et al., 2011; Neugut et al., 2011; Sedjo and Devine, 2011; 
Streeter et al., 2011), self report (n=10) (Demissie et al., 2001; Fink et al., 2004; 
Grunfeld et al., 2005; Atkins and Fallowfield et al., 2006;  Lash et al., 2006; Kahn 
et al., 2007; Güth et al., 2008; Kirk and Hudis, 2008; Marques and Pierin, 2008; 
Regnier Denois et al., 2010) or a combination of both (n=2) (Lebovits et al., 
1990; Noens et al., 2009). Only two studies used a Medication Event Monitoring 
System (MEMS) (Eliasson et al., 2011; Partridge et al., 2010), an electronic 
monitoring system to compile the dosing histories, including one study using a 
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combination of MEMS and self report. No objective methods such as biological 
markers were used in the included studies.  
Determinants and associated factors of medication (non-)adherence and  
(non-)persistence to oral anticancer drugs 
This review shows that (non-)adherence and (non-)persistence to OACD therapy 
are influenced by different factors (see table 2). A distinction is made between 
factors influencing medication (non-)adherence and factors influencing 
medication (non-)persistence. Determinants and associated factors of (1)  
(non-)adherence and (non-)persistence and (2) higher adherence and higher 
persistence will be structured according to the five categories suggested by the 
World Health Organization (WHO, 2003) framework of factors influencing 
medication adherence.  
Patient- related factors 
Several patient-related factors were found to be associated with medication non-
adherence in patients taking OACD. They can be divided into intentional non-
adherence and unintentional non-adherence. Lower perceived necessity by the 
patient for taking the drug (n=1) (Grunfeld et al., 2005), perception of no benefit 
to be gained from taking the drug (n=1) (Grunfeld et al., 2005), concerns about 
symptoms (n=1) (Noens et al., 2009), the opinion that missing a dose makes no 
difference (n=1) (Eliasson et al., 2011), and lower perceived quality of life (n=1) 
(Eliasson et al., 2011) were found as intentional patient-related factors 
associated with medication non-adherence in patients on an OACD therapy. 
Forgetting (n=2) (Kirk and Hudis, 2008; Eliasson et al., 2011) and accidentally 
taking too much of the prescribed drug (n=1) (Eliasson et al., 2011) were found 
to be the most common patient-related factors being associated with 
unintentional medication non-adherence. Self-efficacy (n=1) (Noens et al., 2009) 
and the belief that medication intake as being prescribed would help to cure from 
cancer (n=1) (Grunfeld et al., 2005) were reported as important patient-related 
factors associated with higher adherence to OACD therapy. Having neutral or 
negative beliefs about the value of the drug (n=1) (Fink et al., 2004) was found to 
be a patient-related factor associated with non-persistence.  
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Therapy-related factors 
Treatment related side effects are the most frequently reported therapy-related 
factors associated with non-adherence to OACD therapy (n=5) (Grunfeld et al., 
2005; Atkins and Fallowfield, 2006; Kirk and Hudis, 2008; Regnier Denois et al., 
2010; Eliasson et al., 2011). The study by Grunfeld et al. (2005) reported that 
46% of the non-adherent breast cancer patients mentioned side effects as 
primary reasons for non-adherence to tamoxifen. The main side effects reported 
were hot flashes (32%), night sweats (24%), concentration or memory difficulties 
(22%), sleep problems (16%), emotional problems (anxiety, panic, depression; 
15%), weight gain (15%), and loss of libido (12%). Treatment related side effects 
were also reported as the primary reason (70%) for medication non-adherence 
in the study by Kirk and Hudis (2008). OACD side effects were not associated 
with a specific type of drug in this study. Atkins and Fallowfield (2006) found also 
a significant association (p=0.001) between disliked aspects (e.g. side effects, 
difficulties swallowing tablets and inconvenience) of oral anti-tumoral medication 
in breast cancer patients (e.g. side effects) and non-adherence. Treatment 
related side effects were also reported as underlying factors for non-adherence 
in the two qualitative studies.3;4 One of these two studies focused on CML 
patients (Eliasson et al., 2011) and the other study focused on different types of 
cancer (metastatic breast, metastatic colon, and adjuvant colon) (Regnier 
Denois et al., 2010). 
Other therapy-related factors of medication non-adherence included longer 
duration of therapy (n=3) (Partridge et al., 2003; Marques and Pierin, 2008; 
Noens et al., 2009), having a mastectomy rather than breast-conserving 
treatment (n=2) (Partridge et al., 2003; Partridge et al., 2010), starting with a 
higher dose of OACD (n=2) (Darkow et al., 2007; Noens et al., 2009), changed 
doses (n=1) (Eliasson et al., 2011), type of drug (mercaptopurine, 
dexamethasone, thalidomide, and hormone therapy drugs) (n=1) (Marques and 
Pierin, 2008), having a lumpectomy (n=1) (Hershman et al., 2010), and variation 
in timing for medication intake (e.g. before or after meals) (n=1) (Regnier Denois 
et al., 2010).   
Chapter 2 
 
61 
Side effects (n=3) (Demissie et al., 2001; Lash et al., 2006; Kahn et al., 2007), 
increased number of prescriptions (n=3) (Barron et al., 2007; Neugut et al., 
2011; Streeter et al., 2011), having a mastectomy rather than breast-conserving 
surgery (lumpectomy) and radiation (n=1) (Ma et al., 2008), and the type of drug 
(imatinib, sorafinib, sunitinib, erlotinib, lapatinib versus capecitabine) (n=1) 
(Streeter et al., 2011) were associated with non-persistence in patients taking 
OACD. Having a lumpectomy rather than having a mastectomy (n=1) 
(Hershman et al., 2010) was found to be associated with higher non-persistence 
in one study.  
Having a higher number of medication prescriptions at baseline was found to be 
associated with higher persistence in one study (Lash et al., 2006). Women 
needing to take more medications during follow-up were more likely to 
discontinue the OACD therapy. Longer intervals between two prescriptions (n=1) 
(Hershman et al., 2010), more medications to be taken daily (n=1) (Lash et al., 
2006), and patients who had radiotherapy before (n=1) (Hershman et al., 2010) 
were factors associated with higher medication persistence in patients on an 
OACD therapy.  
Disease-related factors 
Co-morbidities (n=2) (Hershman et al., 2010, Sedjo and Devine, 2011), unknown 
tumor size (n=1) (Hershman et al., 2010), and having a node-positive disease 
(n=1) (Partridge et al., 2010) were associated with medication non-adherence in 
patients on an OACD therapy. However, co-morbidities were also found to be 
associated with higher persistence in one study (Kimmick et al., 2009). 
Disease-related factors associated with non-persistence to OACD were similar 
to those associated with non-adherence. However, other factors associated with 
medication non-persistence were history of antidepressant use (n=1) (Barron et 
al., 2007), ductal pathology (n=1) (Ma et al., 2008) and negative and unknown 
hormone receptor status (n=1) (Kahn et al., 2007). 
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Healthcare system factors 
Shorter duration of treatment follow-up visits (n=1) (Noens et al., 2009), 
prescribing errors (n=1) (Eliasson et al., 2011), and conflicting information 
regarding consequences (n=1) (Eliasson et al., 2011) were associated with non-
adherence in patients on an OACD therapy. Different doctors responsible for 
follow-up (n=1) (Kahn et al., 2007), and follow-up by a primary physician rather 
than an oncologist (n=2) (Güth et al., 2008; Neugut et al., 2011) were associated 
with medication non-persistence in patients taking OACD.  Not previously being 
informed about side effects (n=1) (Kahn et al., 2007), less patient participation in 
decision making than wanted (n=1) (Kahn et al., 2007), and receiving too much 
or too less support than needed (n=1) (Kahn et al., 2007) were also factors 
associated with medication non-persistence in these patients. 
Enhanced knowledge of the disease and treatment (n=1) (Noens et al., 2009), 
having consulted an oncologist in the year before beginning tamoxifen therapy 
(n=1) (Partridge et al., 2008), longer duration of the first visit with a patient newly 
diagnosed with CML (n=1) (Noens et al., 2009), and physicians’ higher number 
of CML patients seen in the past year (n=1) (Noens et al., 2009) were 
associated with higher medication adherence in patients taking OACD. 
Social and economic factors 
Younger age (n=3) (Partridge et al., 2003; Atkins and Fallowfield, 2006; Sedjo 
and Devine, 2011), older age (n=3) (Partridge et al., 2003; Noens et al., 2009; 
Neugut et al., 2011), and higher out-of-pocket costs (n=3) (Kirk and Hudis, 2008; 
Neugut et al., 2011; Sedjo and Devine, 2011) were associated with non-
adherence in patients taking OACD. Younger age was defined as ≤45 (Partridge 
et al., 2003; Sedjo and Devine, 2011), older age as ≥85 (Partridge et al., 2003), 
and higher out-of-pocket costs as ≥$30 (Sedjo and Devine, 2011). A higher 
educational level (n=1) (Noens et al., 2009) was associated with higher 
adherence in patients taking OACD.  
Older age (n=6) (Barron et al., 2007; Kahn et al., 2007; Owusu et al., 2008; 
Hershman et al., 2010; Nekhlyudov et al., 2011; Neugut et al., 2011) was also 
Chapter 2 
 
63 
found to be associated with lower persistence of the OACD treatment. Higher 
out-of-pocket costs (n=2) (Neugut et al., 2011; Streeter et al., 2011), younger 
age (n=2) (Ma et al., 2008; Hershman et al., 2010), lower income (n=2) 
(Nekhlyudov et al., 2011; Streeter et al., 2011), and female gender (n=1) 
(Darkow et al., 2007) were also influencing medication non-persistence. Married 
status was found to be associated with higher persistence (n=1) (Hershman et 
al., 2010). 
 
DISCUSSION  
The aim of this review was to determine factors associated with medication 
(non-)adherence and (non-)persistence in patients taking OACD. This review 
suggests that (non-)adherence and (non-)persistence in this patient group is 
multi-factorial, complex and influenced by patient-related, therapy-related, 
disease-related, healthcare system and social-economic factors. However, 
generalizations require caution as the included studies used different definitions, 
methods for assessing medication adherence, and cut-off rates for defining 
medication adherence.  
Methodological quality of the included studies 
In general, methodological quality of the included studies was moderate. No 
studies were excluded after considering methodological quality. The most 
common methodological limitations were the absence of clear data on 
withdrawals or drop-out, the absence of a power calculation, and not taking into 
account possible confounders in the analysis. Further, the self-report 
questionnaires used in the included studies to assess medication non-
adherence were often self-constructed and not always tested for validity and 
reliability. Only in a few studies, validated self-report questionnaires were used 
(Grunfeld et al., 2005; Marques and Pierin, 2008; Noens et al., 2009). Future 
studies need to address these issues, as they can influence the validity of the 
study findings.  
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Study characteristics 
Twelve studies used a retrospective study design. This design has several 
limitations: (1) it often only includes data that are necessary for administrative 
statistical purposes (Güth et al., 2008), (2) it is often limited to specific patient 
populations and thus findings from these studies may have limited 
generalizability, and (3) it cannot report on unintentional non-adherence. Causal 
relationships between non-adherence or non-persistence and determinants of 
medication non-adherence can also not be detected by using a retrospective 
design.  
In studies with a cross-sectional (n=5) or prospective study design (n=6), the risk 
of a sample bias has to be considered due to the voluntary character of study 
participation (Mann et al., 2003). Prospective study designs are more 
appropriate to study determinants of medication non-adherence or non-
persistence in patients taking OACD than cross-sectional designs due to the 
longitudinal character (Noens et al., 2009). One study used a qualitative 
approach and one study a mixed method approach. It seems that qualitative 
study designs are scarce in our review and in adherence research. This is 
remarkably as qualitative study designs possess the ability to apprehend an 
overall view of underlying factors and processes associated with medication 
non-adherence or non-persistence in order to explain these phenomena (Black, 
1994). Qualitative research is essential and more appropriate to explore the 
influence of interpersonal relation aspects in medication adherence and 
persistence with OACD. These aspects have been identified as important factors 
influencing medication adherence in other pathologies, but are underexplored in 
the included studies (Vervoort et al., 2007; Stavropoulou, 2011; Van Hecke et 
al., 2011).  
Definition and assessment of medication (non-)adherence and (non-)persistence 
To date there is no universally accepted definition of medication adherence nor 
an appropriate method to optimally assess medication adherence and 
persistence (Gebbia et al., 2012). To define medication non-adherence and non-
persistence, different cut-off rates were used. Based on the extracted data from 
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databases, the number of days covered by filled prescriptions or the MPR were 
often calculated with a cut-off ≤ 80% to define non-adherence.  This cut-off rate 
is frequently cited in the literature as achievable or acceptable (Sikka et al., 
2005; Hess et al., 2006; Simpson et al., 2006). For MEMS, a cut-off for non-
adherence was set on ≤ 80% in oral adjuvant chemotherapy in breast cancer 
patients (Partridge et al., 2010) and ≤ 90% in CML patients taking imatinib 
(Eliasson et al., 2011). The rate of ≤ 90% is identified as the most important 
factor for an adequate molecular response with imatinib (Marin et al., 2010). In 
defining medication non-persistence, several different cut-offs in number of days 
without subsequent refill of pills were used (Barron et al., 2007; Owusu et al., 
2008; Neugut et al., 2011; Streeter et al., 2011). There is a need to further 
explore clinically significant cut-off rates when measuring (non-)adherence to 
increase comparability in research.   
Existing methods to assess medication adherence and persistence include 
objective methods such as the measurement of metabolites of the medication in 
body fluids, and subjective methods such as counting tablets, self report and 
MEMS. In this review, only subjective methods were used, mainly self-report 
questionnaires or self report in patient interviews (Lebovits et al., 1990; Demissie 
et al., 2001; Fink et al., 2004; Grunfeld et al., 2005; Atkins and Fallowfield, 2006; 
Lash et al., 2006; Kahn et al., 2007; Güth et al., 2008; Kirk and Hudis, 2008; 
Marques and Pierin, 2008; Noens et al., 2009; Eliasson et al., 2011). However, 
patient self reported medication adherence or persistence is often overestimated 
because of psychological reasons (fear to be considered unreliable and 
willingness to please healthcare providers) (Gebbia et al., 2012), and because 
patients may not be fully aware of their lapses in doses (Gebbia et al., 2012). In 
measuring adherence, a Hawthorne effect must be taken into account (Ruddy et 
al., 2009) as patients might be aware that their adherence or persistence is 
being studied. MEMS was used in two studies (Partridge et al., 2010; Eliasson et 
al., 2011). This method has previously showed to be more accurate than self 
report or pill counts (Arnsten et al., 2001), but measuring adherence by using 
MEMS is expensive and not always feasible in daily practice (Shi et al., 2010). A 
combination of MEMS and self-report questionnaires, is found to be most 
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accurate in measuring medication adherence (Shi et al., 2010). The combination 
of these methods was only used in one study (Eliasson et al., 2011). Other data 
were obtained from retrospective databases such as pharmacy or insurance 
records with refill data (Sedjo and Devine, 2011; Darkow et al., 2007; Güth et al., 
2008; Partridge et al., 2003; Hershman et al., 2010; Kimmick et al., 2009; 
Nekhlyudov et al., 2011; Neugut et al., 2011; Owusu et al., 2008; Barron et al., 
2007; Ma et al., 2008; Streeter et al., 2011). None of the included studies 
defined non-adherence as doses being taken at the wrong time. Despite, this 
might be a critical factor in treatment effectiveness (Ruddy et al., 2009). Future 
research should also focus on this type of non-adherence and take into account 
the specific margin of the OACD whereas in between the OACD needs to be 
taken without losing efficacy of the treatment. 
Determinants and associated factors of medication (non-)adherence and  
(non-)persistence to oral anticancer drugs 
Treatment related side effects are predominant factors associated with non-
adherence and non-persistence in patients on an OACD therapy. Being 
inadequately informed about side effects in advance is found to be a factor 
associated with increased medication non-persistence (Kahn et al., 2007), while 
a better knowledge of the disease and therapy is associated with a higher 
adherence (McPherson et al., 2001; Gysels and Higginson, 2007; Noens et al., 
2009). The study by Kirk and Hudis (2008) showed that understanding the 
clinical importance of OACD is helpful for 90% of the patients to adhere to their 
therapy. The majority of the patients in the study of Kirk and Hudis (2008) also 
indicated an appropriate management of treatment-related side effects as an 
important factor influencing medication adherence. These findings support the 
need for patient tailored educational support (Vermeire et al., 2001; Hartigan, 
2003; Moore, 2007) and management of symptoms during follow-up (Kav et al., 
2008).  
Both younger and older age, were major factors associated with non-adherence 
and non-persistence in patients taking OACD. This association was primarily 
found in breast cancer patients. Several studies indicate that younger women do 
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not adjust to breast cancer as well as older women, affecting their medication 
adherence (Ganz, 1994; Wenzel et al., 1999). The study by Compas et al. 
(1999) suggests that younger women with breast cancer are more affectively 
distressed and tend to cope with stressors in a less adaptive way. However, the 
reasons for non-adherence and non-persistence in this group of patients remain 
unclear.  A factor that may increase non-adherence and non-persistence in 
younger women with breast cancer is that younger women are more likely to 
undergo early menopause caused by breast cancer treatment (Petrek et al., 
2006), which may affect women’s child wish. Older patients are often more 
influenced by polypharmacy for comorbidities and chronic conditions, physical 
challenges, psychosocial issues (e.g. decreased social support), and increasing 
incidence of memory problems (Balkrishnan, 1998; Chia et al., 2006). These 
factors can also impede medication adherence and persistence. 
Implications for practice  
The findings from this review provide insight into the complexity of determinants 
associated with (non-)adherence to OACD in cancer patients. An important 
finding from the review is that patients taking OACD differ widely (e.g. age, 
disease entity, co-morbidities, and severity of side effects) underlining the need 
for different and tailored approaches in support, depending on their preferences, 
age, therapeutic regimen, disease entity, and severity of side effects. Clinicians 
should help patients to understand that early recognition of treatment related 
side effects can be of great benefit to them (Hartigan, 2003). Further, patients 
should be well informed about the long-term benefits of the treatment and how 
treatment related side effects could be managed in daily life. This education 
should be tailored and based on patient preferences instead of being uniformly 
organized (McPherson et al., 2001). This tailored approach should be performed 
in a context of reciprocity between the physician and the patient, so patients’ 
expectations and individual beliefs could be discussed and patients could 
become active actors of their therapy. 
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Limitations 
Some limitations of this review need to be considered. Generalizations require 
caution as the data obtained from the studies are difficult to compare due to their 
specific focus (different types of drugs, disease entities, and design), and the 
different cut-off rates and methods for assessing non-adherence and non-
persistence. Only two studies used MEMS to assess non-adherence, so the 
results should be interpreted with caution.  
Performing a meta-analysis to generalize results and compare subgroups of 
cancer patients taking OACD was not possible due to the heterogeneity of the 
studies.   
Most of the studies focus on breast-cancer patients (80%) so the conclusions 
from this study are mainly relevant for this group. Data on other types of cancer 
are scarce, for example research in patients taking oral tyrosine kinase inhibitors 
is limited to the three included studies with CML patients. Therefore, further 
research should pay more attention to other types of cancer. 
In studies using a retrospective design based on pharmaceutical or commercial 
databases (n=8), and in articles written by authors supported by pharmaceutical 
grants (n=6), a potential conflict of interest needs to be considered (Boyd et al., 
2003). 
 
CONCLUSION 
This systematic review gives an updated overview of the literature on associated 
factors and determinants of medication (non-)adherence and (non-)persistence 
in patients on an OACD therapy. Older and younger age, and the influence of 
therapy related side effects are predominant factors associated with medication 
adherence and persistence to OACD therapy. However, influencing factors to 
medication adherence and persistence to OACD therapy are multifactorial and 
interrelated. Caution is needed in the interpretation and with the generalizability 
of the results as the studies differ widely in study focus, definitions and 
measurements of medication adherence and persistence. Qualitative research 
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could facilitate the development of patient tailored complex interventions by 
exploring patients’ needs and underlying processes influencing medication 
adherence and persistence to OACD. 
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Table 1. Search strategy with MeSH terms and free text words  
  OR   OR   OR 
MeSH 
terms Medication adherence 
  
Administration, oral 
  
Neoplasms 
  Patient compliance   Antineoplastic agents   
 
Related 
terms 
Medication compliance 
AND 
Oral drug 
administration 
AND 
Tumor 
Medication persistence Antitumor drugs Cancer 
Medication non-adherence Antitumor agents 
 Medication non-compliance Antineoplastic drugs 
 Patient adherence Antineoplastics 
 Patient cooperation 
  Patient non-compliance 
  Patient non-adherence 
Concordance 
Non-persistence 
  Early discontinuation 
Early discontinuance 
Treatment discontinuation 
Treatment discontinuance 
Treatment interruptions 
Pill discontinuation 
Pill discontinuance 
Abandonment     
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Figure 1. Results of the search strategy 
 
 
 
 
 
 
  
Table 2. Study characteristics, determinants and associated factors influencing medication adherence and persistence to oral 
anticancer drugs 
Author 
(publicatio
n date)  
Research focus Design Defining non-adherence 
and non-persistence 
Measurement of (non-
)adherence and (non-
)persistence 
Participants 
(N) 
Factors associated with 
(-) non-adherence or 
(+) higher adherence 
Factors associated with 
(-) non-persistence or 
(+) higher persistence 
Lebovits et 
al. (1990) 
Patient non-
compliance with 
self-administered 
chemotherapy 
Prospectiv
e cohort 
study 
Taking < 90% or taking 
>110% of oral anticancer 
drugs 
(1) Percentage of drug missed 
during 26 weeks of treatment, 
(2) self-report in interview based 
on direct questioning how many 
pills have been taken during the 
preceding week of the interview 
Patients 
with breast 
cancer (51) 
(-) treatment location 
(private and clinic 
settings rather than 
academic setting), 
lower income (and 
lower socioeconomic 
status) 
NA 
Demissie 
et al. 
(2001) 
Predictors of use, 
side effects, and 
discontinuation 
of adjuvant 
tamoxifen 
Prospectiv
e cohort 
study 
Discontinuation (not 
further specified) 
Self-report by computer-assisted 
telephone interviews at second 
follow-up, asking detailed 
questions (not specified) about 
discontinuance of oral anticancer 
drug 
Older 
women with 
breast 
cancer (303) 
NA (-) Side effects 
(depression, nausea, 
vision problems, and 
vaginal bleeding)            
(+) patients who were 
estrogen receptor-
positive 
Partridge 
et al. 
(2003) 
Non-adherence 
to adjuvant 
tamoxifen 
therapy  
Retrospect
ive 
analysis of 
data 
Taking < 80% of the doses 
of prescribed tamoxifen 
Refill data (dosage, quantity 
dispensed, and number of days 
supplied) extracted from the 
paid claims from the New Jersey 
Medicaid program and the New 
Jersey Pharmaceutical Assistance 
to the Aged and Disabled (PAAD) 
program 
Women 
with primary 
breast 
cancer 
(2378) 
(-) ≤ 45 years old, ≥ 85 
years old, nonwhite 
subjects, longer 
duration of therapy, 
patients who had had a 
mastectomy (rather 
than breast-conserving 
surgery)                                        
(+) patients who had a 
consultation with a 
medical oncologist 
before initiation of 
tamoxifen 
NA 
  
Author 
(publicatio
n date)  
Research focus Design Defining non-adherence 
and non-persistence 
Measurement of (non-
)adherence and (non-
)persistence 
Participants 
(N) 
Factors associated with 
(-) non-adherence or 
(+) higher adherence 
Factors associated with 
(-) non-persistence or 
(+) higher persistence 
Fink et al. 
(2004) 
Patient beliefs 
about risks and 
benefits of 
tamoxifen 
therapy and 
tamoxifen 
discontinuance  
Prospectiv
e cohort 
study 
Discontinuation (not 
further specified) 
Self-report by telephone 
interviews at 3, 6, 15 and 27 
months by asking whether 
women discontinued tamoxifen  
Older 
women with 
estrogen 
receptor-
positive 
breast 
cancer (597) 
NA (-) Having neutral or 
negative beliefs about 
the value of tamoxifen, 
having positive nodes 
Grunfeld 
et al. 
(2005) 
Adherence 
beliefs about 
taking tamoxifen 
Cross-
sectional  
(1) Answering “no” on 
the self-reported 
question; (2) lower scores 
(without a cut-off score) 
on the Medication 
Adherence Report Scale 
(MARS-5)1 indicating non-
adherence 
(1) Self-report with a single 
question: “In the past week, 
have you taken your tamoxifen 
everyday?”, (2) MARS-5 
Women 
with breast 
cancer aged 
35-65 years 
old (110) 
(-) lower perceived 
necessity for tamoxifen 
and no benefit to be 
gained from taking 
tamoxifen, side effects 
(hot flashes, night 
sweats, concentration 
or memory difficulties, 
sleep problems, 
emotional problems, 
weight gain, and loss of 
libido)                                                   
(+) the belief that 
taking tamoxifen would 
stop the patients from 
developing breast 
cancer 
NA 
Atkins & 
Fallowfield 
(2006) 
Intentional and 
non-intentional 
non-adherence 
to oral 
anticancer drugs  
Cross-
sectional 
Anwering ‘occasionally’, 
‘sometimes’, ‘quite 
often’, or ‘very often’ on 
2 questions assessing 
intentional and non-
intentional non-
adherence 
Self-report on 2 questions: “How 
often do you forget to take your 
tablets?” and “How often do you 
choose not to take your tablets?” 
Women 
with breast 
cancer (131) 
(-) younger age, 
disliking aspects of 
medication (side 
effects, inconvenience, 
difficulties swallowing 
tablets) 
NA 
  
Author 
(publicatio
n date)  
Research focus Design Defining non-adherence 
and non-persistence 
Measurement of (non-
)adherence and (non-
)persistence 
Participants 
(N) 
Factors associated with 
(-) non-adherence or 
(+) higher adherence 
Factors associated with 
(-) non-persistence or 
(+) higher persistence 
Lash et al. 
(2006) 
Adherence to 
tamoxifen over 
the five-year 
course 
Prospectiv
e cohort 
study  
Discontinuation (not 
further specified) by self-
report in interviews  
Self report by telephone 
interviews at 3, 6, 15, 27, 39, 51, 
and 63 months after surgery 
(questions not specified) 
Older 
women with 
breast 
cancer (462) 
NA (-) having or developed 
initial severe side 
effects   (+) more 
prescription 
medications at baseline  
Barron et 
al. (2007) 
Early 
discontinuation 
of tamoxifen  
Retrospect
ive 
analysis of 
data 
Non-persistence: ≥180 
consecutive days of no 
tamoxifen supply without 
alternative hormonal 
therapy during that time 
Refill data (number of days 
supply, quantity and dosage of 
tamoxifen) extracted from the 
Irish Health Services Executive 
(HSE) Primary Care 
Reimbursement Services (PCRS) 
pharmacy database 
Women 
with breast 
cancer aged 
35 years or 
older (2816) 
NA (-) history of 
antidepressant use (use 
in the year preceding 
the tamoxifen 
initiation), age (older 
than 75, between 35 
and 44), increased 
number of 
prescriptions per 
month/year before 
starting tamoxifen 
Darkow et 
al. (2007) 
Treatment 
interruptions and 
non-adherence 
with imatinib 
Retrospect
ive 
analysis of 
data 
(1) Treatment 
interruptions: failure to 
refill imatinib within 30 
days from the end of 
supply of the prior 
prescription (2)< 50% low 
MPR2; 50-90% 
intermediate MPR, 90-
95% high MPR, > 95% 
very high MPR 
Refill data from an anonymous  
database including electronic 
pharmacy records and medical 
claims 
Patients 
with CML 
(267) 
(-) increased amount of 
different medication, 
starting with higher 
dose imatinib (≥ 
600mg), high cancer 
complexity (difficulty of 
managing the patient 
because of e.g. 
comorbidities), female 
gender 
(-) female gender, high 
cancer complexity  
  
Author 
(publicatio
n date)  
Research focus Design Defining non-adherence 
and non-persistence 
Measurement of (non-
)adherence and (non-
)persistence 
Participants 
(N) 
Factors associated with 
(-) non-adherence or 
(+) higher adherence 
Factors associated with 
(-) non-persistence or 
(+) higher persistence 
Kahn et al. 
(2007) 
Patient centered 
experiences in 
breast cancer - 
predicting long-
term adherence 
to tamoxifen use 
Prospectiv
e cohort 
study 
Persistence not specified Patient self-report survey. 
Question(s) about non-
persistence: not specified 
Breast 
cancer 
patients 
(881) 
NA (-) older age (>65), 
severe side effects, 
negative and unknown 
hormone receptor 
status, no single doctor 
mainly responsible for 
follow-up, less 
participation in decision 
making than wanted, 
receiving too much or 
too less support than 
needed from 
caregivers, not 
previously informed 
about side effects 
Güth et al. 
(2008) 
Non-adherence 
with adjuvant 
endocrine 
therapy 
Retrospect
ive 
analysis of 
data 
Discontinuation (not 
further specified)  
Self-report during follow-up (not 
further specified) 
Postmenopa
usal patients 
with 
invasive 
breast 
cancer (325) 
NA (-) Patients who did not 
have follow-up in an 
oncologic unit but 
rather with a general 
practitioner 
Kirk & 
Hudis 
(2008) 
Barriers in 
adherence to 
oral hormonal 
therapy  
Cross-
sectional  
Taking < 100% of oral 
anticancer drugs 
Self-reported internet survey 
with 30 questions about intake 
of oral anticancer drugs as 
directed  
Patients 
with breast 
cancer (328) 
(-) treatment related 
side effects, cost of the 
medication, 
forgetfulness, constant 
reminder of cancer 
diagnosis 
NA 
  
Author 
(publicatio
n date)  
Research focus Design Defining non-adherence 
and non-persistence 
Measurement of (non-
)adherence and (non-
)persistence 
Participants 
(N) 
Factors associated with 
(-) non-adherence or 
(+) higher adherence 
Factors associated with 
(-) non-persistence or 
(+) higher persistence 
Ma et al. 
(2008) 
Non-compliance 
with adjuvant 
radiation, 
chemotherapy, 
or hormonal 
therapy  
Retrospect
ive 
analysis of 
data 
Stop or refuse to take 
tamoxifen within the 1st 
year of treatment (if not 
stopped on the advice of 
a physician) 
Data not further specified on 
discontinuation of tamoxifen - 
extracted from the breast cancer 
database of the senior author 
including data from the registry 
as well as electronic medical 
data used in a retrospective 
chart review 
Women 
with breast 
cancer (788) 
NA (-) younger (mean of 54 
versus 59 years old), 
white, larger ductal 
cancers, treated with 
mastectomy rather 
than lumpectomy and 
radiation, ductal 
pathology 
Marques & 
Pierin 
(2008) 
Factors affecting 
cancer patient 
compliance to 
oral anti-
neoplastic 
therapy 
Cross-
sectional  
≤3 points on Morisky and 
Green Test3 
Morisky and Green Test Cancer 
patients 
under anti-
neoplastic 
oral therapy 
in a private 
hospital (61) 
(-) longer treatment 
time, type of 
medication 
(mercaptopurine, 
dexamethasone, 
thalidomide, and 
hormone therapy 
drugs), patients who 
had alternative 
treatment (massage)                                             
(+) patients who 
previously had 
radiotherapy  
NA 
Owusu et 
al. (2008) 
Predictors of 
tamoxifen 
discontinuation  
Retrospect
ive 
analysis of 
data 
Discontinuation: ≥ 60 
days discontinuing 
tamoxifen during 5 years 
after initial tamoxifen 
prescription 
  
Refill data (date of initial 
tamoxifen prescription and date 
of discontinuation) extracted 
from cancer register, 
administrative, and clinical 
databases  
Older 
women with 
estrogen 
receptor-
positive 
breast 
cancer (961) 
NA (-) Older age (>75), 
increasing 
comorbidities, 
indeterminate estrogen 
receptor status, have 
had breast-conserving 
surgery without 
radiotherapy 
  
Author 
(publicatio
n date)  
Research focus Design Defining non-adherence 
and non-persistence 
Measurement of (non-
)adherence and (non-
)persistence 
Participants 
(N) 
Factors associated with 
(-) non-adherence or 
(+) higher adherence 
Factors associated with 
(-) non-persistence or 
(+) higher persistence 
Kimmick et 
al. (2009) 
Adjuvant 
hormonal 
therapy use 
among insured, 
low-income 
women with 
breast cancer 
Retrospect
ive 
analysis of 
data 
(1) Adherence by MPR ≤ 
80%, (2) non-persistence 
as a 90-day gap in 
prescription fill 
Refill data extracted from the 
North Carolina Central Cancer 
Registry (CCR) and North 
Carolina Medicaid Claims 
administrative database 
Insured, 
low-income 
women with 
breast 
cancer 
(1491) 
(+) nonmarried status (+) nonmarried status, 
having more 
comorbidities (Charlson 
comorbidity index4 of 3 
compared with 0), 
regional rather than 
local stage of tumor 
Noens et 
al. (2009) 
Prevalence, 
determinants, 
and outcomes of 
non-adherence 
to imatinib 
therapy  
Prospectiv
e 
observatio
nal study 
(1) patient Visual Analog 
Scale (VAS) rating, (2) ≥ 1 
positive answers on the 
Basel Assessment of 
Adherence Scale (BAAS)5, 
(3) pill count: other dose 
taken than prescribed 
during 90-day period 
BAAS scale, VAS rating the 
overall adherence, pill counts 
Patients 
with CML 
(169) 
(-) bothersomeness of 
symptoms,  number of 
symptoms, number of 
adverse events, third 
person perceptions of 
adherence, higher age6, 
longer time since CML 
diagnosis6, living alone6, 
male sex6,  longer time 
on imatinib6, imatinib 
dose more than or 
equal to 600 mg/day6, 
higher degrees of 
chronic care received6, 
higher (self-)reported 
functional status and 
quality of life6, shorter 
median duration of 
treatment follow-up 
visits (presumably a 
proxy of vigilance)6, 
years of physicians’ 
professional 
experience6                                         
NA 
  
Author 
(publicatio
n date)  
Research focus Design Defining non-adherence 
and non-persistence 
Measurement of (non-
)adherence and (non-
)persistence 
Participants 
(N) 
Factors associated with 
(-) non-adherence or 
(+) higher adherence 
Factors associated with 
(-) non-persistence or 
(+) higher persistence 
(+) knowledge of 
disease and treatment6, 
more medications to be 
taken 
daily6, secondary school 
or higher education6, 
self-efficacy in long-
term medication 
behavior6, physicians’ 
higher number of active 
patients with CML seen 
in the past year6, 
median duration of the 
first visit with a patient 
newly diagnosed with 
CML6, (practicing in a 
university or teaching 
hospital6, holding 
specialization in 
hematology6) 
Hershman 
et al. 
(2010) 
Early 
discontinuation 
and non-
adherence to 
adjuvant 
hormonal 
therapy  
Retrospect
ive 
analysis of 
data 
(1) Non-adherence by 
MPR < 80%, (2) early 
discontinuation if 180 
days elapsed from the 
prior prescription without 
a refill 
Refill data (date of prescription 
and date of refill) from the 
pharmacy information 
management system from the 
Kaiser Permanente of Northern 
California  
Early stage 
breast 
cancer 
patients 
(8769) 
(-) African American 
race, lumpectomy, 
unknown tumor size, 
lymph node 
involvement, 
comorbidities 
(-) younger (<50 years 
old) or older age (≥65 
years old), lumpectomy 
(v mastectomy, 
comorbidities                   
(+) married status, 
receipt of 
chemotherapy or 
radiotherapy, longer 
prescription refill 
interval 
  
Author 
(publicatio
n date)  
Research focus Design Defining non-adherence 
and non-persistence 
Measurement of (non-
)adherence and (non-
)persistence 
Participants 
(N) 
Factors associated with 
(-) non-adherence or 
(+) higher adherence 
Factors associated with 
(-) non-persistence or 
(+) higher persistence 
Partridge 
et al. 
(2010) 
Adherence and 
persistence with 
oral adjuvant 
chemotherapy  
Cross-
sectional  
MEMS  < 80% MEMS Older 
women with 
early-stage 
breast 
cancer (161) 
(-)  having node-
positive disease, 
received partial 
mastectomy/lumpecto
my/excisional biopsy 
NA 
Regnier 
Denois et 
al. (2010) 
Behavior and 
representations 
of patients and 
oncologists on 
adherence with 
oral 
chemotherapy 
Qualitative 
study 
design  
Occasionally forget intake 
of oral anticancer drug 
Self-report in patient interviews 
and focus group interviews  
Patients 
with breast 
cancer (42) 
(-) change in routine 
(town visits, visiting 
friends, going on 
holiday), not 
understand 
prescriptions, side 
effects, changes in 
timing for taking the 
treatment in terms of 
meal times 
 
NA 
Eliasson et 
al. (2010) 
Exploring chronic 
myeloid 
leukemia 
patients' reasons 
for not adhering 
to the oral 
anticancer drug 
imatinib as 
prescribed 
Mixed 
method 
study 
design  
MEMS (Medication Event 
Monitoring System ) ≤ 
90%  
(1) Answering “yes” in a patient 
interview on the question: “It is 
common that patients at times 
miss a few doses, for a whole 
range of reasons. Thinking just of 
the past 7 days have you missed 
any doses?”, (2) data from a 
previous quantitative study 
measuring adherence by MEMS  
Patients 
with CML 
(21) 
(-) (1) Unintentional 
non-adherence 
(forgetting, accidentally 
taking too much, 
prescribing error, no 
imatinib available at 
pharmacy), (2) 
intentional non-
adherence (attributable 
to side effects, 
socializing/dining 
out/drinking alcohol, 
travelling, diversion 
from planned activities, 
temporary illness 
NA 
  
Author 
(publicatio
n date)  
Research focus Design Defining non-adherence 
and non-persistence 
Measurement of (non-
)adherence and (non-
)persistence 
Participants 
(N) 
Factors associated with 
(-) non-adherence or 
(+) higher adherence 
Factors associated with 
(-) non-persistence or 
(+) higher persistence 
(cold), risk of 
pregnancy, negative 
emotions and feelings, 
"no real reason/lack of 
discipline", bad taste, 
changed doses), (3) 
consequences of non-
adherence (perceived 
consequences, 
conflicting information 
regarding 
consequences, "getting 
away with it", reliance 
on monitoring and 
health care providers to 
detect and relay 
changes in clinical 
parameters, do not 
think missing the odd 
dose make a 
difference) 
  
Author 
(publicatio
n date)  
Research focus Design Defining non-adherence 
and non-persistence 
Measurement of (non-
)adherence and (non-
)persistence 
Participants 
(N) 
Factors associated with 
(-) non-adherence or 
(+) higher adherence 
Factors associated with 
(-) non-persistence or 
(+) higher persistence 
Nekhlyudo
v et al. 
(2011) 
Five-year 
patterns of 
adjuvant 
hormonal 
therapy use, 
persistence, and 
adherence  
Retrospect
ive 
analysis of 
data 
(1) Adherence by MPR ≤ 
80%, (2) non-persistence 
by having a gap between 
two consecutive 
prescriptions of at least 
60 days 
Refill data extracted from claims 
submitted to Harvard Pilgrim 
Health Care, a non-profit health 
plan in Massachusetts 
Women 
with early 
stage breast 
cancer 
(2207) 
NA (-) elderly women (>70 
years old at diagnosis - 
compared to younger 
than 50 years old), 
lower income 
neighbourhood 
(associated factor only 
during first year of 
treatment) 
Neugut et 
al. (2011) 
Compliance with 
adjuvant 
hormonal 
therapy  
Retrospect
ive 
analysis of 
data 
(1) Non-adherence: MPR 
< 80%, (2) Non-
persistence: presciption 
supply gap ≥ 45 days 
without subsequent refill 
Refill data extracted from an 
anonymous Information 
Warehouse database of 
medication prescriptions 
Women 
with early 
stage breast 
cancer 
(8110) 
(-) higher out-of-pocket 
cost, older age  
(-) prescription not by 
oncologist (by primary 
care physician), 10 or 
more other 
prescriptions, higher 
out-of-pocket cost,  
older than 85 years  
Sedjo & 
Devine 
(2011) 
Predictors of 
non-adherence 
to aromatase 
inhibitors  
Retrospect
ive 
analysis of 
data 
MPR < 80% Refill data extracted from the 
MarketScan® Commercial Claims 
and Encounters Databases from 
Thomson Reuters 
Commerciall
y insured 
women with 
breast 
cancer 
(13593) 
(-) younger age (<45 
years old), out-of-
pocket costs ≥$30 per 
prescription, no 
mastectomy, higher 
Charlson Comorbidity 
Index  
NA 
  
Author 
(publicatio
n date)  
Research focus Design Defining non-adherence 
and non-persistence 
Measurement of (non-
)adherence and (non-
)persistence 
Participants 
(N) 
Factors associated with 
(-) non-adherence or 
(+) higher adherence 
Factors associated with 
(-) non-persistence or 
(+) higher persistence 
Streeter et 
al. (2011) 
Factors affecting 
abandonment of 
oral oncolytic 
prescriptions 
Retrospect
ive 
analysis of 
data  
Abandonment (reversal 
of an adjudicated 
pharmacy claim without a 
subsequent paid claim for 
oncolytic within the 
ensuing 90 days) 
Refill data extracted from 
administrative claims from the 
Wolter Kluwer Dynamic Claims 
Lifecycle Database (pharmacy 
utilization data) 
Cancer 
patients 
(10508) 
NA (-) high cost, increased 
prescription activity, 
lower income, type of 
drug (imatinib, 
sorafenib, sunitinib, 
erlotinib, lapatinib 
compared with 
capecitabine)   
1 
Medication Adherence Report Scale (MARS-5) is a scale with 5 items to assess various non-adherent behaviours including how often 
patients have deliberately not taken their medicines and forgotten to take them. All questions are answered on a five point Likert-scale, 
resulting in a range from 5 to 25 point, with higher scores indicating greater adherence / 
2
 Medication Possession Ratio (MPR) is a formula 
used to determine adherence that is measured from the first to the last prescription, with the denominator being the duration from index 
to the exhaustion of the last prescription and the numerator being the days supplied over that period from first to last prescription / 
3
Morisky and Green test evaluates attitudes regarding treatment and is made up of four questions / 
4
 Charlson Comorbidity Index predicts 
the ten-year mortality for a patient who may have a range of comorbid conditions. Each condition is assigned with a score of 1,2,3 or 6 
depending on the risk of dying associated with this condition. Then the scores are summed up and given a total score which predicts 
mortality / 
5
 Basel Assessment of Adherence Scale (BAAS) is a 4-question clinical interview guide questioning adherence behavior / 
6 
not 
independent factors and should be interpreted as part of a canonical model of multiple complementary variables
 
  
Table 3. Summary of the quality assessment of the included quantitative studies (23)  
 
Selection bias Allocation 
bias 
Confounders Data collection methods Withdrawals 
and drop-
outs 
Analysis 
 
 
Q11 Q22 Q33 Q44 Q55 Q66 
Lebovits et al. Moderate Moderate Weak Strong Weak N7 P8 Y9 Y Y Y 
Demissie et al. Moderate Moderate Weak NA10 Weak N Y Y Y NR11 Y 
Partridge et al. Moderate Moderate Weak NA Moderate N Y N Y NR Y 
Fink et al. Weak Moderate Weak NA Weak N Y Y Y NR Y 
Grunfeld et al. Weak Moderate Weak Strong Weak N Y Y Y NR Y 
Atkins & Fallowfield Moderate Moderate Weak NA Weak N Y Y Y NR Y 
Lash et al. Moderate Moderate Weak Strong Weak N P Y Y NR Y 
Barron et al. Moderate Moderate Weak NA Moderate N Y Y Y NR Y 
Darkow et al. Moderate Moderate Weak NA Moderate N Y Y Y NR Y 
Kahn et al. Moderate Moderate Weak Moderate Weak N Y Y Y NR Y 
Güth et al. Weak Moderate Weak NA Moderate N Y Y Y NR Y 
Kirk & Hudis Moderate Moderate Weak Moderate Moderate N Y Y Y NR Y 
Ma et al. Moderate Moderate Weak NA Moderate N P Y Y NR Y 
Marques & Pierin Weak Moderate Weak Strong Weak N Y Y Y NR Y 
Owusu et al. Moderate Moderate Weak NA Moderate N Y Y Y NR Y 
Kimmick et al. Moderate Moderate Weak NA Moderate N Y Y Y NR Y 
Noens et al. Moderate Moderate Weak Strong Strong Y Y Y Y NR Y 
       
  
 
Selection bias Allocation 
bias 
Confounders Data collection methods Withdrawals 
and drop-
outs 
Analysis 
 
      Q11 Q22 Q33 Q44 Q55 Q66 
Hershman et al. Moderate Moderate Weak NA Moderate N Y Y Y NR Y 
Partridge et al. Weak Moderate Weak Strong  Weak N Y Y Y NR Y 
Nekhlyudov et al. Moderate Moderate Weak NA Moderate N Y Y Y NR Y 
Neugut et al. Moderate Moderate Weak NA Moderate N Y Y Y NR Y 
Sedjo & Devine Moderate Moderate Weak NA Moderate N Y Y Y NR Y 
Streeter et al. Moderate Moderate Weak NA Moderate N Y Y Y NR Y 
1sample size or power calculation / 2characteristics of study participants extensively described / 3main results of statistical analysis unambiguously described / 
4statistical methods appropriate / 5missing data handled in an appropriate way / 6result section report on all outcome measures mentioned in method-section / 
7No / 8Partially / 9Yes / 10Not applicable  /11Not Reported 
 
 
 
 
 
  
Table 4. Summary of the quality assessment of the mixed method study and qualitative study (2) 
 
Clear 
statement 
of the aims 
Appropriate 
methodolog
y 
Appropriate 
design 
Appropriate 
recruitment 
strategy 
Appropriate 
data 
collection 
Consideration 
relationship 
between 
researcher 
and 
participants 
Considerati
on ethical 
issues 
Rigorousne
ss data 
analysis 
Clear 
statement 
of findings 
Valuability 
of the study 
Eliasson et 
al. + + + - + - + + + + 
Regnier 
Denois et al. + + + + + - + - + + 
+ = yes, - = no 
1Mixed method study 
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FACTORS INFLUENCING (NON-)ADHERENCE IN 
CANCER PATIENTS TAKING ORAL TYROSINE KINASE 
INHIBITORS: A QUALITATIVE STUDY  
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ABSTRACT 
Background 
Non-adherence in cancer patients taking oral anticancer drugs is common. 
Reasons for non-adherence are still not really understood as influencing factors 
are often complex, dynamic and interrelated.  
Objective 
A qualitative study was conducted to gain insight into (non-)adherence behavior 
in patients taking oral tyrosine kinase inhibitors by exploring (1) processes and 
factors influencing (non-)adherence, and (2) their interrelatedness.  
Methods 
Semi-structured interviews were held with 30 patients of different ages and with 
different types of cancer. A grounded theory approach was used.  
Results 
Three foci were found when dealing with oral tyrosine kinase inhibitors: (1) a 
focus on survival, (2) a focus on quality of life, and (3) a balance between 
survival and quality of life. The process of adherence was determined by a set of 
complex and interrelated influencing factors: treatment related side effects, 
hope, anxiety, trust, and feedback mechanisms. 
Conclusion 
This qualitative study gives insight into processes and factors influencing  
(non-)adherence behavior in patients taking oral tyrosine kinase inhibitors. The 
results of this study can help healthcare professionals understand why patients 
taking oral tyrosine kinase inhibitors do not always adhere to their therapy.  
Implications for practice 
Conditions should be created by which patients get maximum opportunity to 
establish a balance between survival and quality of life. An open climate and a 
trust based relationship should be established in which patients feel comfortable 
to openly discuss their therapy and the difficulties they experience. 
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INTRODUCTION 
There is a steady increase in the availability and use of oral anticancer drugs 
(OACD) in the treatment of cancer (Banna et al., 2010). Currently, 25% of the 
anticancer drugs can be taken orally and this will continue to rise in the future 
(Banna et al., 2010). Tyrosine kinase inhibitors (TKIs) are one type of OACD. 
Tyrosine kinase inhibitors allow target-specific therapy for selected malignancies 
(Arora and Scholar, 2005). Most TKIs have to be taken for long periods of time 
and have palliative rather than curative properties. Eleven registered oral TKIs 
are used in the targeted treatment of specific cancers (Levitzki, 2013). Imatinib, 
for example, is used for the treatment of chronic myeloid leukemia (CML), and 
sunitinib for the treatment of renal cell carcinoma, gastrointestinal stromal 
tumors, and neuroendocrine tumors.  
For treatment effectiveness, optimal adherence to OACD is considered 
important (Noens et al., 2009; Marin et al., 2010; Xu et al., 2012). A patient is 
considered to be non-adherent when doses of the prescription to which the 
patient has consented are skipped, extra doses are taken or doses are taken in 
the wrong quantity or at the wrong time (Ruddy et al., 2009). Non-adherence 
rates in patients taking OACD range from 0 to 84% (Foulon et al., 2011) 
depending on (1) the definition of non-adherence, (2) the tool used to measure 
non-adherence, and (3) the type of OACD therapy (e.g. therapy complexity and 
side effects). Adherence studies in patients taking OACD mainly focus on 
hormone therapy in breast cancer patients (Partridge et al., 2010; Nekhlyudov et 
al., 2011; Neugut et al., 2011). Adherence studies in patients taking oral TKIs 
mainly focus on patients with CML taking imatinib (Darkow et al., 2007; Noens et 
al., 2009; Marin et al., 2010; Eliasson et al., 2011; Jönsson et al., 2012). Studies 
reporting on adherence in other malignancies treated with oral TKIs are scarce. 
Mainly quantitative studies are conducted to explore influencing factors of non-
adherence in patients taking OACD. Patient, therapy, disease, healthcare 
system, and social and economic characteristics are found to influence 
adherence in patients taking OACD (Verbrugghe et al., 2013). The influence of 
therapy related side effects (Grunfeld et al., 2005; Atkins and Fallowfield, 2006; 
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Kirk and Hudis, 2008; Regnier Denois et al., 2010; Eliasson et al., 2011), and 
older (Partridge et al., 2003; Noens et al., 2009; Neugut et al., 2011) or younger 
age (Partridge et al., 2003; Neugut et al., 2011; Sedjo and Devine, 2011) are 
found to be predominant factors associated with non-adherence in patients 
taking OACD. However, despite many quantitative studies, reasons for non-
adherence in patients taking OACD are still not fully understood as influencing 
factors of non-adherence are often complex, dynamic and interrelated 
(Verbrugghe et al., 2013). The lack of a clear understanding may partly explain 
the still high prevalence of non-adherence to oral TKIs to date (Anderson et al., 
2014; Kekäle et al., 2014). Qualitative research could give insight into the 
complexity and interrelatedness of factors influencing medication  
(non-)adherence and is more appropriate than quantitative research to discover 
underlying processes (Black, 1994). A better understanding of (non-)adherence 
in patients taking oral TKIs could, in turn, inform patient tailored interventions. 
Furthermore, qualitative research is more appropriate than quantitative research 
to explore the influence of interpersonal relational aspects, known to be 
important factors in medication adherence in other diseases (Vervoort et al., 
2007; Stavropoulou, 2011; Van Hecke et al., 2011).  
To date, qualitative studies in adherence research in patients taking OACD are 
scarce. In a recent systematic review of determinants and associated factors 
influencing adherence to OACD (Verbrugghe et al., 2013), only one qualitative 
study in patients with breast cancer (Kirk and Hudis, 2008) and one mixed 
methods study in patients with CML (Eliasson et al., 2011) were found among 
the 25 included studies. To our knowledge, no qualitative research describes 
processes and factors influencing (non-)adherence in different types of oral 
TKIs.  
This study aims to give insight into (non-)adherence behavior in patients taking 
oral TKIs by exploring (1) processes and factors influencing (non-)adherence, 
and (2) their interrelatedness.  
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METHODS 
A grounded theory approach (Glaser and Strauss, 1967) was used in this study 
because it allowed for understanding patients’ behaviors and actions and 
provided guidance for studying complex and dynamic phenomena (Brown et al., 
2002) such as (non-)adherence behavior. A grounded theory approach is a 
qualitative systematic research method to inductively derive a theoretical 
framework from a systematic, interactive process of data collection and analysis 
(Charmaz, 2006; Threlfall et al., 2007). 
Setting and sample 
Patients were recruited in five hospitals in Belgium: two university and three 
regional hospitals.  The sample consisted of native Dutch speaking patients, ≥ 
18 years old, diagnosed with different types of cancer, and treated with an oral 
TKI. Patients in a palliative care stage (prognosis of <6 months survival) were 
excluded, as previous research demonstrated that other factors sometimes get 
more attention than taking OACD (Krouse et al., 2004; Irshad and Maisey, 
2010). In selecting patients, diversity regarding for instance age, time since 
diagnose, and pathology was taken into account (purposive sampling). 
Ultimately, thirty-one patients were asked to participate, one refused because of 
the progression of the disease. Table 1 shows the participants’ demographic, 
disease, and treatment-related characteristics. The age varied between 36 and 
88 years. Most participants were men (n=18). Participants had been diagnosed 
between 4 months and 8.8 years previously, most with renal cell cancer or CML. 
For most of the participants (n=21) it was the first treatment with OACD since the 
start of oral anticancer treatment. Most participants lived together with a partner 
(n=21) and had children (n=25). 
Data collection 
A designated healthcare professional in the hospital contacted potential 
participants and provided oral information about the study. When patients 
agreed to participate, a researcher contacted the patient to make an 
appointment for the interview. 
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Interviews were held at a location of their choice, to encourage openness and in-
depth conversations.  Twenty-seven interviews took place at the patients’ home 
and three interviews took place at the outpatient department in the hospital. The 
interviews were semi-structured and informed by topics (Table 2) from a recent 
review of determinants and associated factors influencing (non-)adherence in 
patients taking oral anticancer drugs (Verbrugghe et al., 2013). The interviews 
started with an open question to encourage patients to tell their story: “You 
received an oral treatment for cancer, could you tell me what your life has been 
like these last few months?”. Demographic data were collected at the end of 
each interview in order not to disturb the flow of the interview.  
As the process of data collection and data-analysis evolved, the topic list was 
adjusted with more specific subtopics to enrich the process of data collection. 
New subtopics were: (1) the desire to have a normal life, (2) the meaning of 
feedback from medication, follow-up examinations, and healthcare 
professionals, (3) locus of control, (4) the meaning of the unpredictability of side 
effects and the acceptability of side effects, and (5) anxiety and hope. 
The interview style generally became more structured as the number of 
interviews progressed. During and after the interviews, the researcher wrote 
down relevant observations concerning the context of the interview. 
Observations were included in the analysis. 
Data collection took place between May 2012 and November 2013. All 
interviews were conducted by the first author (M.V.). Interviews were tape-
recorded, transcribed verbatim by a third person, and verified for transcription 
accuracy by the first author. Interviews lasted on average 52 minutes (range 15-
88). During 9 of the 30 interviews, a third person was present (often the patient’s 
partner) for all or a part of the interview.  
This study was approved by the Ethical Review Committee of Ghent University 
Hospital and by the local committees of the participating hospitals 
(B670201212975). All participants were given detailed information (written and 
verbal) about the study and signed an informed consent. Possible identifiers 
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were removed from the transcripts. The audio documents were deleted at the 
end of the study.  
Data analysis  
The themes were developed based on discussion by the three main researchers 
(M.V., A.V.H. & V.D.). Each new insight emerging from the group discussion was 
checked against the other data. The analytical process revealed new subtopics 
to include in the following interviews.  
The transcripts were coded and themes were described. Data were entered into 
a software program for qualitative data analysis (NVivo 10, QRS International 
Pty. Ltd.). A coding tree was developed. After 15 interviews, three foci reflecting 
the patients’ basic stance towards their treatment with oral TKIs were developed 
(theoretical framework). After specific recruitment (theoretical sampling) and a 
thorough discussion of the emerged themes, we got a clearer picture of how the 
patients’ focus interacted with factors influencing adherence behavior. All the 
transcripts were reread several times to trace how the themes were represented 
in the interviews.    
In the initial phase of data collection, purposive sampling was used in order to 
assure the representativeness of participants with different ages, different social 
situations, different diagnoses (and type of oral TKIs). By using purposive 
sampling, which is the selection of information-rich cases related to the 
phenomenon of interest (Palinkas et al., 2013), we aimed to have a broad 
exploration of the experiences of patients taking oral TKIs. As soon as patients’ 
foci in dealing oral TKI therapy were developed (after 15 interviews), theoretical 
sampling (Stavropoulou, 2011) was used. Patients were then recruited to further 
explore factors influencing the foci: patients who stopped treatment on their own 
initiative, patients who were less directly faced with the life-threatening nature of 
the disease, and patients for whom the oral TKI was no longer effective. The 
new data contributed to the further development and refinement of the 
theoretical framework developed in this study.   
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After 27 interviews, data saturation was reached in accordance with the constant 
comparison analyzing aspect of grounded theory (altering process of data 
collection and data-analysis in a cyclic way until new interviews no longer 
contribute to the further refinement of the theoretical framework) (Boeije, 2002). 
Three additional interviews were conducted, but revealed no additional 
information. 
To improve the quality of the data collection, a supervisor (A.V.H.) gave 
feedback on the interview style and data analysis. Analysis was validated by the 
process of researcher triangulation. A second researcher (V.D.) followed the 
process closely, read all the transcripts, assisted with the coding, and frequently 
discussed the coding and themes that emerged from the analysis. Additionally, a 
group of five experts met five times in order to discuss the results of the data 
analyses in order to optimize the quality. The five experts were selected 
because of their expertise in qualitative research and/or relevant work 
experience. Two of them were oncology nurse specialists. They read some of 
the interviews and performed their own analysis. These analyses were 
discussed in group.  
 
RESULTS 
In dealing with oral TKI therapy, three foci were developed (theoretical 
framework): (1) a focus on survival, (2) a focus on quality of life, and (3) a 
balance between survival and quality of life. The focus was influenced by a set 
of complex and interrelated factors. The intensity and quantity of side effects 
was found to be a crucial factor.  Foci were not static: they could shift over time. 
The figure gives an overview of the influencing factors and the three foci.   
Three foci  
Within a focus on survival, treatment got the highest priority. In patients with this 
focus, treatment with oral TKI was often seen as the last chance to survive. 
Many of these patients had recently received bad news, for example that 
surgical treatment was not an option anymore. For some patients starting oral 
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TKI therapy meant that they had moved on from a curative to a chronic, 
palliative treatment and this confronted them with the non-curable and life-
threatening nature of the disease. These patients often reported enduring side 
effects without complaining and reported a low quality of life. They felt a great 
responsibility for their survival. They often did not report side effects to 
healthcare professionals out of the fear for a dose reduction and a concomitant 
decrease in efficacy of the treatment. They often believed that bearing side 
effects would lead to better results, as they assumed the prescribed oral TKI and 
dose would lead to higher survival. This putted them at risk for an adverse drug 
reaction (toxicity), which could, in turn, endanger their chances of prolonging life. 
When patients with a focus on survival accidentally forgot to take their 
medication, they often panicked and feared this would reduce their chance to 
survive.  A focus on survival was frequently present in the initial phase of the 
oral anticancer treatment.  
“The oncologist said that surgery was not an option anymore, that they 
only could give medication. That was terrible for me. The day after, I 
started with that medication. And then I thought: “I have to make sure 
that the tumor will shrink.” This medication must must must work. (…) It’s 
hard because it makes me so sick. (…) Even when side effects are so 
intense, I wait to report them to the hospital until I really can’t hold on 
anymore.”  
When the focus was on quality of life, patients often experimented with their 
medication to make quality of life acceptable: they took drug holidays, reduced 
the dosage or deviated from instructions given by healthcare professionals. 
These adjustments mostly happened on their own initiative and without 
consulting their healthcare professionals. These patients frequently reported 
having limited knowledge about their medication. They often did not know the 
rationale for the instructions that were given to them, for example the reason for 
a 12 hour interval between a first and second oral TKI dose. As a result, they 
sometimes made decisions in handling their oral TKI therapy which could 
endanger the effectiveness of the therapy. These patients often reported not 
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having an open relationship with their healthcare professionals. They sometimes 
felt they were not being heard by healthcare professionals. 
“The doctor didn’t give me much information about the medication.  He 
just said I had to leave 12 hours between the first and the second dose. 
But for me, that’s hard because there are not 12 hours between my 
breakfast and my dinner. I often sleep a little longer. Now there is often 
only seven hours between the two doses. I don’t care. It was only in the 
beginning he gave that instruction and he never brought it up again. I 
think it’s because I see that nothing happens when I don’t leave 12 
hours in between.” 
Patients balancing between survival and quality of life reported a sufficient 
quality of life without deviating from medication instructions provided by 
healthcare professionals. These patients often made some adjustments in 
dealing with their medication based on a sound knowledge and in consultation 
with their healthcare professionals; for example, they took the medication in the 
evening instead of in the morning. They often reported to have a trust based and 
open relationship with healthcare professionals. Within this relationship, they 
often could combine their outlook on life and experiences with the therapy with 
the medical instructions they received from healthcare professionals. Most often 
they reported side effects and other problems more easily, which allowed 
healthcare professionals to manage side effects in a better way. In general, they 
had a good basic knowledge of their medication, allowing them to make 
adequate decisions in dealing with their therapy. They were informed as to why, 
for example, it was important to leave 12 hours between the first and second 
dose for some treatments.  
Focus shifts 
Patients shifted foci over time as a result of events or changes in perception.  
Patients shifted, for example, from a focus on survival to a balance between 
focus on survival and focus on quality of life when they came to accept in some 
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way the palliative (and non-curative) character of their therapy whereby space 
was created for quality of life.  
For some patients experiencing intense and severe side effects and low support 
from healthcare professionals, finding a balance between survival and quality of 
life was often difficult. They shifted from a focus on survival to a focus on quality 
of life, and back. They often endured side effects until they reached their 
physical and mental limit, and then used all kinds of mechanisms to decrease 
side effects as quickly as possible, e.g. by taking drug holidays.  
“I continued to take the oral TKI, but after a while I had no appetite 
anymore, I could not eat and drink anymore, It was terrible. Every 
afternoon I had to lie on my bed because I was running on the end of my 
strength. I had no life anymore. I was completely burned out. And then I 
decided to stop the therapy because It became traumatic.” 
When side effects became less severe, patients often started taking their 
medication again. Restarting was often initiated by (1) hope for a prolonged life 
and sometimes hope of being cured of the cancer, and (2) the fear that they 
would not survive without taking the oral TKI.  
Factors influencing foci in dealing oral TKI therapy 
Several factors influencing the focus in dealing oral TKI therapy were found. A 
selection of important influencing factors is presented below:  side effects, hope, 
anxiety, trust, and feedback mechanisms. This selection of influencing factors 
was made because of their relevancy to the aim of this study and/or because 
they have received little attention in literature. Other influencing factors found in 
this study (social support, medication reminder tools, routine, self-efficacy, and 
perception of the medication properties) are not described in this paper as they 
have already been studied in other adherence research in patients taking OACD 
(Verbrugghe et al., 2013). 
 
 
Chapter 3 
107 
 
Side effects  
Side effects, which can be severe in oral TKI treatment, had a major influence 
on the quality of life of patients. For some patients, life became almost 
unbearable due to the intense side effects.  
“I always have to rub ointment on me. And I have enormous acid reflux. 
And my mucous membranes are affected too. I suffered a lot from that. 
I’ve also been burnt by the oral TKI treatment. On my eyelids, I even had 
second degree burns. It was really heavy. It should diminish, if not, I 
cannot hold on any longer. I really try to endure, but life should still be 
worth living. Right now, the margin is very narrow.” 
On the other hand, some patients could lead a normal life to some extent. Side 
effects and their influence on quality of life were important factors influencing the 
patients’ focus. Avoiding side effects in order to maintain an acceptable quality 
of life was the main reported reason why patients did not adhere to the 
prescribed regimen to which they had committed themselves.  
Influence of side effects 
Oral TKI side effects could suddenly appear and could become more intense. 
This made it often difficult for patients to plan in advance and raised a constant 
fear that side effects could emerge. This fear often affected their quality of life. 
The more side effects, the greater their intensity, and the more unpredictable 
their occurrence, the greater the impact was on their quality of life. This made it 
more difficult for most patients to deal with their oral TKI treatment, and 
increased the risk for non-adherence behavior in patients with a focus on quality 
of life. 
Two perceptions of side effects were reported. Some participants indicated that 
side effects were probably unavoidable. They perceived side effects as a sign 
that the treatment worked. Hence, they were willing to accept them up to a 
certain extent. For others, strong side effects were a sign that the treatment was 
too strong for them. Patients with a focus on survival often endured side effects, 
while patients with a focus on quality of life more often stopped the treatment 
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and took drug holidays until side effects decreased and quality of life was 
acceptable again. Side effects becoming less severe and disappearing to some 
extent, often made it easier to start taking their medication again. Drug holidays 
often became more attractive when side effects decreased quickly.   
Being informed about side effects 
Participants indicated that knowing in advance which side effects would occur 
was reassuring because then they could recognize symptoms as being side 
effects of their therapy. When they experienced side effects, they were 
reassured that nothing else was the matter, such as a progression of their 
disease. Participants reported that they were not always well informed about (1) 
the importance of reporting side effects and (2) the normal course of side effects 
(i.e. the increase or decrease of side effects over time). Some participants 
endured side effects and suffered a low quality of life because they thought that 
side effects would become less severe over time after their body got used to the 
oral TKI. However, this was not always the case. In some participants, oral TKI 
side effects accumulated over time.  
Hope 
Many participants tried to retain hope. For participants, hope seemed to involve 
keeping in mind a positive outcome in an uncertain situation, even if they were 
well informed by healthcare professionals about their medical prognosis. They 
needed hope to: (1) stand the multitude of uncertain situations with which they 
were confronted (e.g. How long will the medication work?, How long will my 
body endure the medication?, How long can I live with the medication?, and 
What are the alternatives if the medication does not work?), and (2) continue 
their therapy while they experienced a low quality of life. The more intense the 
side effects and the lower the quality of life, the more they needed hope to 
continue their therapy.  
To maintain hope, four strategies were reported. The first strategy was creating 
the mental perspective of a medication-free period. Due to the intensity of side-
effects, the experienced quality of life was in great contrast with the quality of life 
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they had before the disease. Small things before the disease, associated with 
normal daily life, were no longer possible due to medication prescriptions (such 
as using alcohol) or side effects (such as working in the garden). Participants 
often felt an intense desire for these ‘unreachable daily life things’. Therefore, 
several participants hoped for a medication-free period without side effects in 
which they could do the things they did before. This perspective gave them 
courage to endure their therapy with often intense side effects.  
“I don’t know how long I have to take this medication. The doctor said 
lifelong, but if my next CT scan is positive, I’ll inquire whether I can stop 
the treatment for one or two months during the summer. Then I could 
enjoy a barbecue and drink a glass of wine. Now, I’m often so tired and 
side effects are so intense. I just want to have a normal life again for a 
while.” 
The second strategy was looking for illustrations of the outcomes participants 
hoped for. Several participants looked e.g. for stories of patients undergoing oral 
TKI therapy for a long time without becoming resistant to the oral TKI or patients 
who had been cured of cancer with oral TKI. Another strategy was expressing 
their belief in scientific progress. Several patients hoped that medication would 
become available that would cure their cancer and that would not be harmful to 
other organs. The last strategy was hoping for a positive outcome. Some 
patients indicated that keeping in mind a positive outcome such as the oral TKI 
being effective or being the exceptional patient who survived  and was cured of 
the cancer gave them courage to endure the therapy or start to take their oral 
TKI again after a drug holiday or after a medication free period. 
Participants were often driven by hope when they started to take their oral TKI 
again after a longer drug holiday. After side effects were mitigated by taking a 
drug holiday, patients regained courage and started to take their oral TKI again.  
When hope was undermined by healthcare professionals who emphasized 
medical reality or negated hopeful reactions, participants often lost their trust in 
these healthcare professionals. By withdrawing their trust, they often decreased 
the importance of what healthcare professionals said. 
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“When I said I felt the medication was working, the doctor said I would 
never be cured again from the cancer. I think that’s a wrong reaction. 
Instead, they should encourage patients. I do not listen anymore to what 
she (the doctor) says. My body tells me that the medication works.” 
Several participants reported they felt discouraged by such reactions from 
healthcare professionals. As a result, some of the participants no longer 
reported side effects and started to experiment with their oral TKI themselves in 
order to improve their quality of life. This increased the risk of non-adherence 
behavior.  
Anxiety 
Many participants experienced anxiety when being treated with oral TKIs. They 
were anxious and uncertain about the future, they often feared that the 
medication would lose its effectiveness and that their body would become 
resistant to the oral TKI. Participants were often aware of the vital role of oral 
TKI intake. Many described taking the treatment as ‘having no choice’. 
Participants described anxiety about dose reductions, the amount of medication, 
and when confronted with other health problems.  
Anxiety about a dose reduction 
Some participants feared that a dose reduction would decrease their survival 
time. As a result, they often did not report side effects. Especially patients with a 
focus on survival held a strong belief that they were ultimately in control of the 
success of the treatment by enduring and often postponed reporting side effects. 
When doses were reduced as a result of reporting side effects, some 
participants experienced this as a personal failure: they failed to endure the side 
effects.  
“The doctor questioned my quality of life because I’m so sick from this 
medication. She wanted to give me a lower dose: 25mg instead of 
37.5mg, but I refused. I’ll hold on. It’s the only option if I want to have a 
chance. It’s very very hard, but I have to go on, I have to go on. I just 
don’t have any other choice.” 
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Some healthcare professionals communicated to patients that the oral TKI was 
the last treatment option. Furthermore they sometimes communicated that 
further treatment with the oral TKI would only be considered if the oral TKI 
showed significant positive results within a certain period of time, as the 
treatment was very costly (to society). This often made patients fearful and 
reluctant to report side effects, especially patients with a focus on survival.  
Anxiety about the amount of medication 
Beside the oral TKI, patients often had to take other medications to treat side-
effects or comorbidities. They often feared that the amount and combination of 
different medications would affect their body. Several patients worried about this, 
which made the treatment even more burdensome for them. 
“It’s hard, I have to take (counts aloud) 3, 6, 11 pills. Eleven pills, that’s 
almost a meal. I never had to take any medication in the past and now 
suddenly I have to take 11 pills and I was not a pill taker. I think it will 
affect my stomach because I’m not used to taking so many pills. This 
really worries me.” 
 Anxiety when confronted with other health problems 
Several participants indicated that they feared that their body could not bear side 
effects when they were confronted with other health problems (for instance flu). 
Due to the additional health problem, patients often felt exhausted and no longer 
had the capacity to endure side effects. As a result, some patients stopped 
(temporarily) taking the oral TKI.  
"When you feel so sick and miserable [due to the combination of the 
side effects from the oral TKI treatment and flu], you just can’t think 
about tomorrow. Then you just want the misery to end. " 
Trust 
A relationship based on trust with healthcare professionals increased the 
likelihood of finding a balance between survival and quality of life. Such a 
relationship made most patients feel more comfortable about reporting side 
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effects and able to be honest about their quality of life and about the difficulties 
they experienced in dealing with their oral TKI. Within a relationship of trust, 
most patients were confident that the best was being done for them. They often 
did not feel they were undermining their chances of survival by being open with 
healthcare professionals.  
Participants reported a relationship based on trust as a result of a supportive 
approach by healthcare professionals. This approach gave them the feeling they 
were treated as a person and not only as a patient. They felt supported and 
were reassured that the best was being done for them.  
"If you have any questions, they are there. You never feel alone. I think 
that's very important to many patients. You do not have the feeling to be 
just one of many and if you have any questions, you also get the chance 
to talk about it." 
From the patients’ perspective, elements that contributed to a trusting and 
supportive relationship were: (1) openness, (2) taking time, (3) an informative 
approach, (4) support in treating side effects, (5) accessibility and continuous 
availability of healthcare professionals, (6) seeing patients on a regular basis, 
and (7) signs of a good multidisciplinary collaboration between healthcare 
professionals.  
Feedback mechanisms 
Feedback mechanisms from medication, healthcare professionals, and follow-up 
examinations played an important role in adherence behavior.  
Some participants expected feedback from their body by a physical reaction 
when they were non-adherent to their treatment regimen. Some participants 
expected that ‘something’ would happen, for instance that side effects would 
become more severe and intense. When physical reactions did not clearly occur, 
this risk for non-adherence behavior in the future increased.  
 “The first time I forgot to take the medication, I thought something was 
going to happen such as a reaction in my blood, or side effects that 
would increase. But that was not so. Nothing happened.” 
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Participants did not always receive feedback on their behavior from healthcare 
professionals. When participants forgot to take their oral TKI, and reported it to 
healthcare professionals, they received the feedback that forgetting one time is 
not harmful. This often reinforced non-adherence behavior. They learned that 
occasionally forgetting to take the oral TKI was not that bad. When they forgot to 
take the oral TKI a second time, they often did not report it anymore to 
healthcare professionals. 
Blood tests and scans provided participants with feedback on their behavior. At 
that point, they received feedback about the progression of the disease and the 
impact of the medication on the disease. Positive scan results were often a 
motivation to continue therapy. Some participants with a focus on survival saw 
the positive results as a reward for their efforts: enduring the side effects led to 
the results they hoped for.  
 
DISCUSSION 
This study shows that in dealing with oral TKI therapy, three foci can be defined: 
a focus on survival, a focus on quality of life, and a balance between survival 
and quality of life. The foci (theoretical framework) developed in this study help 
to explain how non-adherence behavior arises, which increases the 
understanding of the phenomenon of non-adherence to oral TKIs. A complex 
and interrelated set of factors was found to influence the patients’ focus. 
Researching processes and factors influencing (non-)adherence by means of 
qualitative research instead of quantitative research made it possible to explain 
how e.g. side effects, hope, and anxiety contribute to adherence or non-
adherence behavior in these patients. The influence of hope, anxiety, trust, and 
feedback mechanisms on adherence behavior have received little attention in 
literature until now. 
Treatment related side effects were found to be a crucial factor influencing  
(non-)adherence in patients taking oral TKIs in this study. This corroborates 
other research findings on factors associated with non-adherence to OACD 
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(Grunfeld et al., 2005; Kirk and Hudis, 2008; Regnier Denois et al., 2010; 
Eliasson et al., 2011). 
Patients focusing on survival often do not report side effects, fearing a dose 
reduction and a decrease in efficacy of the treatment. This has been reported 
previously (Regnier Denois et al., 2010). Based on in-depth analyses of our 
interviews, three interrelated mechanisms could explain this finding. First, some 
patients believe that bearing the side effects will lead to better results, as they 
assume the prescribed oral TKI and dose will lead to higher survival rates. 
Second, some patients might have a high internal locus of control (i.e. the belief 
to be personally responsible for the own health) (Wallston et al., 1978).  They act 
as if they believe they are ultimately in control of the success of the treatment by 
enduring and often not reporting side effects. Third, some patients are not 
adequately informed about (1) the course of side effects (i.e. the increase or 
decrease of side effects over time), and (2) the importance of reporting side 
effects.  
Hope was found to be an important influencing factor in this study. This confirms 
other studies’ findings in cancer patients (McMillan and Weitzer, 1998; Thorne et 
al., 2008). Hope is crucial for patients to cope with their disease and treatment. 
The meaning of hope for patients often contrasts with the meaning of hope for 
healthcare professionals. For patients, hope is a mechanism to stand the 
disease and the therapy and is a necessity for living (Thorne et al., 2007). For 
healthcare professionals, hope is often the objective chance for a positive 
outcome (such as survival rates) (Thorne et al., 2006). Healthcare professionals 
can undermine hope by emphasizing medical reality, for example by quoting 
statistical information on prognosis (Thorne et al., 2006). Undermined hope is 
found to be associated with emotional distress, problematic coping or poor 
disease management (Thorne et al., 2007). Undermined hope leads to a 
reduced capacity to continue to engage with life (Elliot and Olver, 2006; Kim et 
al., 2006). Our study adds that undermining hope may affect the relationship 
between healthcare professionals and patients. As a result, patients may no 
longer report side effects and may start to experiment with their oral TKI without 
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consulting healthcare professionals. Consequently, the choices patients make 
are not always based on sound knowledge and could endanger the 
effectiveness of the therapy, the quality of life, and could increase the risk for 
toxicity. 
Implications for practice and future research 
The results of this study could help healthcare professionals to deal in a more 
nuanced way with the non-adherence behavior of patients taking oral TKIs. 
Patients could have good reasons to be non-adherent to the oral TKI therapy. 
Healthcare professionals should be aware that an oral TKI regimen is stressful 
(severity, intensity and unpredictable character of side effects) and strongly 
impacts quality of life, as previously reported by Philips and colleagues (2013).  
Healthcare professionals should take care that adherence does not  become the 
sole focus, but should also take into account the patients’ perspectives of quality 
of life, since a balance between quality of life and survival makes the therapy 
more feasible for patients. A patient’s motivation and energy to endure therapy 
may be reduced by the demands of the disease and therapy, referred to as ego 
depletion (Baumeister et al., 1998; Baumeister, 2003). In patients experiencing 
severe side effects, healthcare professionals should be aware that each new 
demand may lead to ego depletion, which can result in decreased quality of life 
and a decreased adherence to medical recommendations (Solberg Nes et al., 
2013). 
Conditions should be established by which patients get maximum opportunity to 
establish a balance between survival and quality of life. An open climate and a 
trust based relationship should be created so that patients can report side 
effects without the fear of undermining their chance of survival.  Reporting side 
effects enables healthcare professionals to support patients in dealing with side 
effects or changing a dosage or medication in order to make quality of life as 
acceptable as possible. The association between trust and adherence behavior 
has previously been studied in other pathologies (Van Hecke et al., 2011). 
Based on the results of our study, a relationship based on trust could be 
established by (1) not undermining patients’ hope, (2) interpersonal competence 
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(active listening, caring, empathy, providing information and answering 
questions), (3) regular contacts, (4) accessibility of healthcare professionals (e.g. 
by telephone permanence), and (5) sufficient time during appointments to listen 
to the patients’ experience of the treatment and the disease. Not undermining 
patients’ hope and interpersonal competence were also found to contribute to a 
relationship based on trust in other studies (Benzein and Saveman, 1998; 
Mechanic and Meyer, 2000). However, our study adds to the literature how 
undermining hope could withdraw trust and may, in turn, lead to non-adherence 
behavior.  
Furthermore, patients should be guided in making adequate decisions regarding 
their therapy by: (1) patient-centered education about (the development of) side-
effects to set realistic expectations, (2) informing patients as to how medication 
works and why it is important to follow instructions, and (3) discussing the 
possible ways of incorporating the regimen adequately into daily life.  
Methodological considerations and limitations  
Despite the heterogeneity of the sample (i.e. different types of cancer and 
different oral TKIs), data saturation was reached for the study population. The 
reported findings apply to blood cancers as well as solid tumors and their 
treatments with different oral TKIs. 
The study was conducted in Belgium so the results of this study should be 
interpreted in the context of Western European healthcare systems. Caution 
should be used when generalizing the findings to other countries as cultural 
differences may influence illness experience and healthcare practice (Kleinman 
and Benson, 2006). 
In 9 of the 30 interviews, a third person was present (mostly the patient’s 
partner) for all or part of the interview at the request of the patient. In some 
interviews, the third person answered a part of the questions. The perspective of 
the third person however, may be different from the patient’s perspective. 
Despite the interview techniques employed to create openness, the patients’ 
openness may have been affected by the presence of a family member in some 
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of the interviews. Patients may have avoided a discussion of fears and concerns 
in order to protect their family members (Leydon et al., 2000; Bachner and 
Carmel, 2009). 
Despite emphasizing anonymity before the start of each interview and the 
encouragement to be open, it was still possible that some participants did not felt 
comfortable talking openly about non-adherence. Talking about non-adherence 
could have created feelings of guilt or patients could have been afraid to be 
stigmatized as a non-adherent patient. To promote a climate of comfort to talk 
about (non-)adherence, special attention was paid to the use of non-threatening 
and non-judgmental questions such as: “For some patients, it is hard to take 
their medication as prescribed because of various reasons. How is that for 
you?”. 
 
CONCLUSION 
This qualitative study gives insight into the processes and factors influencing 
(non-)adherence in patients taking oral TKIs and their interrelatedness. Three 
foci, determined by a set of influencing factors on adherence in patients taking 
oral TKIs is presented. A focus on survival, a focus on quality of life, and a 
balance between survival and quality of life were found. Treatment related side 
effects, hope, anxiety, trust, and feedback mechanisms were found to be major 
influencing factors. The results of this study may help healthcare professionals 
to understand why patients taking oral TKIs do not always adhere to their 
therapy and aid them in developing interventions to support these patients in 
coming to a balance between survival and quality of life. 
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Table 1: Demographic-, Disease-, and Treatment-related Characteristics of the 
Participants 
    Mean (SD) Range 
Age 
   
 
Men (n=18) 58.1 (12.2) 36-79 
 
Women (n=12) 60.5 (13.0) 42-88 
 
Total 59.1 (12.3) 36-88 
Years since diagnosis 
 
3.7y (1.9y) 4m – 8.8y 
    n   
Current social situation 
   
 
Living with a partner 21 
 
 
Living alone 9 
 Children 
   
 
Yes 25 
 
 
No 5 
 Number of OACD since start oral therapy 
  
 
1 21 
 
 
2 6 
 
 
3 2 
 
 
≥4 1 
 Diagnosis 
   
 
RCCa 12 
 
 
CMLb 8 
 
 
Breast cancer 4 
 
 
Skin cancer 3 
 
 
GISTc 1 
 
 
HCCd 1 
   Non-small cell lung cancer 1   
aRenal Cell Cancer, bChronic Myeloid Leukemia, cGastrointestinal Stromal Tumour, dHepatocellular 
Carcinoma 
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TABLE 2: Topic List 
______________________________ 
Patients’ attitude towards the medication regimen 
 Perceptions about the medication 
 Worries about the medication 
 Trust and belief 
 Expectations 
 Barriers and facilitators of medication adherence  
Principles of self-management 
 Fit medication into daily life 
 Adherence 
 Coping with the therapy and its consequences 
Information  
 Information from healthcare professionals 
 Information seeking 
 Understanding and evaluation of received information 
Social support 
Side effects 
______________________________ 
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Figure. Foci in dealing with oral TKI therapy 
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FACTORS INFLUENCING THE PROCESS OF MEDICATION 
(NON-)ADHERENCE AND (NON-)PERSISTENCE IN BREAST 
CANCER PATIENTS WITH ADJUVANT ANTIHORMONAL 
THERAPY: A QUALITATIVE STUDY 
 
 
 
 
 
 
 
 
 
 
Based on the article of Verbrugghe M, Verhaeghe S, Decoene E, De Baere S, 
Vandendorpe B, Van Hecke A. (2015). Factors influencing the process of 
medication (non-)adherence and (non-)persistence in breast cancer patients 
with adjuvant antihormonal therapy: a qualitative study. Accepted for publication 
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ABSTRACT 
Non-adherence and non-persistence in breast cancer patients taking 
antihormonal therapy is common. However, the complex patterns and dynamics 
of adherence and persistence are still not fully understood. This study aims to 
give insight into the process of (non-)adherence and (non-)persistence by 
researching influencing factors and their interrelatedness in breast cancer 
patients taking antihormonal therapy by means of a qualitative study with semi-
structured interviews. The sample consisted of 31 breast cancer patients treated 
with antihormonal therapy. Purposive and theoretical sampling and the constant 
comparison method based on a grounded theory approach were used. 
Expectations regarding the impact of antihormonal therapy, social support from 
family and friends, and recognition from healthcare professionals were found to 
influence the process of non-adherence and non-persistence. The results of this 
study can help healthcare professionals understand why breast cancer patients 
taking antihormonal therapy do not always adhere to or persist in taking the 
therapy and may facilitate patient-tailored interventions. 
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INTRODUCTION 
Breast cancer is the most prevalent cancer in women (Brennan and Houssami, 
2011). In approximately 75%, the cancer is oestrogen-receptor positive 
(Anderson, 2002). Most of the breast cancer patients with oestrogen-receptor 
positive breast cancer cells receive adjuvant antihormonal therapy (AHT) to 
reduce the risk of recurrence (Early Breast Cancer Trialists’ Collaborative Group, 
2011).  Two main types of AHT are currently used in the treatment of breast 
cancer: aromatase inhibitors and selective estrogen receptor modulators 
(SERMs). A treatment regimen of at least five years with tamoxifen, a SERM, is 
the most commonly prescribed AHT for patients with oestrogen-receptor positive 
breast cancer. A five year regimen with adjuvant tamoxifen has been shown to 
reduce the recurrence risk by 46% and the breast cancer mortality risk by 26% 
(Early Breast Cancer Trialists’ Collaborative Group, 1998). 
For optimal treatment effectiveness, adherence to AHT and persistence are 
important (Early Breast Cancer Trialists’ Collaborative Group, 1992). Adherence 
is the extent to which patients follow the instructions on taking their medication 
(Osterberg and Blaschke, 2005). Optimal persistence is the time period during 
which patients continue to take their medication as prescribed (Ruddy et al., 
2009). In literature, early discontinuation is often used as a synonym for non-
persistence.  Non-adherence to AHT ranges from 11 to 60% (Doggrell, 2011; 
Fontein et al., 2012; Güth et al., 2012), depending on (1) the tool used to 
measure non-adherence, and (2) the definition of non-adherence (Güth et al., 
2012). Non-persistence rates for the five-year course of AHT ranges from 31 to 
34% (Lash et al., 2006; Güth et al., 2008; Hershman et al., 2010). Non-
adherence and non-persistence rates increase with time treated with AHT 
(Barron et al., 2007; Fontein et al., 2012). In a study by Herk-Sukel et al. (2010), 
the cumulative percentage of patients discontinuing tamoxifen was 17% in the 
first year, 30% in the second year, 45% in the third year, 50% in the fourth year 
and 60% in the fifth and last year.  
Factors associated with non-adherence and non-persistence in breast cancer 
patients taking AHT are complex and interrelated (Ruddy et al., 2009; Verma et 
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al., 2011; Verbrugghe et al., 2013). Treatment related side effects, longer 
duration of therapy, and younger- and older age are found to be predominant 
factors associated with non-adherence in breast cancer patients taking AHT 
(Verbrugghe et al., 2013). In a study by Grunfeld et al. (2005), 46% of the non-
adherent patients taking AHT reported side effects as the primary reasons for 
non-adherence to tamoxifen. The main side effects reported in that study were 
hot flashes, cognitive disfunctions, night sweats, emotional problems, sleep 
problems, weight gain, and loss of libido. Predominant factors associated with 
non-persistence in breast cancer patients taking AHT are older age, younger 
age, and treatment-related side effects (Verbrugghe et al., 2013).  
Extensive quantitative research has been conducted to explore factors 
associated with non-adherence and non-persistence in breast cancer patients 
taking AHT (Verbrugghe et al., 2013). However, the complex patterns and 
dynamics of (non-)adherence and (non-)persistence in breast cancer patients 
taking AHT are still not fully understood. A qualitative study can give us insight 
into the process of (non-)adherence and (non-)persistence to AHT as qualitative 
research is more appropriate for the study of experiences in the context of an 
experiential process (Morse and Field, 1996). Furthermore, qualitative research 
can show us how to understand the findings of quantitative research by 
providing insight into the way several factors found to be associated with  
(non-)adherence and (non-)persistence contribute to the process of  
(non-)adherence and (non-)persistence. To our knowledge, only one qualitative 
study on (non-)adherence with AHT has been conducted, focusing exclusively 
on (non-)adherence in breast cancer patients taking tamoxifen (Pellegrini et al., 
2010). However, in the study by Pellegrini et al. (2010), the focus was narrowed 
to the exploration of the relation between adherence and perceptions of the 
treatment and experienced side effects. 
This study aims to give insight into the process of (non-)adherence and  
(non-)persistence by researching influencing factors and their interrelatedness in 
breast cancer patients taking AHT (both SERMs and aromatase inhibitors). 
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METHODS 
A qualitative study based on principals of grounded theory, e.g. purposive and 
theoretical sampling and the constant comparison method (Glaser and Strauss, 
1967) was used. 
Setting and sample 
In total, thirty-one patients were recruited in a university hospital in Belgium. 
Inclusion criteria were: diagnosed with breast cancer within the last six years, 
receiving AHT, ≥ 18 years old, and Dutch speaking.  
In the initial phase of data collection, participants with different characteristics 
were recruited, with the aim of broadly exploring the experience of breast cancer 
patients treated with AHT. Purposive sampling was used to assure the 
representativeness of participants who had been on AHT for different periods of 
time. As soon as influencing factors of (non-)adherence and (non-)persistence to 
AHT were found from the initial data, theoretical sampling was used in order to 
elaborate, refine and test the discovered influencing factors and their 
interrelatedness (Coyne, 1997). Patients with suspected non-adherence to the 
AHT, those in a further stage of the AHT treatment, and those who had stopped 
the treatment, were recruited. The new data furthered insight into the process of  
(non-)adherence and (non-)persistence. 
Data collection 
A team consisting of a clinical nurse specialist and breast cancer nurses working 
in the university breast clinic contacted potential participants and informed them 
about the study. If patients wanted to take part in the study, a researcher 
contacted the patients to give them further information and to make an 
appointment for the interview. 
Semi-structured interviews were held at the place of preference of the 
participants. The interview topics included the care provided, the received 
information about AHT, the use and perception of AHT, adherence, social 
support, and patients’ needs. The interviews started with the open question: 
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“How have you experienced the antihormonal therapy so far?”, to encourage the 
participants to tell their story in their own words. Demographic data were 
collected at the end in order not to interrupt the narrative flow of the interview. 
Data collection was part of a cyclic process of data collection and analysis. As 
the process of data collection and analysis advanced, the topic list was adjusted 
and new topics were added to the topic list. New topics were: perceptions on 
finishing the five year AHT, coping with side effects of the AHT in daily life, 
(evolution of) social support, the influence of feeling supported by healthcare 
workers, and the influence of information on and expectations about the impact 
of the AHT. As the insight into the process of (non-)adherence to AHT and  
(non-)persistence progressed, a more structured interview style was used. 
Interviews were held between November 2011 and May 2014. All the interviews 
were conducted by two researchers. Every interview was audio taped, 
transcribed verbatim, and verified for transcription accuracy. After the interviews, 
memos on the context and reflections on the interpretation of themes were 
made. The interviews took on average 44 minutes (range 14-125).  
Data analysis 
The interviews were read and re-read in order to become familiar with the data. 
The factors influencing (non-)adherence to AHT and (non-)persistence were 
developed based on thorough discussion among five researchers. Every new 
insight that emerged from the group discussion was compared to the data. The 
analytical process revealed new topics to be included in the following interviews. 
Data were entered into NVivo 10 (QRS International Pty. Ltd.). A code tree was 
developed. After 9 interviews, factors were distilled out of the data. After specific 
recruitment (e.g. patients who had stopped AHT) and a thorough discussion, we 
were able to see how the factors were related and how they influenced  
(non-)adherence behavior and (non-)persistence. All the transcripts were reread 
with the identified factors to trace how they were represented in the interviews.  
Data collection and analysis took place iteratively. Data were analyzed based on 
the constant comparison analyzing aspect of grounded theory (Boeije, 2002) 
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until theoretical saturation was achieved. This means that new interviews no 
longer furthered the refinement of the theoretical framework (the process of 
(non-)adherence and (non-)persistence). 
Validity 
To enhance the validity of the interpretations, researcher triangulation was used 
in all the phases of the study. To improve the quality of data collection, two 
supervisors (A.V.H. & E.D.) gave feedback on the interview style, the codes and 
data analysis. Additionally, an expert in qualitative research (S.V.) who was not 
previously involved in the data analysis, verified the data analysis by reading 
several interviews and discussing the analyses on two occasions at the end of 
the study. 
Ethical considerations 
The study was approved by the Ethical Review Committee of the participating 
hospital. All participants were given written and verbal information about the 
study and gave informed consent to participate. Identifiable information was 
removed from the transcripts. Audio files were deleted at the end of the study.    
 
RESULTS 
First demographic data will be presented. Second, a selection of the most 
important factors influencing the process of (non-)adherence and  
(non-)persistence will be presented (experiences with the previous trajectory, 
expectations regarding the impact of AHT, impact of the AHT and the 
experience of the follow-up period, perceptions of AHT, social support, and 
support by healthcare professionals). Third, the way influencing factors lead to 
(non-)adherence or (non-)persistence, will be presented (theoretical framework). 
The second part is mainly the result of purposive sampling and analysis aiming 
at the broad exploration of the experiences of breast cancer patients treated with 
AHT. The third part is mainly the result of theoretical sampling and analysis 
aiming to get insight into the interrelatedness of the influencing factors 
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(experiences) until theoretical saturation was achieved. In the third part, the 
findings presented in part two are combined and presented in a theoretical 
framework: the process of (non-)adherence and (non-)persistence.   
Demographic data 
Table 1 shows the demographic and treatment-related characteristics of 
participants. Most participants were > 50 years old (n=21), married (n=20) with 
children (n=23). Almost all participants previously received surgery (n=30), and 
received chemotherapy (n=22) and/or radiotherapy (n=23). Fourteen participants 
were treated with an aromatase inhibitor, while 17 participants were treated with 
tamoxifen. The time participants were on AHT was equally distributed over the 
five years of AHT treatment. Two participants were interviewed after the five 
year treatment period had ended.  
Factors influencing the process of (non-)adherence and (non-)persistence  
Experience with the previous trajectory: the context for antihormonal therapy 
The way participants experienced the previous trajectory (from cancer diagnosis 
until the start of the AHT), influenced the way they gave meaning to the AHT.  
Participants often compare the AHT with previous treatments (chemotherapy, 
radiotherapy, surgery, targeted therapy). Previous treatment was perceived as 
very intense, both physically and psychologically.  
During previous trajectory, they generally felt well supported and recognized by 
family, friends, and healthcare professionals. Most participants felt to be 
intensively managed and well informed by healthcare professionals about the 
treatment and the impact thereof. This often made participants less anxious, as 
it helped them to prepare for what to expect in the near future.  
Expectations regarding the impact of antihormonal therapy 
Expectations regarding the impact of the AHT are strongly influenced by the 
information given to the participants by healthcare professionals (mostly 
physicians). Being poorly informed about the possible impact of the AHT 
strengthens the expectation that the AHT is not a difficult regimen to follow. 
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Patients may also expect that the impact of the AHT will be limited because they 
believe that AHT could not be any worse than the previous treatment. They 
expect to be able to resume their normal lives after chemotherapy or radiation 
therapy ended.  Participants often attached most importance to the information 
they received from the physician, especially when they felt they had been well 
informed and supported during the previous treatment. 
“The physician only told me I had to take the AHT medication and that I 
didn't have any other choice than taking the AHT. She didn’t say much 
about side effects. She said that side effects were different for every 
person and that I would find out.” 
Impact of the antihormonal therapy and the experience of the follow-up period 
How the AHT affects someone’s life depends on the seriousness of side effects, 
the psychological and social consequences of these side effects, and on the 
contrast between life with AHT and life before the disease.  
Side effects such as fatigue impede participants in performing their normal daily 
activities. Physical changes such as weight gain and vaginal dryness constantly 
confront participants with the fact that they are not the same person anymore, 
and perhaps will never be again.  
“After the previous treatments, I wanted to put it out of my head and go 
on with my life. But when I buy new clothes, I have to buy a bigger size, 
which confronts me with that goddamn disease. I want to leave this 
chapter behind and be like before. I do not think I will ever be the same 
again, and that is very hard to accept.” 
The impact of side effects also depends on the phase of life. For premenopausal 
women, taking AHT means they almost immediately go into menopause, while 
this process otherwise takes years. This makes the contrast with the past 
suddenly very large and irreversible. It often entails a further perceived loss of 
their femininity (after e.g. mastectomy) over which they have no control or 
influence.  As a result of the sudden, irreversible and uncontrollable change, 
participants feel alienated from themselves and their future.  
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Participants for whom the impact of the AHT is high, often feel compromised in 
their roles as mother, partner, housewife, and friend. Due to the side effects they 
can no longer fulfill these roles as before. Because of fatigue, for example, 
participants are not able to see friends the way they were used to, or they are 
not able to do as much housework. Faced with side effects such as vaginal 
dryness and a strong reduction of libido, participants have less sexual 
intercourse with their partner, which can make them feel inferior as a woman 
and as a partner. The discrepancy between the participants’ desire and their 
abilities makes them feel frustrated, helpless and worthless. In the interviews, 
the participants suggest feeling inadequate and guilty towards their partner, 
family and friends. In sum, they feel permanently a cancer patient. Because of 
feelings of inferiority and shame, some participants hardly go outside and isolate 
themselves.  
 “In the beginning, it was very difficult for me that my husband had to 
clean the house and I could only look on. I sat there crying because I 
like to clean the house and I could do nothing.” 
“For him, I regret. I do not feel the desire to have sex anymore. That is 
over. And then I think: “He is normal”. I do not feel normal anymore. I do 
not feel like a woman anymore.” 
In the follow-up period, participants are anxious that the breast cancer will recur. 
This anxiety makes them hyper alert to bodily sensations. They feel as if their 
body has let them down, which makes it difficult for them to normalize bodily 
sensations. This increases the need for a framework in which they can check the 
normality of bodily sensations and in which they can find reassurance. 
“I have lost the ignorance of childhood. When I become aware of a 
bodily sensation, I always think it is cancer. The least thing I become 
aware of, I think it’s a tumor.” 
Perceptions of the antihormonal therapy 
Perceptions of the AHT are closely related to the impact of the AHT. Perceptions 
of the AHT treatment like ‘AHT is just taking a pill’ or ‘AHT is insignificant 
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compared to previous treatment’ start to change as soon as they are confronted 
with side effects of the AHT. When participants experience the impact of AHT 
physically, mentally, and in relation to others, they are forced to adjust their 
perceptions of the AHT.  
Taking the pills reminds participants that the cancer fight is not over yet. Even 
participants who experienced fewer side effects and who return to their ‘normal 
life’, are reminded by the daily intake that cancer is an unfinished chapter.  
Further, as the AHT should be taken for at least five years, the end of the 
treatment seems far away for patients, in contrast with the previous treatment. In 
the participant’s experience, this is not just taking a pill but a five-year cure for 
cancer. 
“Everyone acts like the treatment is over. It does not feel like the 
treatment is over. As long as I have to take this medication, I am not like 
before.” 
Taking AHT gives participants the feeling that they have extra protection against 
a recurrence of breast cancer. This makes them feel they have control over their 
health. The perception of protection and control is more pronounced in 
participants experiencing a low impact of side effects. For them, the benefits of 
the therapy (protection against recurrence and feeling of a sense of control) 
exceed the harms (moderate side effects, confrontation with cancer). It makes 
them feel safe as long as they take their AHT medication. These participants are 
often grateful that medication exists that helps them to protect against 
recurrence.  For participants not experiencing many side effects, it is more 
difficult when the end of the therapy approaches. They are anxious about 
recurrence when the protection of the AHT stops, which makes them feel they 
are losing control.  
“The AHT is a protection against cancer. I think it will be hard for me the 
day I have to stop the medication. Suppose I relapse when I am no 
longer taking that medication. Now the medication gives me the feeling I 
am protected against recurrence.” 
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Taking the AHT is perceived as compulsory; the patient has no choice in the 
matter. This perception is more pronounced in participants for whom the impact 
of the AHT is high. They take the AHT medication because they feel responsible 
towards themselves, their family and friends to take care of their health. Not 
taking the medication as prescribed could result in feelings of guilt if they were to 
relapse. Also out of respect for the expertise of the physician who prescribed the 
AHT, participants feel as if they have no other choice than to take the AHT. The 
fact that AHT makes relapse less likely makes it difficult to downplay the 
importance of the AHT.  
“I know I have no other choice than taking the AHT medication. It 
protects me against cancer and we can be reasonably sure that there 
will be no relapse if I take this medication for five years. I have to 
continue now because there is always a little voice that says: “You have 
had cancer.” 
Social support 
Social support is about an understanding attitude by family and friends towards 
participants for the impact they experience. A distinction is made between the 
social support participants receive from family and friends, and social support 
from peers. 
Social support from family and friends 
Family and friends are often the main sources of social support. Social support 
helps participants deal with the difficulties they encounter and makes them feel 
less alone. 
For participants experiencing little social support from family, it is harder. They 
often feel they are not understood and bother others when they vent about their 
difficulties and concerns. Some participants mention that it seems like their 
partner and/or children are acting as if nothing is wrong during the phase of 
AHT. Participants have the feeling that their family has the idea that the AHT is 
something ordinary, which makes participants feel forced to resume ‘normal life’.  
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“Everyone seems to think that, in the end, I've gotten off rather easy: 
"You've only got one pill left to take, no more chemotherapy, no more 
radiotherapy. The worst is behind you.". It's all minimized. They consider 
me to have had only half, or even quarter of a cancer. I have some 
issues with this. I did have the side-effects of the AHT. I felt impaired in 
my femininity. The fact that people then minimized it all, that was the 
most difficult to deal with.” 
Others’ expectations that one can resume ‘normal life’, makes it difficult for 
participants to talk about their problems. As a result, participants often remain 
silent about the way they really feel. In this way they try to avoid the 
incomprehension that disappoints them and makes them feel alone.  Some 
participants hardly go outside in order to avoid confrontation with others (and 
incomprehension) as much as possible.  
 “You always have the same complaints and you always have to repeat 
them, but you can’t do this at home. When you always repeat the same 
complaints to your husband like: “I have got this again, or that again”, 
after a while they say: “Can you ever stop complaining?” or “God, you 
are a selfish person.” The children would say: “You always have to 
complain and whine.”. I really don’t do that anymore, I do not talk about it 
anymore.” 
Social support from peers 
Peers are considered as equals and the only ones who can really understand 
participants as they have been through similar experiences. With peers, 
participants feel understood and supported. Sharing with peers makes them feel 
normal and not exceptional. They look for peers with similar bodily sensations 
and experiences. Participants also find reassurance regarding the cause of a 
bodily sensation by exchanging experiences about side effects. When 
participants identify with peers however, it is very confrontational if a peer suffers 
a relapse. As a result, the fear of being faced with bad news themselves often 
increases.   
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Support by healthcare professionals 
The need to be reassured 
Participants experiencing physical symptoms are often worried about the source 
of these symptoms (cfr. Impact of antihormonal therapy). They are anxious and 
look for reassurance that the symptoms are side effects from the AHT and not 
signs of a relapse. The need to be reassured is especially high for participants 
who were not well informed in advance about the possible side effects of the 
AHT. Participants expect that physicians will discuss in detail the symptoms they 
may experience and take time to listen to them, support them, and help them to 
deal with the impact of the AHT. Participants experiencing that that healthcare 
professionals ignore or skim over the difficulties they mention (e.g. by saying 
that they need to learn to live with side effects), makes them even more worried 
and anxious about the origin of the experienced bodily sensations. Participants 
often start to doubt themselves, wondering whether they are just imagining side 
effects, and they start to feel like they are being particularly bothersome as a 
result of not feeling understood. Consequently, participants often stop sharing 
their experiences during follow-up period and stop reporting side effects.  
As a result of experiencing not getting satisfactory answers from healthcare 
professionals, they often start their own search for answers and ways to handle 
their side effects. This is often a lonely search, looking for answers and 
reassurance by reading brochures, looking on the internet and talking to peers.  
“I read the patient information leaflet and look for testimonials on the 
internet from women who have the same side effects as I have. When I 
find an answer, I feel reassured. I regret I do not find reassurance and 
answers with my physician.” 
The need to be recognized 
Participants need to be recognized for the difficulties they experience. Feeling 
recognized is about an understanding attitude from healthcare professionals, by 
which the patient feels heard. Participants report not feeling recognized when 
follow-up examinations feel rushed, when side effects are minimized or brushed 
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aside, or when self-discovered solutions to deal with side effects are not taken 
seriously. As a result of not feeling recognized, they become hurt, disappointed 
and angry because they feel misunderstood. To avoid the confrontation with 
disbelief and incomprehension, they often do not report their difficulties 
anymore, which places them in a lonely position. 
 “When I mentioned side effects I got the reaction: “You have to accept 
you are getting older.” At that point I disconnected myself from the 
conversation; there was no longer any point in talking to this person. I 
was furious, but you can’t do anything with that furiousness, and I didn’t 
want to do anything with it anymore… At that moment you collapse and 
you think: “It doesn’t make sense anymore to say anything”.  
“I would like to say to the physicians who work by appointment, to take a 
little more time and to listen a little better. I had the feeling that I could 
not be outside fast enough. I was not dressed yet and he was already 
writing a prescription. That hurts.” 
Feeling recognized is also about being valued as an individual by the physician. 
Participants feel a human approach from healthcare professionals when 
attention is paid to non-somatic issues and also when physicians can admit that 
for certain problems there is no direct solutions. Such a relationship is 
experienced as respectful, equal and non-intimidating. The feeling of being 
approached as a human being strengthens the confidence in healthcare workers 
and gives participants the courage to continue the therapy. 
“It's not about the almighty physician, but about admitting that they do 
not know everything. And that physician admitted it and then you feel 
treated in a human way and then that’s ok for me. That is all I need in 
order to continue, then I can be much more accepting.” 
The process of (non-)adherence and (non-)persistence 
Figure 1 (theoretical framework: process of (non-)adherence and  
(non-)persistence) shows how factors contribute to (non-)adherence and  
(non-)persistence/early discontinuation. The term ‘process’ was chosen to 
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describe the interrelatedness of experiences over time leading to non-adherence 
or non-persistence/early discontinuation. 
A distinction is made between participants experiencing a low impact and a high 
impact of the AHT on their lives. The impact is the result of side effects, the 
psychological and social consequences of side effects, and the contrast with life 
before the disease.  
Participants experiencing a low impact  
Participants experiencing moderate or acceptable side effects and for whom the 
contrast with life before the disease is limited, do not need to adjust their 
perceptions of the impact of AHT because it is often close to their expectations. 
In general, these participants attach less importance to the fact they were not 
well informed about side effects. For them, following the prescribed therapy is 
often self-evident because the benefits (protection against recurrence and the 
feeling of a sense of control) exceed the harms. 
Participants experiencing a high impact  
Participants experiencing a high impact of the AHT, the weight of the therapy is 
determined by a balance between the burden of the AHT and the participants’ 
capacity to deal with this burden. When expectations concerning the impact 
contrast with the actual impact and when patients do not feel recognized by 
healthcare professionals, the burden is heavier.  
Participants for whom the impact is high and who are not informed in advance 
about the possible impact of the AHT, have a hard time when faced with its 
impact. They experience side effects of the AHT they did not expect and notice 
that the contrast with life before the disease remains or even increases. 
Because they did not expect the impact, they could not prepare for it. They are 
often disappointed because they have to adjust their perception of AHT, which is 
experienced as emotionally very exhausting. This affects the trust relationship 
with the physician. They feel misled by believing that the AHT regimen would not 
be hard to follow. The contrast makes it more difficult to be open and report side 
effects to healthcare professionals in the future. Consequently, participants have 
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the feeling of standing alone, making them even feel more anxious about the 
source of the symptoms they experience. 
“I think they have explained too little about side effects. They have 
actually minimized them, which makes them worse than I imagined them 
to be. Now I have to learn to deal with it after I have experienced them 
and this is very difficult.” 
“I was prepared for anything, except the fact that I would go into 
menopause from one day to the next. Nobody had informed me about it. 
I was very, very disappointed and saddened. People say it had to 
happen, which is true, but that was the furthest thing from my mind. You 
are losing part of your femininity. For me that was the most difficult part 
of the entire treatment… I did have everything, but that was the worst for 
me. And maybe because they did not inform me in advance.” 
The degree of recognition participants receive from healthcare professionals 
increases or reduces the burden of the AHT. When they do not feel recognized, 
the burden of the AHT is heavier, making it more difficult to continue to take their 
AHT adherently or to persevere.  
The capacity to deal with the burden of the AHT is determined by the presence 
of personal coping resources and the degree of social support. The degree of 
social support counteracts the burden of the AHT. When the degree of social 
support is low, this makes it more difficult to bear the burden. It makes patients 
feel even lonelier in dealing with the difficulties they encounter and in their 
struggle to continue the therapy.  
In most cases, participants develop strategies to cope with the impact and the 
burden of the AHT. When the balance tilts to the burden side, in order to be able 
to continue the AHT, they resort to strategies such as:  
- Relativize experienced difficulties by putting them into the perspective of 
other life issues and by comparing themselves with patients who are 
experiencing more difficulties than they are, which helps them to 
continue the AHT.  
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“I am more fatigued, but that’s due to the aging. Every normal 
person gets more tired by the evening.” 
- Rationalizing experienced shortcomings in relation to healthcare 
professionals. They indicate, for example, that physicians have little time 
during consultations to talk in detail about the difficulties patients 
experience. This way they try to avoid the feeling of being disappointed. 
The more shortcomings they experience, the more difficult it is to 
rationalize these away.  
- Seeking social support with peers when to compensate the lack of social 
support from family and friends.   
- Creating one’s own perspective to be able to continue therapy when the 
impact of the AHT is high. Having a known ending date gives 
participants courage to continue the therapy. Some participants make an 
agreement with their physicians to continue therapy for a shorter period 
than five years in order to create a less distant perspective. Some 
participants create a perspective for themselves by dividing the 
treatment period into shorter periods. 
“I hope that those five years will pass quickly. In September it 
will be two years, then another half year and then I am halfway. 
Once I am halfway, it will pass more quickly, so I will be glad to 
be halfway.” 
- Adapting expectations of life and future to the AHT (e.g. activity level 
and goals). The extent to which patients succeed is often related to age. 
The younger and/or the more active participants are, the more their life 
is changed with respect to the life they had before the disease and the 
more difficult it seems to adapt life to the treatment. 
The extent to which participants succeed in finding effective strategies to cope 
with the impact and the burden of the AHT determines whether participants 
continue AHT. When the balance remains tilted towards the burden side, 
participants think about quitting therapy. When considering giving up therapy, 
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they are often doubtful because of the fear they might relapse, making them feel 
guilty towards themselves, family and friends. When the potential higher risk of a 
relapse does not outweigh the low quality of life they are experiencing, they stop 
the AHT temporarily (non-adherence) or permanently (non-persistence/early 
discontinuation).  
When participants stop the treatment, they try to legitimize their decision and to 
convince themselves it was the right thing to do. In this way, they try to counter 
the feeling of guilt in case of a relapse. Participants use arguments such as: ‘I 
have been taking AHT for four years; one year will not make a difference’, 
‘research is still under development; they do not know if it helps or not’ or ‘A 
friend died from breast cancer, she also took AHT and did not survive anyway’. 
In some cases, however, patients restart the treatment or shift to another 
because the physician was able to persuade them to start again and because 
they were afraid of relapse. 
 
DISCUSSION 
The aim of this study was to gain insight into the process of (non-)adherence 
and (non-)persistence in breast cancer patients with AHT by researching 
influencing factors and their interrelatedness.  This study shows how factors 
such as expectations regarding the impact of treatment, information, recognition 
and social support contribute to the process of (non-)adherence and  
(non-)persistence in breast cancer patients with AHT.  
The process of (non-)adherence and (non-)persistence presented in this study 
facilitate the interpretation of factors influencing (non-)adherence and  
(non-)persistence found in quantitative studies. Our study highlights the 
interrelatedness of influencing factors and reveals processes underlying factors 
frequently found in quantitative studies. Side effects, for example, are the most 
commonly found predictors of non-adherence and non-persistence in breast 
cancer patients taking AHT (Kirk and Hudis, 2008; Grunfeld et al., 2005; Atkins 
and Fallowfield, 2006; Lash et al, 2006; Demissie et al., 2001). This study adds 
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that not only the impact of side effects per se, but also expectations regarding 
the impact of the AHT and feeling recognized by healthcare professionals 
contribute to the process of (non)-adherence and (non)-persistence.  
For participants experiencing side effects they did not expect, the burden of the 
AHT is heavier, which increases the risk of non-adherence and non-persistence. 
Kahn and colleagues (2007) also found that breast cancer patients taking 
tamoxifen who experienced side effects that they were not told about in 
advance, were less likely to continue tamoxifen in comparison to patients who 
did know what side effects they could expect (62% vs. 85%, p<0.001). Side 
effects that affect the quality of life of patients taking AHT are usually not life-
threatening, and may therefore differ from those side effects that physicians are 
mostly concerned about (Fellowes et al., 2001). As a result, such side effects 
may not be discussed with patients or only to a limited extent and may not be 
recognized as affecting patients’ quality of life. Our study shows that this 
reinforces the idea that AHT is not a hard regimen to follow, leading to feelings 
of disappointment when patients are confronted with unexpected side effects 
resulting in a greater emotional and physical burden.   
The degree of recognition participants receive from healthcare professionals 
increases or reduces the burden of AHT. In this way, recognition can act as an 
important buffer against the impact of the AHT. Kahn and colleagues (2007) 
found that patient-centered care processes and behavior were associated with 
better adherence, even in patients experiencing a high impact of the AHT. 
Patient-centered care processes and behavior included, amongst other things, 
caring interactions with patients, involving patients in decision-making and 
counseling patients about (potential) side effects. The qualitative study of Burkitt 
Wright and colleagues (2004) showed that physicians were valued the most 
when they were technical experts, formed individual relationships with them, and 
respected them. When patients thought that they had been misled as a result of 
poor communication, the trust in the physician was irretrievable. Our study adds 
that the feeling of being misled makes patients disappointed, puts them in a 
lonely position, and makes the burden of the AHT heavier for them. This mostly 
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affects patients who lack sufficient personal coping resources and enjoy less 
social support.  
Implications for practice 
The results of our study highlight the patients’ need to be clearly informed about 
the impact of the AHT in order not to raise false expectations. Being well 
informed helps patients to prepare for what is coming and to avoid expectations 
that need to be adjusted afterwards, which is perceived as emotionally very 
exhausting. This study also emphasizes the need for patient centered care with 
regular follow-up consultations over the total course of AHT, during which 
patients are given sufficient space to express their difficulties and worries. An 
equal relationship in which they are being taken seriously by healthcare 
professionals encourages them to express their difficulties and feelings. Further, 
patients need to be supported in dealing with the impact of AHT by helping them 
manage the side effects and giving them psychological support and recognition. 
Therefore, a multidisciplinary approach during follow-up should be implemented 
and healthcare professionals should be sensitized about the importance of 
recognizing patients and trained to do this in an appropriate way.  Reassuring 
patients about the cause of bodily sensations is an ongoing duty of healthcare 
professionals. As this study also highlights the importance of social support, it is 
recommended to inform family and friends about the possible impact of the AHT 
and involve them in patient care during the follow-up period with AHT. Contact 
between patients should be encouraged during follow-up as this study highlights 
the importance of social support from peers. 
Strengths and limitations  
This is the first qualitative study giving insight into the processes of  
(non-)adherence and (non-)persistence in breast cancer patients considering 
both SERMs and aromatase inhibitors. Despite the strengths, some limitations 
need to be addressed.  
Saturation was achieved early in the study for some of the influencing factors. 
This may be the result of recruiting in one hospital. Consequently, it is likely that 
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care was perceived as similar which could have led to a selection bias. Future 
research could be conducted in more additional settings in order to explore 
generalization of the study findings.  
Participants who had received chemotherapy may experience more late side 
effects of the chemotherapy during follow-up period with AHT than other 
participants. In this study, late side effects of the chemotherapy may also have 
influenced the impact of the therapy and contributed to the process of  
(non-)adherence and (non-)persistence. In future research, the consequences of 
side effects of previous chemotherapy could be more taken into account. 
 
CONCLUSION 
This qualitative study gives insight into the process of (non-)adherence and 
(non-)persistence in breast cancer patients taking AHT. Expectations regarding 
the impact of AHT, social support from family and friends, and recognition from 
healthcare professionals were found to influence (non-)adherence and  
(non-)persistence. The results of this study can help healthcare professionals 
understand why breast cancer patients taking AHT do not always adhere to or 
persist in taking the therapy and may facilitate patient tailored interventions. 
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Table 1. Demographic and treatment-related characteristics 
   Characteristics  N 
Age (years) 
  
 
30-39 2 
 
40-49 8 
 
50-59 11 
 
60-69 8 
 
70-79 2 
Married 
  
 
Yes 20 
 
No 11 
Children 
  
 
Yes 23 
 
No 8 
Working 
  
 
Yes 14 
 
No 17 
Level of education 
 
 
Secondary  16 
 
Tertiary  15 
Previous treatment 
 
 
Surgery 30 
 
Chemotherapy 22 
 
Radiotherapy 23 
 
Targeted therapy 6 
Antihormonal medication 
 
 
Aromatase inhibitor 14 
 
Tamoxifen 17 
Time on antihormonal therapy (years) 
 
 
< 1  5 
 
1-2 7 
2-3 5 
 3-4 5 
 4-5 7 
 >5 2 
  
 
Figure 1. Theoretical framework: the process of (non-)adherence and (non-)persistence
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CHAPTER 5 
 
ADHERENCE TO ORAL ANTICANCER AGENTS: HEALTHCARE 
PROVIDERS’ PERCEPTIONS, BELIEFS AND SHARED 
DECISION MAKING IN BELGIUM AND THE NETHERLANDS 
 
 
 
 
 
 
 
 
 
 
 
 
Based on the article of Verbrugghe M, Timmers L, Boons C, van den Bemt B, 
Hugtenburg J, Van Hecke A. (2015). Adherence to oral anticancer agents: 
healthcare providers’ perceptions, beliefs and shared decision making in 
Belgium and the Netherlands. Under review.  
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ABSTRACT 
Background 
Little is known about healthcare providers’ perceptions of adherence 
management of oral anticancer agents. The study aims to explore healthcare 
providers’ perceptions of oral anticancer agents and adherence. 
Methods 
A cross-sectional, multi-center observational study among healthcare providers 
in hemato-oncology settings in Belgium and the Netherlands was conducted. 
Physicians, nurse practitioners, nurses and pharmacists were asked to complete 
questionnaires on their perception of patient adherence and its management 
(PAMQ) and their beliefs about oral anticancer agents (BMQ-Specific). 
Physicians were also asked to complete a questionnaire on their perception of 
shared decision making (SDM-Q-Doc).  
Results  
The sample consisted of 254 healthcare providers. 56, 50, 28 and 23% of 
respectively physicians, nurse practitioners, nurses and pharmacists reported to 
know the level of adherence of their patients and 59, 53, 43 and 10% think that 
patients discuss adherence with them. 70, 82, 63 and 62% and 78, 87, 76 and 
80% of physicians, nurse practitioners, nurses and pharmacists reported to have 
knowledge of causes respectively consequences of non-adherence. 81, 92, 83 
and 67% of physicians, nurse practitioners, nurses and pharmacists felt able to 
influence adherence. Lower concerns about oral anticancer agents were 
associated with a higher total score on the PAMQ (β[SE]= -.85[.24]; CI -1.33 to -
.38). Physicians scored a mean of 75 on the SDM-scale. 
Conclusion 
A considerable part of the healthcare providers states they do not know the 
adherence of their patients, nor do they think patients discuss adherence with 
them. However, they feel to have knowledge of adherence and perceive to be 
able to influence adherence of their patients.  
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INTRODUCTION 
Non-adherence to oral anticancer agents (OACA) is complex and determinants 
are interrelated (Verbrugghe et al, 2013). For OACA treatment effectiveness, 
optimal adherence is considered important (e.g. better clinical response, 
survival) (Noens et al, 2009; Marin et al, 2010; Xu et al, 2012). A patient is 
considered optimally adherent (100%) to the agreed prescribed therapy when no 
doses have been missed, no more doses have been taken than prescribed, and 
doses have not been taken at the wrong time or wrong quantity (Ruddy et al, 
2009; Staddon, 2011).  
The framework suggested by the World Health Organization (WHO, 2003) is 
frequently used to describe the multidimensional phenomenon of medication 
adherence. It includes five interacting dimensions influencing adherence: social 
and economic factors, condition-related factors, therapy-related factors, patient-
related factors, and healthcare provider (HCP) and system-related factors. HCP-
related factors found to influence OACA (non-)adherence were observed in 
patients with breast cancer on chronic endocrine therapy (e.g. a poor physician’s 
explanation of treatment effects) (Kahn et al, 2007) and in patients with chronic 
myeloid leukemia (CML) on long-term imatinib (e.g. feedback from physicians 
that seems to reinforce the belief that ‘occasional’ non-adherence does not 
matter) (Eliasson et al, 2011). Shared decision making was found to influence 
persistence to OACA in breast cancer patients in a prospective cohort study 
(Kahn et al, 2007). Women who were satisfied about the role they played in the 
OACA therapy decision making process, were more likely to continue their 
therapy (81%) as compared to patients playing a more (73%) or less expanded 
role (59%) than wanted regarding the decision making process (Kahn et 
al,2007). Studies on HCP- related factors influencing non-adherence in patients 
treated with short-term OACA (e.g. erlotinib, sunitinib) are scarce (Timmers et al 
2014, Timmers et al 2015).  
Studies exploring adherence issues have predominantly focused on the patient’s 
perspective (Osterberg and Blaschke, 2005). Beliefs about medicines have 
previously been shown to influence adherence in patients taking OACA 
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(Grunfeld et al, 2005; Bhattacharya et al, 2012). However, insight into HCPs’ 
beliefs about OACA and perceptions about OACA adherence are also important 
because perception and beliefs may influence HCPs’ behavior and care (Ajzen, 
1991; Valente Teixeira et al, 2012). In turn, this may influence patients’ 
adherence behavior (Marteau and Johnston, 1991; Eliasson et al, 2011). Until 
now, HCPs’ perceptions about OACA adherence, HCPs’ beliefs about OACA 
and the physicians’ perceptions towards the shared decision making process in 
OACA therapy have hardly been explored. Insight into these topics may inform 
the development of interventions targeted to HCPs’ capacity to counsel patients 
taking OACA. 
The present study aims to (1) explore HCPs’ perceptions about OACA 
adherence management and beliefs towards OACA, (2) explore the physicians’ 
perceptions towards the shared decision making process, and (3) report on 
factors influencing HCPs’ perceptions about OACA adherence management.  
 
METHODS 
Design 
A cross-sectional, multi-center observational study among HCPs working in 
hemato-oncology settings in Dutch-speaking Belgium and the Netherlands was 
performed. This paper reports on one part of a larger study.  The other paper 
describes usual care activities in adherence care provided in the same settings 
(Adherence to oral anticancer agents: HCPs’ perceptions and usual care in 
Belgium and the Netherlands).  
Setting and sample 
The study was conducted between April and October 2014. HCPs were included 
if they met the following criteria: being a medical oncologist, hematologist, nurse, 
nurse practitioner, or pharmacist; working in a hemato-oncology setting, in 
Dutch-speaking Belgium or the Netherlands. 
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Data collection procedure 
Participants were informed about the study by their professional associations in 
Belgium and the Netherlands. An e-mail with information and an invitation to 
complete the online questionnaire was sent to all members of professional 
associations involved. After the initial invitation, one or two reminders were sent. 
Additional recruitment took place by distributing the online questionnaire within 
the authors’ network, and by handing out a paper version of the questionnaire at 
a scientific meeting where HCPs from the targeted groups were present.  
Measurements 
A composite electronic questionnaire starting with demographic characteristics 
like profession, number of years employed, gender, type of hospital, and 
specialization (hematology or medical oncology) was used. 
Five items on HCPs’ perceptions of management of adherence (Perceptions 
about Adherence Management Questionnaire - PAMQ) were developed by a 
team consisting of a medical oncologist, hematologist, three pharmacists, and 
three researchers (nurse, psychologist, health scientist) with experience in the 
field of medication adherence in oncology and hematology. The five items were: 
knowing the level of adherence of all my patients, thinking that patients discuss 
non-adherence with me, being able to influence adherence behavior of my 
patients, having sufficient knowledge about consequences of non-adherence, 
and having sufficient knowledge about causes on non-adherence to discuss this 
with patients. Each item was scored on a 5-point Likert scale, ranging from 
strongly disagree (1) to strongly agree (5). The scores agree (4) and strongly 
agree (5) were dichotomized into yes (1) and the other scores (1-3) into no (0). A 
total score (ranging from zero to five) was calculated by summing the five 
dichotomized items. A higher total score on the PAMQ indicated a higher 
number of perceptions about managing adherence the HCP agree with.   
The Shared Decision Making Questionnaire – physician version (SDM-Q-Doc) 
was used to assess the shared decision making process in medical consultation 
from the physician’s perspective (Scholl et al, 2012). The SDM-Q-Doc has 
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shown to be a well-accepted and reliable instrument (Scholl et al, 2012). Items 
were rated on a 6-point Likert scale from zero (absolutely inappropriate) to six 
(absolutely appropriate). A sum score of the nine items was made (range 0 to 
45). This sum score was standardized using a linear transformation into a scale 
from 0 to 100 as recommended by Scholl et al (2012), in order to facilitate 
interpretation.  A higher score on the SDM-Q-Doc indicated perceptions of more 
shared decision making. The SDM-Q-Doc was only assessed by physicians 
because treatment-decisions primarily occur at the physicians’ level.  
Beliefs about OACA were assessed by using the Beliefs about Medicines 
Questionnaire (BMQ-Specific) (Horne et al, 1999). The BMQ-Specific has been 
validated in different populations including patients with a chronic disease or a 
malignancy (Horne et al, 1999; Horne and Weinman, 1999). The BMQ-HCP 
version was translated in Dutch following the inverse translation method (Koller 
et al, 2007) by CB and LT and authorized by R. Horne, the main author of the 
BMQ-Specific (Horne et al, 1999). The BMQ-Specific consists of two scales: a 5-
item necessity scale assessing beliefs about the necessity of the medication to 
control the disease and a 5-item concerns scale assessing concerns about the 
potential negative impact of the medication (Horne et al, 1999). Items were rated 
on a 5-point Likert scale ranging from strongly disagree to strongly agree. 
Individual scores obtained from each 5-item scale were summed (range 5 to 25). 
Higher scores on the BMQ-necessity indicate stronger beliefs in the necessity of 
OACA to control the disease, higher scores on the BMQ-concerns indicate 
stronger concerns about the potential negative impact of OACA (Horne and 
Weinman, 1999; Horne et al, 1999). A cutoff score of 15 or above was used to 
determine low/high necessity or concerns (Van Steenis et al, 2014). Four 
profiles of HCPs representing HCPs’ beliefs were created based on scores of 
the BMQ-Specific necessity/concerns scales (Menckeberg et al, 2008; Mann et 
al, 2009; Van Steenis et al, 2014): indifferent (low necessity, low concerns), 
skeptical (low necessity, high concerns), accepting (high necessity, low 
concerns), and ambivalent (high necessity, high concerns). A necessity-
concerns differential score was calculated to assess the relative importance of 
the medication by subtracting the concerns-scale from the necessity-scale 
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(range -20 to 20). A positive differential score indicates stronger necessity 
beliefs than concerns.  
Validation of the questionnaire 
The questionnaire was pilot-tested by nine HCPs in the Netherlands and 
Belgium (i.e. three pharmacists, three nurses, one hematologist, one medical 
oncologist, and one general practitioner). In individual interviews with HCPs, it 
was explored whether the items were understood as intended. 
Ethics 
The study procedure was approved by the Ethical Review Committee of the 
Ghent University Hospital (Belgium) and assessed not governed by the Dutch 
Medical Research Involving Human Act by the Medical Ethics review board of 
the VU University Medical Center in Amsterdam (the Netherlands). 
Statistical analysis 
Descriptive data were presented as frequencies (percentages) and means 
(standard deviations [SD]). Differences between groups were tested by means 
of the Pearson Chi-square test, the unpaired t-test, and one-way Anova test. 
The Pearsons correlation coefficient was used to test the association between 
continuous data. For statistical analyses, the professions hematologists and 
medical oncologists were merged into the group ‘physicians’.  
To identify associated factors of HCPs’ perceptions about adherence 
management, linear regression analysis was performed with the total PAMQ-
score as dependent variable and potential predictors as independent variables. 
Variables with a value p<0.25 were entered in a multiple linear regression model 
to evaluate the associations’ independency. SPSS 22.0 (SPSS Inc., Chicago, IL, 
USA) was used to perform statistical analyses. 
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RESULTS 
Demographic characteristics 
In total 329 HCPs initiated the online questionnaire, of which 236 completed the 
demographic characteristics and at least one section with questions. 
Recruitment at the conference yielded 18 additional questionnaires. In total, 254 
questionnaires were used for the analysis. Demographic characteristics of 
participants are shown in Table 1. The median number of years employed was 
14 years (IQR= 7-25). Most participants were female (73.2%) and 51.2% worked 
in the Netherlands. The sample consisted of 23.6% pharmacists, 29.9% nurses, 
15% medical oncologists, 16.5% hematologists, and 15% nurse practitioners 
working in different hospitals (n=106). The majority of the HCPs worked in the 
field of medical oncology (70.5%) in a non-academic hospital (67.6%).  
HCPs’ perceptions about adherence management (PAMQ) 
In total, 254 HCPs completed the PAMQ.  An overview of the perceptions about 
adherence management according to profession, gender, country, type of 
hospital, and specialization is presented in Table 2. Slightly more than half of the 
physicians and half of the nurse practitioners indicated to know the level of 
adherence of their patients (56% and 50% respectively) and perceived that 
patients discuss adherence with them (59% and 53% respectively). Most HCPs 
(especially physicians [81.3%], nurse practitioners [92.1%] and nurses [82.9%]) 
indicated to be able to influence adherence behavior of their patients. Most 
HCPs thought to have sufficient knowledge about the consequences of non-
adherence (79.1%), less HCPs indicated to have sufficient knowledge about the 
causes of non-adherence to discuss this with patients (67.7%).   
For the total PAMQ-score, both physicians and nurse practitioners scored 
significantly higher than nurses (unpaired t-test; p=0.022 and p=0.008 
respectively) and pharmacists (both p<0.001). No significant difference was 
found between physicians and nurse practitioners.  
A supplementary analysis was performed to determine significant differences 
between the subgroups of physicians (medical oncologists vs. hematologists). 
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More medical oncologists than hematologists indicated to know the level of 
adherence of all their patients (Pearson Chi-square; n[%] = 27[71%] vs. 18 
[43%]; p=0.011) and thought that patients discussed non-adherence with them 
(n[%] = 28[74%] vs. 19 [45%]; p=0.01). 
Beliefs about OACA (BMQ) 
The BMQ-Specific was completed by 222 HCPs. An overview of the necessity 
and concerns scale and the differential score according to profession, gender, 
country, type of hospital, and specialization, is presented in Table 2. The 
necessity-scale and the concerns-scale were normally distributed. The mean 
score on the BMQ-necessity was 18.3 (SD=2.94), the mean score on the BMQ-
concerns was 13.5 (SD=2.57). The strongest necessity beliefs were found for 
the items “My patients’ health, at present, depends on these medicines” (Mean 
[SD]=3.97[.49]), “The future health of my patients will depend on these 
medicines” (Mean [SD]=3.9[.77]), and “These medicines protect my patients 
from becoming worse” (Mean[SD]=3.79[.76]). The strongest belief about 
concerns was found for the item “I sometimes worry about the long-term effects 
of these medicines” (Mean [SD]=3.34[.98]). 
The BMQ-necessity score was significantly higher among physicians than 
nurses (unpaired t-test; p=0.005) and nurse practitioners (p=0.046); pharmacists 
scored significantly higher than nurses (p=0.010). Necessity beliefs and 
concerns about OACA scores were significantly higher among Belgian HCPs 
than among Dutch HCPs. The BMQ-necessity was significantly higher among 
HCPs in hematology than HCPs in oncology. The association between the 
differential score and number of years employed was found to be significant (r= -
0.13, p=0.045), indicating the longer HCPs are employed, the higher concerns 
compared to necessity beliefs. When considering HCPs’ profiles, 56.8% are 
accepting, 33.3% ambivalent, 7.7% indifferent, and 2.3% skeptical towards 
OACA. No significant differences between professions, gender, countries, 
number of years employed, and types of hospital were found.  
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Shared decision making (SDM) 
In total, 95 of the 99 physicians, completed the SMQ-Q-Doc. Table 2 shows the 
SDM-Q-Doc scores according to gender, country, type of hospital, and 
specialization. The mean sum score (scale 0 to 100) was 75.53 (SD=19.26).The 
lowest scores on item level were found for the items “I wanted to know exactly 
from the patient how he/she wants to be involved in making the decision” (Mean 
[SD]=3.39[1.21]) and “My patient and I selected a treatment option together” 
(Mean [SD]=3.36[1.41]). The highest scores were found on the items “I precisely 
explained the advantages and disadvantages of the treatment options to my 
patient” (Mean [SD]=4.15[1.07]), “I helped my patient understand all the 
information” (Mean [SD]=4.11[.79]), and “My patient and I reached an agreement 
on how to proceed” (Mean[SD]=4.08[1.13]). No significant differences were 
found for profession (hematologists vs. oncologists), gender, country, 
specialization, and type of hospital. No significant association was found for the 
number of years employed. 
Factors influencing HCPs’ perceptions about adherence management 
The independent associations between the total PAMQ-score and other factors 
are presented in Table 3. No multi-collinearity was observed among the 
independent variables (Spearmans’ρ<0.60). Univariate analysis showed that 
being a nurse or pharmacist, and having higher concerns beliefs was associated 
with lower total PAMQ-scores. The multivariate analysis showed that being a 
pharmacist was associated with lower total PAMQ-scores. No significant 
associations were found between BMQ-Specific profiles and total PAMQ-score. 
When comparing the two most common profiles (accepting vs. ambivalent) at 
PAMQ item-level, more accepting HCPs thought to know the level of adherence 
of all their patients (Pearson Chi-square; n[%] = 58[46%] vs. 22 [30%]; p=0.028) 
and felt  able to influence adherence behavior of their patients (n[%] = 110[87%] 
vs. 53 [73%]; p=0.009). A higher sum score on the SDM-Q-Doc (more shared 
decision making) was independently associated with a higher total PAMQ-score 
(p=.019; β [SE] = .017[.007]; 95% confidence interval: 0.003 to 0.031). 
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DISCUSSION 
The results of the present study showed that only slightly more than half of the 
physicians thought to know the level of adherence of their patients and 
supposed that patients discussed non-adherence with them. In line with these 
results, patients reported that physicians do not always discuss OACA  
(non-)adherence (Eliasson et al, 2011). Underlying reasons may be the 
assumptions that patients are highly adherent due to the severity of the disease 
and that the relationship of confidence physicians have with their patients 
naturally leads to adherence (Regnier Denois et al, 2011). Talking about non-
adherence has also been considered detrimental to the unspoken contract of 
trust in the therapeutic relationship (Regnier Denois et al, 2011). Openness to 
talk about adherence should be established. To be able to talk about adherence, 
an open and trust-based relationship and providing patients with a knowledge 
base of why it is important to be open about adherence behavior is important 
(Verbrugghe et al., 2015). 
An interesting finding was that all HCPs felt able to influence adherence of their 
patients and have sufficient knowledge of causes and consequences of non-
adherence.  Even if we leave out of account to what extent these HCPs counsel 
their patients about adherence, this finding is at least a ground for the 
performance of adherence support programs. In the second part of this study, 
which we will publish separately, we will report the actual adherence care which 
is provided by these HCPs. 
Pharmacists had lower scores on the perceptions about adherence 
management. A likely explanation is that pharmacists have generally less 
contact with patients taking OACA and also have a less active role in counseling 
these patients. Few pharmacists indicated items implying face-to-face contact 
with patients (i.e. know the level of adherence and think that patients discuss 
non-adherence with them), while most of them indicated to have sufficient 
knowledge about the consequences of non-adherence and the causes to 
discuss this issue with patients. 
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Scores on beliefs about the necessity of OACA were higher than scores on 
concerns about the potential negative impact of OACA among all professions 
(positive necessity-concerns differential scores). HCPs are perhaps indeed quite 
aware of the necessity of OACA treatment and its effectiveness or may be, 
despite the increasing attention for quality of life, more focused on survival and 
the continuation of treatment until there is no more treatment to offer (Keating et 
al, 2010). 
Comparing HCPs’ beliefs about OACA with patients’ beliefs reported in 
literature, the mean necessity-concerns differential score in the present study 
was lower than a comparable score of patients taking the OACA capecitabine 
(4.8 vs. 7.8) (Bhattacharya et al, 2012). However, in both studies the necessity-
concerns differential scores were positive indicating that on average the beliefs 
of patients and HCPs in necessity outweigh concerns about the potential 
negative impact of OACA treatment. 
Nurses scored lower on the necessity-concerns differential than physicians, 
nurse practitioners and pharmacists.  Nurses appear to express more worries 
about the use of OACA than physicians, nurse practitioners and pharmacists. 
Nurses have more frequent and intense contact with patients taking OACA when 
they are hospitalized, mostly as a result of severe and intense side effects or 
disease progression. Seeing patients suffering is confrontational and may be 
emotionally demanding (Corner, 2002). 
We also found that HCPs who were accepting (high necessity beliefs, low 
concerns) considered themselves more able to influence adherence and thought 
to have a better notion of patient adherence than HCPs who were ambivalent 
towards OACA (high necessity, high concerns). Patients with a chronic non-
oncological disease being accepting towards medicines were previously found to 
have the highest adherence levels (Tibaldi et al, 2009). In future research, the 
association between (1) HCPs’ perceptions about OACA adherence 
management, beliefs about OACA, and usual care, and (2) patients’ adherence 
levels should be studied.  
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Particularly the SDM scores of items with regard to giving patients a good 
knowledge base about their treatment options (explaining advantages and 
disadvantages of the treatment options and helping to understand all 
information), were considered high. The high score on the item “My patient and I 
reached an agreement on how to proceed” indicates that physicians are willing 
to give patients a role in the decision making process. However, the lowest 
mean score was found for the item regarding involvement of patients in the final 
decision making (“my patient and I selected a treatment option together”). This is 
very likely as in current practice the physician is often the person to finally select 
the treatment option. As patients who were assigned a more extensive role than 
wanted in the decision-making process, appeared to be less adherent to their 
OACA (Kahn et al, 2007), physicians should firstly discuss whether patients 
want a role in the decision making process and secondly, discuss which role 
would be fitting.  
Limitations and methodological considerations 
This study was the first to explore perceptions about adherence management 
and beliefs about OACA of different HCPs involved in the care for patients taking 
OACA in Belgium and the Netherlands. Despite the strengths, some limitations 
need to be addressed. 
One limitation is the method of recruitment. The questionnaire was sent out by 
several professional associations and distributed in the own network (snowball 
sampling). We could not calculate response rates.  Furthermore, we assume 
that particularly HCPs who are affiliated with the research topic, have completed 
the questionnaire. Presumable, this has influenced our results. The results of the 
recruitment at the meeting (with HCPs assumable more affiliated with the topic) 
were not significantly different from the results from the recruitment by 
professional associations (online questionnaire). This may indicate the presence 
of selection bias in the sample recruited by professional associations. 
Nevertheless, this study provides an interesting insight in HCPs’ views upon 
adherence to OACA. Furthermore, the sample in this study was not truly 
random, so statistical significance should be interpreted with caution. 
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Another limitation is that the questionnaire is not specified to specific patient 
groups. HCPs could have kept in mind patients treated with long-term or short-
term OACA. It is possible that differences between HCPs (e.g. hematologists vs. 
medical oncologists) could be partly explained by specific properties associated 
to one of both groups of OACA.  
 
CONCLUSION 
A considerable part of the HCPs states they do not know the adherence of their 
patients, nor do they think their patients discuss adherence with them. However, 
they feel to have knowledge of adherence and perceive to be able to influence 
adherence of their patients. There seems to be a good basis for adherence 
supportive care. Their statements about the care they provide will be published 
separately. 
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Table 1 Demographic characteristics of participants 
    
Total n=254 
(%) 
Median (IQR) 
Number of years 
employed  
  
14 years 
  
  
(7-25 years) 
Gender Male 68 (26.8%)  
 
Female 186 (73.2%)  
Profession  Medical oncologist  38 (15%)  
 
Hematologist  42 (16.5%)  
 
Nurse  76 (29.9%)  
 
Nurse practitioners  38 (15%)  
 
Pharmacist  60 (23.6%)  
Country  Belgium  124 (48.8%)  
 
The Netherlands  130 (51.2%)  
Specialization Hematology 70 (29.5%)  
 
Medical oncology 167(70.5%)  
Type of hospital  Academic  81 (32.4%)  
  Non-academic 169 (67.6%)  
IQR: Interquartile Range 
 
 
 
 
 
  
 
Table 2 Results on the Perceptions about Adherence Management Questionnaire (PAMQ), Beliefs about Medicines Questionnaire (BMQ-Specific) 
and Shared Decision Making Questionnaire (SDM-Q-Doc) according to profession, gender, country, type of hospital, and specialization 
 
  
TOTAL  PROFESSION   GENDER 
 
COUNTRY   TYPE OF HOSPITAL  SPECIALIZATION   
N=254 
Physician  
N=80 
Nurse 
practitioner 
N=38 
Nurse  
N=76 
Pharmacist 
N=60 
 
Male 
N=68    
Female  
N=186 
 
The 
Netherlands  
N=130 
Belgium 
N=124 
 
Academ
ic 
N=81 
Non-
academi
c 
N=169 
 
Hemato
logy 
N=70 
Medical 
oncology 
N=167 
 
  n(%) n(%) n(%) n(%) 
Pearson 
Chi-
square 
n(%) n(%) 
Pears
on 
Chi-
squar
e 
n(%) n(%) 
Pearson 
Chi-
square 
n(%) n(%) 
Pearson 
Chi-
square 
n(%) n(%) 
Pearson 
Chi-
square 
PAMQ 
 
  
 
                              
 I know the level of adherence 
of all my patients 98 (38.6%) 45 (56.3%) 19 (50%) 21 (27.6%) 14 (23%)  <.001* 
31 
(44.9%) 
68 
(36.6%) 
.22 54 (41.2%) 
45 
(36.3%) 
.42 
32 
(39.5%) 
65 
(38.2%) 
.85 
27 
(38.6%) 
66 (39.3%) .92 
 I think that patients discuss 
non-adherence with me 
106 
(41.7%) 
47 (58.8%) 20 (52.6%) 33 (43.4%) 6 (10%) <.001 
30 
(44.1%) 
76 
(40.9%) 
.64 57 (43.8%) 
49 
(39.5%) 
.48 
30 
(37%) 
74 
(43.8%) 
.31 
31 
(44.3%) 
69 (41.3%) .67 
 I am able to influence the 
adherence behavior of my 
patients 
203 
(79.9%) 
65 (81.3%) 35 (92.1%) 63 (82.9%) 40 (66.7%) .014 
59 
(86.8%) 
144 
(77.4%) 
.10 110 (84.6%) 
93 
(75%) 
.056 
67 
(82.7%) 
133 
(78.7%) 
.46 
60 
(85.7%) 
129 
(77.2%) 
.14 
 I have sufficient knowledge 
about the consequences of 
non-adherence 
201 
(79.1%) 
62 (77.5%) 33 (86.8%) 58 (76.3%) 48 (80%) .60 
51 
(75%) 
150 
(80.6%) 
.33 99 (76.2%) 
102 
(82.3%) 
.23 
66 
(81.5%) 
132 
(78.1%) 
.54 
53 
(75.7%) 
132 (79%) .57 
 I have sufficient knowledge 
about the causes of non-
adherence to discuss this with 
patients 
172 
(67.7%) 
56 (70%) 31 (81.6%) 48 (63.2%) 37 (61.7%) .15 
51 
(75%) 
121 
(64.7%) 
.12 88 (67.7%) 
84 
(67.2%) 
.93 
56 
(68.3%) 
113 
(66.9%) 
.82 
44 
(62.9%) 
117 
(70.1%) 
.28 
 
 
 
 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
ANOVA 
F (p-
value) 
Mean 
(SD) 
Mean 
(SD) 
t-test 
F (p-
value
) 
Mean (SD) 
Mean 
(SD) 
t-test  
F (p-
value) 
Mean 
(SD) 
Mean 
(SD) 
t-test  
F (p-
value) 
Mean 
(SD) 
Mean (SD) 
t-test 
F (p-
value) 
Total PAMQ-scorea 3.07 
(1.39) 
3.44 
(1.39) 
3.63 (1.26) 
2.93 
(1.33) 
2.4 (1.28) <.001 
3.25 
(1.23) 
3.01 
(1.45) 
.22 3.13 (1.39) 
3.01 
(1.39) 
.48 
3.10 
(1.39) 
3.05 
(1.39) 
.81 
3.07 
(1.39) 
3.07 
(1.43) 
.98 
SDM-Q-Docb 75.53 
(19.26) 
75.53 
(19.26) 
n/a n/a n/a n/a 
80.06 
(14.29) 
72.64 
(21.47) 
.07 
73.50 
(21.61) 
80.15 
(11.36) 
.12 
77.68 
(17.82) 
74.73 
(20.02) 
.53 
76.73 
(18.59) 
73.82 
(20.85) 
.50 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
                 
  
 
 
 
 
 
TOTAL 
 
PROFESSION 
  
GENDER 
 
COUNTRY  TYPE OF HOSPITAL  SPECIALIZATION 
 
 
 
N=254 
Physician  
N=80 
Nurse 
practition
er 
N=38 
Nurse  
N=76 
Pharmacist 
N=60  
Male 
N=68    
Female  
N=186  
The 
Netherlands  
N=130 
Belgium 
N=124  
Academ
ic 
N=81 
Non-
academi
c 
N=169  
Hemato
logy 
N=70 
Medical 
oncology 
N=167 N=254 
 
 Mean (SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean (SD) Mean (SD) 
ANOVA 
F (p-
value) 
Mean 
(SD) 
Mean 
(SD) 
t-test 
F (p-
value
) 
Mean (SD) 
Mean 
(SD) 
t-test  
F (p-
value) 
Mean 
(SD) 
Mean 
(SD) 
t-test  
F (p-
value) 
Mean 
(SD) 
Mean (SD) 
t-test 
F (p-
value) 
 BMQ-Specific                   
 
Specific-Necessity
c
 
18.30 
(2.94) 
18.86 
(2.50) 
17.69 
(3.33) 
17.52 
(2.90) 
18.96 (3.00) .010 
18.65 
(2.91) 
18.16 
(2.95) 
.25 17.83 (2.84) 
18.81 
(2.97) 
.013 
18.28 
(2.85) 
18.29 
(2.96) 
.98 
18.97 
(2.73) 
17.94 
(2.99) 
.02 
Specific-Concernsc 
13.50 
(2.57) 
13.14 
(2.88) 
13.17 
(2.44) 
13.98 
(2.37) 
13.60 (2.42) .23 
13.35 
(2.67) 
13.56 
(2.54) 
.57 13.06 (2.60) 
13.96 
(2.47) 
.009 
13.87 
(2.62) 
13.33 
(2.56) 
.15 
13.97 
(2.77) 
13.37 
(2.42) 
.12 
  
NC/diffd 
4.82 
(3.66) 
 5.71 
(3.49) 
4.63 
(3.82) 
3.53  
(3.32) 
 5.37 (3.79)  .003 
5.30 
(3.33) 
4.62 
(3.78) 
.21 4.81 (3.72) 
4.84 
(3.61) 
.94 
4.41 
(3.47) 
4.99 
(3.76) 
.28 
5.00 
(3.68) 
4.59 
(3.65) 
.46 
PAMQ, Perceptions about Adherence Management Questionnaire; SDM-Q-Doc, Shared Decision Making Questionnaire; BMQ-Specific, Beliefs about Medicines Questionnaire (necessity and concerns about medicines) 
 a
Scores range 0 
to 5 - a higher score on the PAMQ indicates a higher number of perceptions about managing adherence the HCP agree with; 
b
Scores range 0-100 – physician version, a higher score indicates perceptions of more shared decision 
making; cScores range 5 to 25 – higher scores indicates stronger beliefs of necessity or concerns; dNecessity-concerns differential score (range -20 to 20) – a positive differential score indicates stronger necessity beliefs than concerns; 
*The bold values indicate statistical significance at the p<0.05 level 
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Table 3 Regression analysis with the Perceptions about Adherence 
Management Questionnaire (PAMQ) – total score as dependent variable and 
potential predictors as independent variables 
  
Univariate 
 
Multivariate 
Variable  β (SE) 95% CI P-value   β (SE) 95% CI P-value 
Professiona       
     Nurse practitioner .19 (.26) -.32 to .71 .46  .33 (.28) -.22 to .88 .24 
 
Nurse -.50 (.21) -.92 to -.085 .019* 
 
-.38 (.24) -.84 to .09 .11 
 Pharmacist -1.04 (.23) -1.48 to -.59 <.001  -.85 (.24) -1.33 to -.38 <.001 
Genderb .25 (.20) -.14 to .63 .22 
 
.26 (.20) -.14 to .66 .20 
Number of years 
employed -.008 (.01) -.024 to .007 .30 
    Countryc .12 (.18) -.22 to .47 .48 
    Type of hospitald .05 (.19) -.32 to .42 .81 
    Specializatione .006 (.20) -.39 to .40 .98 
    Necessity-scale .006 (.03) -.056 to .068 .86 
    Concerns-scale -.08 (.04) -.15 to -.011 .024 
 
-.07 (.03) -.13 to -.003 .060 
NC/difff .046 (.025) -.003 (.096) .066  
   SE = standard error; CI = confidence interval; aReference category is physician; bReference category is 
female; cReference category is Belgium; dReference category is non-academic hospital; eReference 
category is medical oncology; fNecessity-concerns differential score; *The bold value indicates statistical 
significance at the p<0.05 level. 
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CHAPTER 6 
 
ADHERENCE TO ORAL ANTICANCER AGENTS: HEALTHCARE 
PROVIDERS’ PERCEPTIONS AND USUAL CARE IN BELGIUM 
AND THE NETHERLANDS 
 
 
 
 
 
 
 
 
 
 
 
 
Based on the article of Timmers L, Boons C, Verbrugghe M, van den Bemt B, 
Van Hecke A., Hugtenburg J. (2015). Adherence to oral anticancer agents: 
healthcare providers’ perceptions and usual care in Belgium and the 
Netherlands. Under review.  
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ABSTRACT 
Purpose: The objective of this study was to assess current practice of adherence 
supportive care provided to patients using oral anticancer agents (OACA) in 
Belgium and the Netherlands and to explore how healthcare providers’ (HCPs) 
perceptions of and beliefs about OACA are related to the provided adherence 
care. 
Methods:  A cross-sectional, observational study among HCPs, with the 
profession of oncologist, haematologist, nurse practitioner, nurse or pharmacist, 
in (haemato)-oncology settings in Belgium and the Netherlands was conducted 
by means of a questionnaire. Adherence supportive care activities were 
collected by means of a literature search and input of healthcare providers 
(HCPs) and experts and pilot tested in HCPs. 
Results: 208 HCPs (53% male) participated, of whom 107 respectively 101 work 
in 51 hospitals in the Netherlands respectively 26 hospitals in Belgium. A total of 
47 care activities were listed and categorised in eight domains.  The median 
scores per care activities domain for respectively all HCPs, physicians, nurse 
practitioners (NPs), nurses and pharmacist were: Knowledge: 79, 86, 100, 71 
and 29%; Awareness: 75, 75, 75, 63 and 0%; Social influence: 67, 67, 67, 67 
and 0%; Self-efficacy: 40, 60, 80, 50 and 0%; Intention formation: 67, 67, 100, 
83 and 50%; Action control: 25, 25, 50, 25 and 0%; Adverse event management: 
100, 100, 100, 100 and 29%; Facilitation: 64, 64, 73, 55 and 27%. 
Conclusion: Activities aimed at patients’ knowledge and adverse event 
management were reported most frequently whereas activities aimed at self-
efficacy and the use of cues were reported less frequently.  The provided care 
differs between the professions involved in OACA adherence, with NPs the most 
active and pharmacists reporting the least adherence care. As compared to 
Belgium, in the Netherlands physicians reported less care activities whereas 
nurses and pharmacists report more activities. HCPs’ perceptions of adherence 
management were strongly related to the adherence care they report. 
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INTRODUCTION 
The issue of non-adherence is a rather new phenomenon in oncology. For 
decades, chemotherapy was predominantly administered intravenously (IV). 
During the last years, a substantial and rapidly growing number of oral 
anticancer agents (OACA) has been introduced (O’Neill and Twelves, 2002; 
Timmers et al., 2012). Oral administration may improve quality of life by its 
convenience and ease of use. Most patients prefer oral administration being 
ensured that OACA’s efficacy is at least similar to that of IV treatment (Liu et al., 
1997; Borner et al., 2001; Fallowfield et al., 2006). With the growing use of 
OACA, the relevance of medication adherence has become more urgent in 
oncology.  
Non-adherence with medication is a complex and multidimensional healthcare 
problem.  Adherence is defined as the extent to which a patient follows agreed 
recommendations for prescribed treatments (Sabaté, 2003). Patients may 
intentionally or non-intentionally be non-adherent during different stages of their 
treatment (Vrijens et al., 2012; Hugtenburg et al., 2013). Adherence to long-term 
therapies is estimated 50-70% (Sabaté, 2003; Osterberg and Blaschke, 2005; 
Vrijens et al., 2012; Hugtenburg et al., 2013). It has been shown that adherence 
to OACA can also be a problem; adherence and persistence rates with OACA 
between 16% and 100% are reported (Ruddy et al., 2009). 
Consequences of non-adherence can be tremendous for the individual patient 
(e.g. lack of efficacy or increased toxicity) and society (increased healthcare 
costs). The minimum level of adherence which is necessary for clinical outcome, 
varies by drug and is often not exactly known. Research on adherence to 
tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia (CML) 
revealed a strong relationship between the missing of some intakes per month 
and clinical response (Marin et al., 2010). 
Factors influencing non-adherence are complex. The World Health Organization 
has developed a framework which describes the multidimensional phenomenon 
of medication adherence (Sabaté, 2003). It includes five interacting dimensions 
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influencing adherence: social and economic factors, condition-related factors, 
therapy-related factors, patient-related factors, and healthcare provider (HCP) 
and system-related factors. Studies exploring adherence issues have 
predominantly focused on the patient (Osterberg and Blaschke, 2005; 
Verbrugghe et al., 2013). Few research is published on HCP-related factors 
influencing medication adherence.  
HCP-related factors were found to influence OACA (non-)adherence. In patients 
with breast cancer on chronic endocrine therapy, a poor physician’s explanation 
of treatment effects seemed related to non-adherence (Kahn et al., 2007). In 
addition, patients with CML on long-term imatinib reported that positive feedback 
from physicians reinforced the belief that ‘occasional’ non-adherence does not 
affect response (Eliasson et al., 2011). HCPs’ perceptions of and beliefs about 
OACA may influence their behaviour and care which in turn may influence 
patients’ adherence behaviour (Eliasson et al., 2011). In the paper reporting 
about the first part of this study (Adherence to oral anticancer agents: healthcare 
providers’ perceptions, beliefs and shared decision making in Belgium and the 
Netherlands), we assessed the beliefs of HCPs about OACA and their 
perceptions of management of adherence. Most HCPs indicated to have enough 
knowledge of causes and consequences of adherence and felt to be able to 
influence adherence of their patients. However, many of them, especially nurses 
and pharmacists, reported not to know the adherence of their patients, nor did 
they think their patients discuss adherence with them. It is not known how these 
results are related to their actual performed adherence care.  
The present study focused on the current practice of adherence supportive care 
provided in (haemato-) oncology in Belgium and the Netherlands. 
 
METHODS 
Study design 
An international cross-sectional observational study was conducted between 
April 2014 and October 2014 in the Netherlands and Belgium. HCPs with the 
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profession of oncologist, haematologist, nurse practitioner, nurse or pharmacist, 
and providing patient care in a (haemato-) oncology settings in the Netherlands 
or Dutch-speaking part of Belgium, were asked to fill out a questionnaire. The 
study was assessed not governed by the Dutch law on Medical Research in 
Humans by the Medical Ethics review board of VU University Medical Center 
(VUMC, Amsterdam, the Netherlands) and was approved by the Ethical Review 
Committee of the Ghent University Hospital (Belgium). 
Data collection procedure 
HCPs were invited to fill out an electronic questionnaire by their professional 
association. The questionnaire was available by an internet-link. After two-four 
weeks one or two reminders were sent to stimulate response. Additional 
recruitment took place by distributing the link to the online questionnaire within 
the authors’ network, and by handing out a paper version of the questionnaire at 
a scientific meeting about ‘adherence with oral anticancer agents’, held on the 
14th of October 2014 in Brussels. 
Questionnaire 
A composite questionnaire was used. At the start, the following characteristics of 
the respondents were collected: profession, gender, number of years employed, 
type of hospital (academic or non-academic) and specialization. Respondents 
were asked to fill out the questionnaire with in mind the patient group which they 
treated most. 
The questionnaire consisted of four parts: 
1. HCPs’ perceptions of management of adherence 
Five questions, developed by the research team, were used to assess 
HCPs’ perceptions  of adherence management (PAMQ, HCP’s 
Perceptions of Adherence Management Questionnaire): Insight in 
adherence: I know the level of adherence of all my patients; Patients’ 
communication: I think that patients discuss non-adherence with me, 
Capability to influence: I am able to influence adherence behavior of my 
patients, Consequences: I have sufficient knowledge about the 
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consequences of non-adherence, and Causes: I have sufficient 
knowledge about the causes of non-adherence to discuss this with 
patients. The answers were assessed on a 5-point Likert scale: strongly 
disagree, disagree, neutral, agree, and strongly agree. The answers 
‘agree’ and ‘strongly agree’ were dichotomised into ‘yes’. The total 
PAMQ-score (ranging from zero to five) was calculated by summing the 
five dichotomised items. A higher total score on the PAMQ indicated a 
higher number of perceptions about managing adherence the HCP 
agree with.  
2. Shared Decision Making 
To assess the style of SDM, the validated Shared Decision Making 
Questionnaire – physician version (SDM-Q-Doc), in the authorised 
Dutch translation, was used (Scholl et al., 2012). The questionnaire 
consists of 9 items that are rated on a 6-point Likert scale (absolutely 
inappropriate to absolutely appropriate, scored with 0 to 5). A sum score 
was made (range 0 to 45), and linear transformed into a scale from zero 
to 100 to facilitate interpretation as recommended by Scholl et al. 
(2012). A higher score indicates a higher level of acceptance towards 
shared-decision making. 
3. Beliefs about OACA 
The validated Beliefs about Medicines Questionnaire (BMQ-Specific) 
(Horne et al., 1999; Horne et al., 2013), was used to assess beliefs 
about the necessity of the medication to control the disease and the 
concerns about the potential negative impact of the medication. The 
BMQ-Specific consists of twice 5 items for the subscale ‘Concerns’ 
respectively ‘Necessity’, which are scored on a 5-point Likert scale 
(‘strongly disagree’ to ‘strongly agree’, scored from 1 to 5) resulting in a 
score for the subscales ranging from 5 to 25. BMQ-Specific was adapted 
for use in HCPs by Lesius at al (unpublished) and was translated into 
Dutch following the inverse translation method (Koller et al., 2007) by 
CB and LT. The Dutch HCPs-version was authorised by the original first 
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author R. Horne. HCPs were profiled in four groups: accepting (high 
necessity, low concerns), ambivalent (high necessity, high concerns), 
indifferent (low necessity, low concerns) and sceptical (low necessity, 
high concerns) with the scale midpoint of 15 used as a cut-off to divide 
low and high (Menckeberg et al., 2008). 
4. Usual care activities 
To assess usual care (UC) in supporting adherence to OACA, a list of 
care activities used in adherence supportive care was prepared. The list 
was based on the Quality of Standard Care questionnaire as used by de 
Bruin et al. to assess UC in supporting patients to adhere to HAART-
therapy (de Bruin et al., 2009; de Bruin et, 2010). The list was adapted 
to oncology by the research team consisting of a haematologist, a 
medical oncologist, three pharmacists, and three researchers [nurse, 
psychologist, health scientist] with expertise in the field of medication 
adherence in oncology and haematology. Items were sorted in three 
parts: activities carried out at the start-up of therapy, activities carried 
out during follow-up appointments, and activities which were not 
connected to specific time-points.  For each item, HCPs had to indicate 
whether they delivered the UC activity during the last six months for the 
majority of their patients (yes or no).  
The complete questionnaire was pilot-tested by nine HCPs (i.e. three 
pharmacists, three nurses, one haematologist, one medical oncologist, and one 
general practitioner) in Belgium and the Netherlands. During individual 
interviews, it was explored whether the items were understood as intended. 
Furthermore HCPs were asked about items of supportive adherence care and to 
add items if anything was missing. After processing the comments, the final 
version of the questionnaire was defined. 
Categorising items in domains 
Items were categorised in eight domains. Seven domains are based on the 
categorization as developed by de Bruin et al. (2009): Knowledge, Awareness, 
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Self-efficacy, Intention formation, Social influence, Action control and 
Facilitation. One additional domain was developed: Adverse events 
management. Each member of the research group independently categorised 
the care activities into one of the domains. Then, the categorization of these 
items into the domains was discussed in the group in two rounds until 
consensus was reached. Table 1 gives an overview of the domains, its 
definitions, and typically used techniques of activities within the domain. 
Statistics 
Respondent descriptive data were analysed as frequencies (percentages) for 
categorical variables and as the median and interquartile range (IQR) for 
continuous data. The UC sum score of HCPs in the Netherlands and the UC 
sum score of HCPs in Belgium were compared for all professions by means of 
the non-parametric Chi2-test for nurse practitioners (NP) and the T-test for all 
other professions (normally distributed scores). Associations between 
respondent characteristics and the sum score of care activities were assessed in 
univariate linear regression analyses in which UC sum score was taken as the 
dependent variable. A multivariate linear regression was performed using all 
characteristics which had a p<0.25 in the univariate analyses. For all analyses, a 
two-tailed significance level of 0.05 was used. P-values below this level were 
considered statistically significant. Statistical analysis was performed with SPSS 
22.0 for Windows (IBM Corp, Armonk, NY, USA). 
 
RESULTS 
Respondent characteristics 
A total of 208 HCP (53% male) were included, of whom 107 worked in 51 
hospitals the Netherlands and 101 were employed in 26 hospitals in Belgium. 
Characteristics of the HCPs are shown in Table 2. The scores of the HCPs on 
PAM-Q, SDM-Q-doc, and BMQ are also listed in Table 2. Detailed results and 
discussion about these topics are reported in the paper ‘Adherence to oral 
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anticancer agents: healthcare providers’ perceptions, beliefs and shared 
decision making in Belgium and the Netherlands (submitted)’. 
Usual Care in adherence supportive care  
Table 3 depicted how many HCPs performed one or more of 47 predefined care 
activities in the last six months for the majority of their patients. The items are 
categorised in domains and scores are shown for all HCPs as well as for 
professions separately. Most activities were reported by 50-75% of respondents. 
Activities within the domain Self-efficacy were reported less often (by 45-50% of 
HCPs) while most activities within the domain Adverse event management were 
provided by 75-85% of HCPs. The use of a medication electronic monitoring 
system (MEMS) was reported by only 5% of HCPs.  The median and 
interquartile range per domain is listed for all HCPs together and by profession 
in Table 4. As the domains consist of a different number of items; the range per 
domain varies. 
In figure 1, the maximum score of all domains is presented as 100%. The 
median scores per domain for respectively all HCPs, physicians, NP, nurses and 
pharmacist are: Knowledge: 79, 86, 100, 71 and 29%; Awareness: 75, 75, 75, 
63 and 0%; Social influence: 67,67,67, 67 and 0%; Self-efficacy: 40, 60, 80, 50 
and 0%; Intention formation: 67, 67, 100, 83 and 50%; Action control: 25, 25, 50, 
25 and 0%; Adverse event management: 100, 100, 100, 100 and 29%; and 
Facilitation: 64, 64, 73, 55 and 27%. 
Belgium versus the Netherlands 
Table 5 shows the UC sum scores of HCPs and by profession for the 
Netherlands and Belgium separately. Belgian physicians had a higher UC sum 
score compared to their Dutch colleagues (31.0 versus 27.0). Whereas Dutch 
nurses and pharmacists had a higher UC sum score than their Belgian 
colleagues (35.0 vs 28.0 for nurses and 18.5 versus 3.0 for pharmacists). 
Associations with Usual Care in adherence supportive care 
Univariate associations of UC sum score are presented in Table 6. The sum 
score of NP were higher than physicians and the sum score of pharmacists were 
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significantly lower. The perceptions of adherence management were significantly 
related to the UC sum score. Higher scores on the scales ‘Insight in adherence’, 
‘Patients’ communication’, ‘Capability to influence’ and ‘Causes’ were 
significantly related with a higher UC sum score. In the multivariate analyses the 
following HCPs’ characteristics were significantly associated with the UC sum 
score: Profession (p<0.001), Country (OR -3.95; 95%CI: -6.59 to - 1.30, 
p<0.001) and Total PAMQ- score (OR 2.21; 95%CI: 1.25 – 3.80, p<0.001). 
 
DISCUSSION 
The assessment of adherence supportive care revealed a wide range of UC  
activities provided in the Netherlands and Belgium. Activities aimed at adverse 
event management were reported most frequently; most physicians, NP, and 
nurses provided all activities within this domain. The attention which is given to 
adverse events management in supportive care for OACA does not surprise, as 
in oncology adverse events occur very often and can be serious. Adverse events 
may have great impact on patients’ quality of life (Verbrugghe et al., 2015) and 
have shown to be related to non-adherence and early discontinuation of OACA-
treatment (Verbrugghe et al., 2013; Timmers et al., 2014; Wouters et al., 2014). 
All physicians reported to inquire after experienced adverse events and the 
severity of the adverse events. For several OACA the dosing regimen is 
individually adjusted by the physician in case of adverse events, especially in 
case of grade II-IV. Therefore, information about adverse events is essential for 
physicians.  
Although many UC activities are performed by all HCPs in our study, UC 
activities related to the self-efficacy domain seemed to be less common. Less 
than 50% of HCPs performed care activities related to self-efficacy. However, 
self-efficacy is known to be an important factor influencing adherence and 
adequate self-management, addressed in theoretical behavioral frameworks 
(Bandura, 2004) as well as in medication adherence oncology research (Noens 
et al., 2009; Wouters et al., 2014). Also the domain Action control received 
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relatively little attention. The care activities within this domain focus on cues 
which are especially relevant to avoid unintentional non-adherence. As we know 
that adherence decreases during time (Partridge et al., 2003), supportive 
adherence care as included in the domain Action Control is especially relevant 
for OACA which are planned to be used for longer periods. 
The reported provided care differed between professions and countries. The role 
of the different professions did not seem to vary much per domain. Nurse 
practitioners provided the widest range of care activities. They were more active 
within all domains of care compared to the other HCPs. This might be due to 
their specialization, training in education and focus on self-management support 
and the time spent on patient-contact. The positive impact of NPs in quality of 
care in oncology was demonstrated before (van Hezewijk et al., 2011; McCorkle 
et al., 2012). Pharmacists provided significantly less care activities compared to 
the other HCPs. In four out of eight domains they usually did not provide any 
care activity at all.  
HCPs in the Netherlands and Belgium seem to have organised the care in 
different ways. The role of the various HCPs seemed different in both countries. 
Whereas the physician performed more adherence care activities in Belgium, in 
the Netherlands a higher percentage of nurses and pharmacists were involved in 
UC activities related to medication adherence. Striking is the difference in 
reported adherence supportive care between Dutch and Belgian pharmacists. In 
Belgium, OACA are delivered by the pharmacist working in a hospital pharmacy. 
In the Netherlands OACA are delivered from the hospital as well, but most 
hospitals organise this from a pharmacy specialised in outpatients. This 
pharmacy is equipped for direct patient contact. Furthermore, all Dutch 
pharmacists have access to patients’ list of (co-)medication due to electronic 
services. This might contribute to the differences in the level of provided 
pharmaceutical care. Nevertheless, the role of pharmacists in management of 
adherence to OACA is low in both countries compared with the other HCPs. 
There is a strong relationship between the perceptions of adherence 
management and the number of adherence care activities provided. HCPs who 
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scored higher on the statements about insight and knowledge to manage 
adherence actually performed more adherence care activities. However, 
remarkable is the discrepancy of the PAMQ-score and UC sum score for 
pharmacists: though they stated to have enough insight and knowledge and felt 
able to influence patients’ adherence, they did not provide many care activities. 
Probably within the multidisciplinary team, involvement of pharmacists might be 
optimised as they have a unique contribution in medication therapy management 
(Mancini, 2012). 
Research on current practice of care to support adherence to OACA in Spain, 
Japan and the USA, revealed great variation. A survey of 647 nurses in the USA 
in 2014 revealed that about half of them worked in practices without specific 
policies and procedures to support patients using OACA and inadequate 
interdisciplinary communication (Roop and Wu, 2014). The results of a nurse-
based survey in Japan in 2014 indicated that practices varied, but nurses were 
less likely to ask adherence-related questions to patients in follow-up than in 
new patients (Komatsu et al., 2014). In Spain a study among oncology 
pharmacists in 2013 found that the majority of responding hospitals had safety 
and adherences practices for oral OACA. However, the level of these practices 
varied and they reported significant opportunities for improvement, monitoring 
OACA-adherence (Conde-Estevez et al., 2013). 
There are strengths and limitations to discuss. This study provides an extensive 
survey of care activities provided by HCPs (physicians, as well as NPs, nurses 
as pharmacists) in supporting adherence to OACA. The list of 47 items was 
literature based and adjusted and supplemented with input from oncologists, 
haematologists, NPs, nurses, pharmacists and researchers specialised in 
adherence with OACA from two different countries. We expect our list to be by 
itself of value for HCPs and researchers working with OACA. Three main 
limitations of the study need to be mentioned. First, the reported adherence care 
is not specified to specific patient groups. It might be that adherence care 
provided to patients using long-term medication consists of different activities 
compared to care provided to patients with an expected short-term treatment. 
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This paper gives a general overview of UC in (haemato-) oncology. The second 
limitation of this study is the selection bias. Though we recruited respondents 
from 87 different hospitals, the questionnaire might be filled out mainly by HCPs 
interested in adherence care. Furthermore, answers may be overstated as 
people tend to give socially desirable information. It is not unlikely that the 
adherence care is less extensive in daily practice. It would be interesting to 
study the provided care by using video observations in daily practice, which has 
shown to be a reliable and valid method (Ram et al., 1999). Third, the sample in 
this study was not truly random, so statistical significance should be interpreted 
with caution. 
 
CONCLUSION 
In conclusion, we provide a unique and complete list of 47 items of care 
activities provided by HCPs in supporting adherence to OACA, which we expect 
to be of value for HCP as well as researchers. 
The assessment of adherence supportive care revealed a wide range of UC 
activities provided in the Netherlands and Belgium. The extent of UC activities 
provided differs by profession; NPs are the most active, pharmacists provide 
least adherence care. For all HCPs, activities aimed at increasing patients’ 
knowledge and adverse event management were reported most frequently 
whereas activities aimed at self-efficacy and action control were performed less. 
We advise to focus on these latter domains when developing interventions to 
support patients taking OACA and enhance quality of care as self-efficacy and 
action control have shown to be associated with higher adherence to 
medication.  
There is a strong relationship between the perceptions of adherence 
management and the number of reported adherence care activities that are 
provided. The provided care differs between the professions that are involved in 
OACA adherence and also by country. This confirms that in intervention 
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research, a clear description of which care is provided in the reference group is 
obligated. 
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  Table 1. Domains of Usual Care activities in adherence supportive care     
  Domain Definition Typically used technique(s)   
  
Knowledge Usual care activities focussing on the knowledge of patients about their 
diseases and the medicines used for treatment, excluding knowledge 
related to adverse events. 
- providing information 
- increase patient understanding 
  
  
Awareness Usual care activities aimed to increase the awareness of patients with 
respect to non-adherence to treatment and consequences of non-
adherence 
- risk communication 
- giving feedback on patients’ behaviour 
  
  
Self-efficacy Usual care activities that focus on self-efficacy; a patient's belief in her/his 
ability in succeeding to adhere to treatment 
- the planning of coping responses like discussing 
adherence barriers and finding ways to overcome 
barriers   
  
Intention Formation Usual care activities which focus on fostering the intention to adhere by 
planning how and when to take the medication 
- the development of a tailored medication schedule 
  
  
Social Influence Usual care activities that provide patients with professional social support 
with respect to the correct use of their medication 
- organising social support 
  
  
Action Control Usual care activities which focus on the effective implementation of the 
intended use of medication 
- stimulating the use of cues 
  
  
Adverse Events 
Management 
Usual care activities which focus on patients' management of adverse 
events 
- providing information 
- coping with adverse events   
  
Facilitation Usual care activities which facilitate a correct use of medication and 
which are not categorised in one of the other domains 
- reducing environmental barriers 
  
  
  Table 2. Basic characteristics         
  N = 208 All NL Be   
    N = 208 N = 107 N = 101   
  Gender (%) 
   
  
      male 29.3 33.6 24.8   
      female 70.7 66.4 75.2   
  Profession (%) 
   
  
       oncologist 15.9 10.3 21.8   
       hematologist 15.9 26.2 5.0   
      NPs 16.8 17.8 15.8   
      nurse 28.8 21.5 36.6   
      pharmacist 22.6 24.3 20.8   
  Work experience (yr) 
 
      
      median 16 16 17   
      range  1-46  2-46 1-40   
  Type of hospital (%) 
 
      
      academic 29.6 22.4 37.4   
      non-academic 70.4 77.6 62.6   
  Number of different hospitals 87 51 36   
  Specialisation (%) 
   
  
      hematology 30.6 38.0 22.6   
      oncology 69.4 62.0 77.4   
  Adherence (PAMQ) (%) 
   
  
      Insight in adherence 41.8 43.9 39.6   
      Patients' communication 43.8 45.8 41.6   
      Capability to influence 82.2 86.0 78.2   
      Consequences 78.8 75.7 82.2   
      Causes 68.3 69.2 67.3   
      Total PAMQ-score (0-5) 
   
  
      - median 3.0 3.0 3.0   
      - IQR 2.0-4.0 2.0-4.0 2.0-4.0   
  SDM*-score (0-100) 82.2 84.4 80.0   
  BMQ-group (%) 
   
  
      accepting 58.3 61.3 55.0   
      ambivalent 31.1 24.5 38.0   
      indifferent 8.3 11.3 5.0   
      sceptical 2.4 2.8 5.0   
  Abbreviations: NL, the Netherlands; Be, Belgium; NPs, nurse practitioners;   
  yr, year; IQR, interquartile range; SDM-score, sum score of the Shared   
  Decision Making-doc-Questionnaire – a higher sum scores indicates perceptions of more   
  
 
shared decision making; PAMQ, HCP's Perceptions of 
  
Adherence Management Questionnaire – a higher score on the PAMQ indicates a higher 
number of perceptions about managing adherence the HCP agree with; BMQ, Beliefs about 
Medicines Questionnaire. * - higher scores indicates stronger beliefs of necessity or concerns;    
  SDM only assessed for physicians (N=66).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
Table 3. Usual care activities in supporting adherence           
      all HCPs physician NPs nurse pharmacist 
  
 
N* 208* 66* 35* 60* 47*   
   
 
% % % % %   
  Knowledge 
      
  
  Provide information on the disease 208 74.0 100.0 100.0 75.0 17.0   
  
Provide information on the expected effect(s) of the 
drug 206 73.3 100.0 88.2 69.5 29.8   
  Discuss the action of the drug 206 72.3 95.5 88.2 61.0 42.6   
  
Hand out brochures or written information about the 
disease and/or medication used for treatment 
205 69.3 67.2 91.2 66.7 59.6   
  
Discuss when the first effect of the medication can be 
expected 206 64.1 100.0 76.5 50.8 21.3   
  
Monitor and/or discuss possible interactions with other 
medicines or foods 204 77.0 84.4 93.9 66.7 68.1   
  Discuss (changes in) sexuality 197 32.5 32.3 66.7 39.3 0.0   
  Awareness               
  
Discuss the importance of treatment adherence  
200 76.0  85.9  87.9 80.7 47.8   
  
Discuss the consequences of non-adherence (to 
treatment) 199 57.8 71.4 69.7 59.6 28.3   
  
Ask the patient if he/she has missed one or more 
doses 198 56.6 65.1 81.8 66.1 15.2   
  
Discuss the use and results of the Medication Event 
Monitoring System (MEMS) 195 4.6 4.9 6.3 5.4 2.2   
  Social influence               
  Involve partner and/or relatives in the treatment 199 71.9 85.9 87.5 82.5 28.3   
  Encourage patients to organise social support 197 40.1 49.2 54.5 52.6 2.2   
  Refer a patient to a patients' association 198 36.4 54.0 60.6 30.4 2.2   
  Self-efficacy               
  
Encourage patients to timely plan the intake of 
medicines during holidays and weekends 197 43.7 53.2 57.6 42.9 21.7   
  
Discuss potential barriers regarding treatment 
adherence 198 49.0 55.6 62.5 52.6 26.1   
  
Discuss possible ways to overcome  potential barriers 
regarding treatment adherence (at start of the 
treatment) 199 50.3 57.1 69.7 49.1 28.3   
  
Inquire after barriers regarding treatment adherence 
198 49.5 58.7 75.8 50.0 17.4   
  
Discuss  ways to overcome potential barriers regarding 
treatment adherence (at follow-up) 197 45.7 56.5 69.7 42.9 17.4   
  
 
    all HCPs physician NPs nurse pharmacist  
  N* 208* 66* 35* 60* 47*   
   % % % % %   
  Intention formation               
  
Discuss the scheduled duration of medication 
treatment 206 70.9 100.0 91.2 57.6 31.9   
  
Explain how often the medicine should be taken. If 
necessary, explain the treatment schedule 
205 90.2 96.9 97.1 90.0 76.6   
  
Discuss the intake of the medicines relative to that of 
meals and why 202 81.2 72.6 97.0 88.3 72.3   
  
Discuss what to do if there is vomiting shortly after 
ingestion of the medicine 203 64.0 60.3 91.2 76.3 34.0   
  Explain what to do if a dose is missed 198 67.2 61.9 97.0 75.0 43.5   
  
Development of an individual written medication 
schedule 195 43.1 27.9 81.3 50.0 28.3   
  Action control               
  
Identify daily routines and encourage patients to align 
the taking of medicines with their routines 
199 58.8 55.6 90.9 71.9 23.9   
  Encourage patients to use a seven day pillbox 197 27.9 17.5 50.0 35.7 17.4   
  
Encourage patients to use the Medication Event 
Monitoring System (MEMS) 194 5.2 5.0 9.4 3.6 4.3   
  
Encourage patients to use alarm devices for properly 
timing their medication intake 196 22.4 11.3 48.5 26.8 13.3   
  Adverse events management               
  Discuss the common side effects of the drug 207 83.6 97.0 94.1 83.3 57.4   
  
Discuss options to mitigate the impact of side effects 
(at start of treatment) 205 77.6 81.3 97.1 85.0 48.9   
  
Discuss the possibility of dose adjustment if side 
effects occur 205 66.8 90.8 73.5 67.8 27.7   
  
Inquire after (perceived) side-effects of treatment 
198 84.3 100.0 100.0 85.7 50.0   
  Inquire after the severity of the side-effects 198 82.3 100.0 97.0 87.5 41.3   
  
Discuss options to mitigate the impact of side effects 
(during treatment) 198 77.3 92.1 93.9 80.4 41.3   
  
Give the patient a telephone number and tell who to 
contact in the case of side-effects 195 70.8 85.0 97.0 80.4 21.7   
  Facilitation               
  
Explain how and where the product is available 
204 76.0 83.1 91.2 70.7 61.7   
  Discuss drug storage recommendations 200 61.0 33.3 72.7 64.9 85.1   
  
 
 
 
 
 
 
 
 
    all HCPs physician NPs nurse pharmacist  
  N* 208* 66* 35* 60* 47*   
   % % % % %   
 Give feedback about treatment efficacy 198 60.1 100.0 67.7 48.2 13.0  
  Inquire after positive effects of treatment 198 69.2 96.8 78.8 69.6 23.9   
  
Ensure the timely transfer of medication information to 
other health care providers 197 61.9 80.6 59.4 40.4 65.2   
  
Call the patient after the start of treatment to ask about 
experiences 194 22.7 8.5 51.5 35.7 4.3   
  
Give the patient a telephone number and tell who to 
contact in case of problems with treatment adherence 
196 59.2 67.2 87.9 62.5 23.9   
  
Inform the patient about 24 hour availability of 
assistance 197 67.5 85.2 81.8 73.7 26.1   
  
Intensify the number of follow-up visits if patients have 
problems with treatment adherence 
197 30.5 38.7 51.5 26.8 8.7   
  
Refer patients to another healthcare provider for (co-
)treatment (e.g. in the case of adverse events) 
198 48.5 60.3 63.6 42.9 28.3   
  
Refer to another healthcare provider in case of 
(suspected) psychosocial problems 197 61.4 77.4 81.8 76.9 6.5   
  Abbreviations: HCPs, healthcare providers; NPs, nurse practitioners         
  * Note: missings excluded from analyses               
  
  Table 4 Usual Care Domain-scores               
  
 
  Knowledge Awareness 
Social 
Influence 
Self-
efficacy 
Intention 
Formation 
Action 
Contol 
Adverse Events 
Management Facilitation   
  range:   (0-7) (0-4) (0-3) (0-5) (0-6) (0-4) (0-7) (0-11)   
  All HCPs N 194 195 195 195 190 193 194 191   
      median 
 
5.5 2.0 2.0 2.0 4.0 1.0 7.0 7.0   
      IQR 
 
3-6 1-3 1-2 0-5 3-6 0-2 5-7 4-8   
  Physicians N 59 61 61 61 58 60 59 58   
      median 
 
6.0 3.0 2.0 3.0 4.0 1.0 7.0 7.0   
      IQR 
 
5-6 2-3 1.5-2 1-5 3-5 0-1 6-7 6-8   
  NPs N 33 32 32 32 31 32 33 32   
      median 
 
7.0 3.0 2.0 4.0 6.0 2.0 7.0 8.0   
      IQR   6-7 2-3 2-3 1.3-5 6-6 1-3 6-7 7-10   
  Nurses N 56 56 56 56 55 56 56 55   
      median 
 
5.0 2.5 2.0 2.5 5.0 1.0 7.0 6.0   
      IQR 
 
3-6 1-3 1-2 0-5 3-6 1-2 5.3-7 4-9   
  Pharmacists N 46 46 46 46 46 45 46 46   
      median 
 
2.0 0.0 0.0 0.0 3.0 0.0 2.0 3.0   
      IQR 
 
0-3.3 0-2 0-1 0-2 1-4 0-1 0-6 1-6   
  Abbreviations: HCPs, healthcare providers; IQR, interquartile range; NPs, nurse practitioners.   
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  Table 5. Total score Usual Care NL vs Be     
  
 
NL Be NL vs Be   
  
 
N UC-sum N UC-sum p   
  Physician 27 27,0 25 31,0 0.043 * 
  NPs 13 38,0 16 36,5 0.307   
  Nurse 17 35,0 37 28,0 <0.001 * 
  Pharmacist 24 18,5 21 3,0 0.026 * 
  Abbreviations: NL, the Netherlands; Be, Belgium; vs, versus;     
  UC-sum, usual care activities sum score; HCPs, healthcare    
  providers; NPs, nurse practitioners.       
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  Table 6. Univariate associations with Usual Care sum score   
  N=180     
  
 
OR 95% CI p-value   
  Gender (male) 1.97 -1.35 - 5.28 0.244   
  Profession 
  
<0.001 * 
      Physician as reference: 
   
  
      - Nurse Practioner 4.19 0.38 - 8.01 0.031 * 
      - Nurse -1.60 -4.80 -  1.59 0.324   
      - Pharmacist -12.69 -16.04 -  -9.34 <0.001 * 
  Work experience (yr) -0.03 -0.17 - 0.11 0.673   
  Type of hospital (academic) -3.20 -6.45 - 0.06 0.054   
  Specialisation (oncology) -2.36 -5.80 - 1.09 0.178   
  Country (the Netherlands) -2.51 5.50 - 0.48 0.100   
  Adherence (PAMQ)         
      Insight in adherence 6.80 3.93 - 9.68 <0.001 * 
      Patients' communication 9.32 6.62 - 12.01 <0.001 * 
      Capability to influence 5.78 2.08 - 9.47 0.002 * 
      Consequences 3.60 -0.04 - 7.24 0.053   
      Causes 3.70 0.59 - 6.81 0.020 * 
      Total PAMQ-score 3.23 2.26 - 4.19 <0.001 * 
  SDM*-score -0.00 -0.09 - 0.09 0.973   
  BMQ-group 
  
0.972   
      Accepting as reference: 
   
  
      - Ambivalent -3.34 .-3.72 - 3.05 0.844   
      - Indifferent 0.32 -5.45 - 6.08 0.866   
      - Sceptical -2.22 -12.55 - 8.11 0.680   
  Abbreviations: OR, odds ratio; 95%CI, 95% confidence interval, yr,   
  year; SDM-score, sum score of the Shared Decision Making-doc-   
  Questionnaire; *, SDM only assessed for physicians (N=66);   
  BMQ, Beliefs about Medicines Questionnaire.     
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The aims of this PhD thesis were (1) exploring factors and processes influencing 
(non-)adherence and (non-)persistence to oral anticancer drugs (OACD), (2) 
exploring healthcare professionals’ perceptions about managing OACD 
adherence and shared decision making (SDM) and beliefs towards OACD, and 
(3) exploring usual care in supporting adherence to OACD. In chapter 2, a 
systematic literature review on associated factors of (non-)adherence and (non-
)persistence in patients taking OACD was described. Chapter 3 and 4 described 
two qualitative studies giving insight into influencing factors and processes 
underlying (non-)adherence and (non-)persistence in patients taking oral 
tyrosine kinase inhibitors (TKIs) and antihormonal therapy (AHT). Chapter 4 and 
5 described two quantitative studies exploring healthcare professionals’ 
perceptions about managing OACD adherence and SDM and beliefs towards 
OACD, and usual care.  
In the general discussion, four main issues will be addressed. First, adherence 
and self-management support: a complex intervention design will be addressed.  
The building blocks needed for a complex intervention design which could be 
derived from this PhD thesis will be discussed (literature review, problem and 
needs analysis, and current practice analysis). Second, some methodological 
considerations will be provided. Third, implications for practice will be provided 
and fourth, recommendations for future research will be outlined.  
 
ADHERENCE AND SELF-MANAGEMENT SUPPORT: A COMPLEX INTERVENTION DESIGN 
Our study showed that factors influencing (non-)adherence and  
(non-)persistence in patients taking OACD are multifaceted. Several OACD 
(non-)adherence and (non-)persistence influencing factors were found to interact 
with each other. Also the importance of the patients’ perspective, patients’ 
experiences and needs were highlighted. Furthermore, the importance of not 
solely focusing on adherence and persistence to OACD, but also on taking into 
account the patients’ perspectives of quality of life was emphasized. Based on 
our findings, we could conclude that (non-)adherence and (non-)persistence in 
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patients taking OACD are complex phenomena. Consequently, facilitating 
adherence and persistence in patients taking OACD and supporting them in 
ongoing self-management require a complex intervention. Based on the 
previous findings, the complex intervention should consist of a number of 
components. First, a clustering of different components to address the different 
influencing factors should be included. Second, interventions should not be 
aimed at all patients taking OACD but should be tailored to the specific needs of 
the patients. Third, multiple intervention outcomes should be evaluated (e.g. 
adherence, quality of life, self-management). 
To develop complex interventions, the van Meijel model is appropriate (van 
Meijel et al., 2004). The model describes a planned and systematic approach for 
the development of complex nursing interventions. A strong emphasis is placed 
on patients’ experiences and perspectives. The building blocks needed for 
intervention design (van Meijel et al., 2004) could be derived from this PhD 
thesis. Within this chapter, the discussion of our study findings will be structured 
according to these building blocks: literature review (chapter 2), problem and 
needs analysis (chapter 3, 4, and 5), and current practice analysis (chapter 6).  
 
Literature review 
A thorough literature review is the starting point of complex intervention 
development (van Meijel et al., 2004). In this phase, information is needed to 
inform the intervention development. It is explored whether there is sufficient 
knowledge about factors influencing OACD (non-)adherence and  
(non-)persistence, patients’ needs and problems, and interventions to support 
patients in adhering to OACD (see chapter 1: general introduction).  
In chapter 2, an overview was given of factors influencing (non-)adherence and 
(non-)persistence in patients taking different types of OACD. Factors positively 
and negatively associated with adherence and persistence were described. 
Influencing factors were structured according to the five categories suggested by 
the World Health Organization framework of factors influencing medication 
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adherence (WHO, 2003). Patient-related, therapy-related, disease-related, 
healthcare system-related, and social-economic factors were found to influence 
(non-)adherence and (non-)persistence. Side effects, younger and older age, 
longer duration of therapy, increased number of prescriptions, co-morbidities, 
and higher out-of-pocket costs were found to be associated with non-adherence 
and non-persistence in multiple studies included in the systematic review.  
The systematic review revealed that much of the research on factors influencing 
(non-)adherence and (non-)persistence to OACD was conducted from a 
reductionist perspective (Gater et al., 2012). However, complex behavioral 
phenomena such as adherence and persistence to OACD could not be reduced 
to its constituent elements. For example, the focus on objective assessment of 
(factors influencing) adherence by reviewing retrospective databases supports 
the reductionist perspective assertion (Gater et al., 2012). In retrospective 
research, factors that may predict adherence are often limited to demographic, 
disease or treatment-related factors as found in our systematic review. These 
factors may be considered as ‘weak’ predictors of (non-)adherence (McHorney, 
2009). For patient demographic variables, the lack of a consistent relationship 
with adherence is well documented (Dimatteo, 2004). Age, for example, which is 
frequently found to be associated with (non-)adherence and (non-)persistence to 
OACD, could be interpreted as a ‘distal’ predictor. Our systematic review 
highlighted the need for exploration of underlying processes influencing 
adherence and persistence to OACD, and to get more insight into the needs and 
problems from the patients’ perspective to inform patient-tailored interventions.  
 
Problem and needs analysis 
The literature review (chapter 2) showed that the complex patterns and 
dynamics of (non-) adherence and (non-)persistence in patients taking OACD 
are still not fully understood. More insight was needed into the patients’ needs 
and the interrelatedness of influencing factors and underlying processes of  
(non-)adherence and (non-)persistence from the patients’ perspective. 
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Therefore, two qualitative studies were conducted to get insight into patients’ 
needs and experiences in an open and inductive manner. Insight into underlying 
processes was revealed and some new influencing factors were found.  
The literature review showed that side effects, for example, are a predominant 
factor associated with (non-)adherence and (non-)persistence in patients taking 
OACD. In the qualitative studies, important factors were found to be related to 
side effects such as the information patients received about side effects and the 
normal course of side effects, perceptions and expectations about side effects, 
the discrepancy with normal daily life, the healthcare professionals’ recognition 
(for difficulties such as side effects), and the need to be reassured that side 
effects of the OACD are not signs of a relapse. A recently published paper 
showed that 60% of the physicians did not react on side effects patients 
experienced (Wuensch et al., 2015). Patients who reported having received 
detailed answers to their questions were significantly better adherent (Wuensch 
et al., 2015). Our study showed that in patients taking AHT who felt well 
informed about side effects and feel recognized for the difficulties they 
experienced, the burden was lower. In contrast, patients who did not feel 
recognized when they mentioned side effects, often did not report their 
difficulties anymore in order to avoid the confrontation with disbelief and 
incomprehension. This placed them in a lonely position, which made the burden 
of the AHT higher and made it more difficult to adhere/persist to the therapy. 
Previous results show that multiple factors influenced (non-)adherence. 
Consequently, only reducing side effects may not lead to improved adherence.  
Recently published studies show that, in spite of the current (mostly 
quantitatively based) knowledge, non-adherence to OACD is still high (Kekäle et 
al., 2014; Anderson et al., 2015). Non-adherence is especially high in patients 
treated for a malignancy with a chronic character such as chronic myeloid 
leukemia (CML), using long-term OACD. Adherence rates to OACD in patients 
treated for a cancer type with a more acute, life threatening character, such as 
renal cell cancer with short-term OACD seems to be higher (Wolter et al., 2012; 
Timmers et al., 2014; Timmers et al., 2015). Despite the lack of extensive 
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research in the latter type of cancer, our study could offer an explanation for the 
higher adherence rates found in patients treated with short-term OACD. In the 
oral TKI study (chapter 3), patients treated with OACD for a cancer type with a 
more acute, life threatening character considered treatment with oral TKI often 
as the last chance to survive. For some patients, starting oral TKI therapy meant 
that they had moved on from a curative to a chronic, palliative treatment. This 
confronted them with the non-curable and life-threatening nature of the disease. 
These patients reported to be highly adherent to their therapy. For these 
patients, treatment mostly got the highest priority (focus on survival). They often 
felt a great responsibility for their survival and often did not report side effects to 
healthcare professionals out of the fear for a dose reduction and a concomitant 
decrease in efficacy of the treatment. These study findings could also reveal a 
plausible explanation on how overadherence (Allen & Williamson, 2014), which 
is taking more medication than prescribed to OACD, arises. Patients with a 
focus on survival could be at risk for overadherence.  
In literature, a distinction is often made between unintentional and intentional 
non-adherence. Unintentional non-adherence is often seen as the result of a 
lack of capacity and resource (e.g. forgetting, not knowing exactly how to use 
medicines), while intentional non-adherence is often seen as more deliberate 
and associated with patient motivation (Clifford et al., 2008). Both types of non-
adherence were found and discussed during the interviews. However, our 
results mainly report on the understanding of intentional non-adherence. We 
have chosen to highlight this type of non-adherence because this seems to be 
the most complex and interrelated phenomenon and therefore the most difficult 
to intervene on. However, unintentional and intentional non-adherence are not 
entirely independent. Forgetting, for example, is more likely when motivation for 
medication is low.  
In chapter 5, healthcare professionals’ perceptions about managing OACD 
adherence, SDM and beliefs towards OACD were explored. Few studies 
focused on the physicians’ perspective (Regnier Denois et al., 2010; Kekäle et 
al., 2014). No studies reported on perspectives of pharmacists, nurses, and 
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physicians simultaneously. The study by Kekäle et al. (2014) compared CML 
patients’ adherence with adherence as estimated by their physicians. The 
physicians’ estimate of adherence was too optimistic in 73% of the cases. In our 
study, significantly more medical oncologists indicated to know the level of 
adherence of all their patients and thought patients discussed non-adherence 
with them compared to hematologists. As stated earlier, adherence is especially 
low in patients treated for a malignancy with a chronic character such as the 
hematologic malignancy CML, using long-term OACD and mostly treated by 
hematologists (Kekäle et al., 2014; Anderson et al., 2015). Adherence rates to 
OACD in patients treated for a cancer type treated with short-term OACD in the 
field of medical oncology, seems to be higher (Timmers et al., 2014; Timmers et 
al., 2015). It is plausible that in patients treated with short-term OACD, medical 
oncologists may assume that patients are highly adherent given the acute and 
life-threatening character of the disease, which might have been reflected in the 
higher scores of medical oncologists. Also, both medical oncologists and 
hematologists might be aware of the different adherence rates of their patient 
population in literature which might influence their perception of adherence in 
their patients. 
In our study, necessity beliefs about OACD outweighed concerns among all 
studied healthcare professionals. However, extensively emphasizing the 
importance of taking the OACD could make patients feel responsible for their 
own survival. The qualitative study in patients taking oral TKIs showed that 
patients with a focus on survival, as a result, did not report side effects out of the 
fear of a dose reduction, which put them at risk for an adverse drug reaction 
(toxicity). Healthcare professionals mainly focusing on necessity of OACD and 
patients focusing on survival could reinforce each other in persevering OACD 
therapy while suffering a low quality of life and being at risk of toxicity.  
The problem and needs analysis showed that oral TKI and AHT regimen may 
strongly impact on patients’ quality of life. The importance of taking into account 
patients’ experiences and needs in following OACD therapy to inform complex 
intervention development was emphasized in the two qualitative studies. From 
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the healthcare professionals perspective, a considerable part stated they do not 
know the adherence of their patients and do not think patients discuss 
adherence with them indicating little openness to talk about adherence. Based 
on the problem and needs analysis, patient tailored counseling, supporting 
ongoing self-management, recognition for the difficulties patients experience, 
and establishing a trust-based and open relationship are key elements to inform 
complex intervention development.  
 
Current practice analysis 
Current practice analysis is the last building block to inform the development of a 
complex intervention to support patients following OACD therapy, according to 
the model of van Meijel (2004). In chapter 6, usual care activities in supporting 
adherence to OACD in (haemato-) oncology in Belgium and the Netherlands 
among different healthcare professionals were explored. A wide range of care 
activities were revealed. The extent of usual care activities provided differs by 
profession; nurse practitioners are the most active, pharmacist provided least 
adherence care. For all healthcare professionals, activities in the domain 
Knowledge and Adverse Event Management were reported most frequently 
whereas activities of the domains Self-efficacy, Social influence and Action 
Control are performed less. Most physicians, nurse practitioners, and nurses 
provided all activities within the domain Adverse Event Management. In 
oncology, adverse events occur very often and can be serious. Physicians need 
to know the occurrence and the grade of adverse events to determine the dosing 
of OACA. Furthermore adverse events have great impact on patients’ quality of 
life as shown in our two qualitative studies. The attention which is giving to 
adverse events management in supportive care for OACA is justified. However, 
in complex intervention development, an emphasis should be placed on the 
domains Self-efficacy, Social influence and Action Control and the 
interrelatedness of the different domains to support adherence and enhance 
quality of care and life. More attention is needed for organizing social support 
Chapter 7 
 
220 
 
 
and self-efficacy increasing interventions in the context of ongoing self-
management support. 
 
METHODOLOGICAL CONSIDERATIONS 
In the systematic review we aimed at providing an updated overview of 
determinants and associated factors of medication (non-)adherence and  
(non-)persistence in patients taking different types of OACD. Therefore, both 
qualitative as quantitative research were considered. However, in this systematic 
review, we did not consider the strength of the associations of the different 
determinants in relation to (non-)adherence and (non-)persistence in the 
quantitative studies.  
By using both qualitative and quantitative research, it was possible to compare 
findings from the quantitative studies from healthcare professionals’ 
perspectives to patients’ perspectives from the qualitative studies. Furthermore, 
it enabled us to detect contradictions between the qualitative and quantitative 
studies and provide explanations for this. 
In both qualitative studies, it was possible that some participants did not feel 
totally comfortable talking openly about non-adherence and non-persistence. 
Patients who were non-adherent could have felt guilty about their non-
adherence. For example, as found in the study in patients taking AHT, the fact 
that the OACD makes relapse less likely makes it difficult to downplay the 
importance of AHT. Admitting that they did not take the medication as prescribed 
could have resulted in feelings of guilt if they were to relapse. Furthermore 
patients could have been afraid to be stigmatized as a ‘bad’ patient. To promote 
openness, the interviewer explained the importance of being open to understand 
what patients are going through and emphasized anonymity. To promote a 
climate of comfort to talk about non-adherence and non-persistence, special 
attention was paid to the use of non-threatening and non-judgmental questions. 
In the quantitative studies, the role of different healthcare professionals was 
explored. Until now, only a small number of studies focused on the role of 
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specific professions (mostly nurses and pharmacists) to support adherence in 
patients taking OACD. However, we did not study the integral interdisciplinary 
support given to patients taking OACD. In the quantitative studies, the role of the 
psychologist was not studied in relation to adherence care. Yet, the qualitative 
studies showed the great psychological demands associated with the cancer 
trajectory and the treatment with OACD. Furthermore, the questionnaire used in 
the quantitative studies did not allow e.g. to explore how coordination occurs 
between healthcare professionals, and to explore the consistency of the 
provided information to patients by different healthcare professionals.  
 
IMPLICATIONS FOR PRACTICE 
As described in the introductory chapter, interventions including a tailored 
approach seem to be promising (Kavookjian and Wittayanukorn, 2014; Mathes 
et al., 2014). However, more high quality intervention studies are needed. 
Emphasis must be placed on the patients’ experience to understand  
(non-)adherence and (non-)persistence and to inform tailored interventions to 
support patients taking OACD. On the hospital level, the patient’s perspective 
should be essential in the strategic choices hospitals make.   
Healthcare professionals should create conditions wherein patients get maximal 
chances to come to a balance between surviving and quality of life (see chapter 
3). Interventions should be discussed with the patient so that it fits the patients’ 
life and needs. For example, healthcare professionals should not give a 
standard tool such as a mobile phone reminder to prevent unintentional non-
adherence, but should discuss the patients’ needs and habits and discuss what 
could be particularly helpful for them.  
Patients should be provided with ongoing self-management and care support. 
Supporting patients to adequate self-management means that patients should 
be empowered to find the best possible compromise between the demands from 
life and the demands of the disease as defined by Grypdonck (1999). In 
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addition, patients should be supported to prevent inadequate self-management. 
Based on the results of our study, the following should be addressed:  
 Support of adequate self-management (including the support of self-
efficacy) 
 Support patients to be open about side effects and to handle side effects  
 Patient tailored counseling and the understanding of the patient’s 
knowledge, beliefs and concerns 
 Recognition for the difficulties patients experience 
 Providing an individualized knowledge base about medication, disease, 
therapy, and adherence tailored to the patients’ needs and level of 
understanding to increase insightful knowledge about the treatment and 
side effects. Without insightful knowledge, patients could not make well-
informed decisions. This could increase the risk of inadequate decisions, 
which may (unnecessary) affect the efficacy of the treatment or the 
patients’ quality of life.  
 Enhancing social support (family/friends/peers) 
 Communication and sufficient time taking during contacts 
 A trust-based relationship  
 Not undermining patients’ hope  
 Regular contacts (e.g. by means of telephone follow-up) 
 Permanence and an accessible trust contact person 
 Interdisciplinary approach 
Healthcare professionals should be careful that adherence does not become the 
sole focus, but should also take into account the patients’ perspectives of 
(quality of) life. A distinction should be made between health coaching and life 
coaching. Health coaching mainly focuses on improving health, while life 
coaching more broadly focuses on the patients’ life and wellness rather than 
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pathology (Ammentorp et al., 2013). Life coaching could be recommended as a 
complementary strategy to support patients, starting from their values, needs, 
and priorities. Consequently, a well informed and supported patient, who 
decides to stop the treatment in favor of quality of life, should not be categorized 
as being non-persistent. When this decision is well-informed, this could be 
described as an act of adequate self-management.  
Our study showed that a trust based relationship is crucial to make patients feel 
comfortable about reporting side effects and reporting on quality of life and 
experienced difficulties. Reporting side effects enables healthcare professionals 
to support patients in dealing with side effects or changing of dosage or 
medication in order to make quality of life as acceptable as possible. Based on 
the qualitative study in patients taking oral TKIs, a practice with sufficient space 
for individual, regular and easy accessible consultations could be recommended 
to increase the likelihood of establishing a trust-based relationship. Furthermore, 
healthcare professionals’ interpersonal skills play an important role in 
establishing a relationship of trust (Burkitt Wright et al., 2004; Kahn et al., 2007). 
Authentic, open communication and a supportive, proactive and encouraging 
attitude are important to ensure that the patient is comfortable to share 
information that might cause feelings of having done something wrong, fear of 
reprimand, or feelings of embarrassment. The qualitative study on AHT 
highlighted the importance of recognizing patients for the experienced difficulties 
and valuing patients as an individual. The qualitative study on AHT also stressed 
the importance of active listening, an empathic attitude, and patient-centered 
communication. Additionally, the importance of a communication style 
reinforcing adequate behavior and not undermining patients’ hope was 
highlighted in the oral TKI study.  
Based on the results of our study, an interdisciplinary approach to support 
patients in adequate self-management could be recommended. The qualitative 
study in patients taking oral TKIs showed that signs of a good interdisciplinary 
collaboration (for example, when patients noticed that healthcare professionals 
exchanged information with each other and no conflicting advice was provided) 
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increased trust. The emphasis on productivity in physicians could make it difficult 
to provide sufficient time for patient tailored education, follow-up and adequate 
self-management support. The qualitative study in AHT indicated that patients 
do not expect this from physicians. Therefore, nurse practitioners/clinical nurse 
specialists could play an important role by communicating, educating, and 
supporting patients in ongoing self-management. Research in chronically ill 
patients also indicated that involvement of nurse practitioners increased patient’s 
self-efficacy (Richardson et al., 2014; Broderick et al., 2014), which is an 
important factor in medication adherence and adequate self-management. The 
quantitative study of usual care showed that nurse practitioners are the most 
active in providing usual care activities, especially in the domains self-efficacy, 
knowledge, intention formation, adverse event management, and facilitation. A 
strong nurse-patient relationship with individualized education has previously 
shown to be crucial for successful management of adherence to OACD (Wood, 
2012). Nurse practitioners/clinical nurse specialists could play a key role in 
augmenting the patient-provider interaction and further adherence within a trust 
based relationship. Identification of a single nurse practitioner/clinical nurse 
specialist as a point of contact besides the physician may promote trust in 
patients and increase openness to express the experienced difficulties. Given 
the important role of nurse practitioners/clinical nurse specialists for the support 
of patients following OACD therapy, a nomenclature for nurse consultations may 
be developed. This may enable hospitals to increase patient tailored care by 
nurse practitioners/clinical nurse specialists.   
Nurses may have (had) more frequent and intense contact with the patient 
and/or may have built a trust and open relationship with the patient during 
hospitalizations. Therefore, nurses could have an important signal function (for 
example about (the impact of) side effects, the patients’ needs, concerns and 
support) within an interdisciplinary team. Furthermore, nurses may be important 
to provide psycho-social support to patients. 
The study in patients taking oral TKIs showed that patients are often anxious 
about the amount of medication they have to take. Pharmacists could have an 
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important role as an expert in medication review. Pharmacists could support 
patients or other healthcare workers by clarifying information about the 
medication, interactions, administration, and side effect management.  
General practitioners could play an important role as being a confidant for some 
patients. General practitioners could act as intermediate between patient and 
hospital. However, therefore transmural care should be supported and general 
practitioners should be involved standard from the beginning of the trajectory. A 
central contact person (e.g. nurse practitioner/clinical nurse specialist) could be 
indicated to facilitate communication in both ways.  
Involvement of different healthcare professionals (e.g. pharmacists and general 
practitioners) could be optimized when electronic health records are made more 
accessible for different healthcare professionals. This way, patient-centered care 
and integrated care could be supported. 
The qualitative studies showed that the disease and the OACD therapy are often 
very stressful and demanding and strongly impacts on quality of life. Therefore, 
every healthcare worker should provide psychosocial support. Yet, for some 
patients, a psychologist may be an important actor for psychological help and 
the enhancement of coping abilities. However, previous studies showed that 
some patients may be reluctant to appeal on a psychologist because they fear 
that their positive attitude that they consider important to stand the therapy, may 
be threatened (Maher and De Vries, 2011; Matthews et al., 2003). Therefore, a 
psychologist should be integrated in an interdisciplinary team approach. Team 
members could reduce barriers towards psychological help by emphasizing the 
normality of psychosocial needs and by transferring trust when referring to a 
psychologist (Daem et al., 2013).  
 
FUTURE PERSPECTIVES 
In a future study, a complex patient tailored intervention following the van Meijel 
model (2004), could be developed based on the results of our findings to support 
adherence and self-management in cancer patients taking OACD. In 
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constructing and evaluating the intervention, patient reported outcomes 
measures (PROMs) should be included (e.g. quality of life). Non-adherence and 
non-persistence are multidimensional complex phenomena so interventions 
should include multiple components as described above. In annex, components 
for an intervention are provided based on our study findings. This may provide a 
point of departure for the construction of an intervention in a specific setting. A 
future implementation study is needed to validate the intervention in a specific 
setting.  
The intervention should be evaluated by using a cyclical procedure of trying out, 
evaluating, and revising (Van Meijel et al., 2004) on multiple levels: patients (e.g. 
self-management, adherence, quality of life), healthcare professionals (e.g. 
counseling skills), and organization (e.g. appropriateness and feasibility of the 
intervention). To ensure high quality reporting of studies on the development and 
evaluation of complex interventions, a set of 16 criteria for reporting complex 
interventions in healthcare (CReDECI) could be used (Möhler et al., 2012). The 
criteria list is categorized into three stages, according to the British Medical 
Research Counsil’s framework on the development and evaluation of complex 
interventions (MRC): development (e.g. description of underlying theoretical 
considerations), feasibility and piloting (e.g. information on pilot-testing), and 
introduction of the intervention and evaluation (e.g. description of the control 
intervention).  By using the CReDECI criteria, more transparent and 
comprehensive reporting of complex interventions could be established (Möhler 
et al., 2012). 
Both qualitative studies showed the importance of social support in patients 
taking OACD. The quantitative usual care study showed that partners and/or 
relatives are mostly involved in the treatment. However, few patients seem to be 
encouraged to organize social support and referred to a patients’ association. In 
future research, the role of family members and/or relatives, as well as the role 
of peers in supporting patients taking OACD should be studied to get more 
insight into their roles from their perspective and the patients’ perspective.  
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As stated in the methodological considerations, we did not study the integral 
interdisciplinary support given to patients taking OACD. More insight is needed 
in how to organize the support of self-management and adherence of patients 
taking OACD from an integral interdisciplinary approach. Furthermore, the role 
of the psychologist into the interdisciplinary team supporting patients taking 
OACD should be taken into account in future research.  
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COMPONENTS FOR AN INTERVENTION  
KEY PRINCIPLES  
 The patients’ perspective and experience (Chapter 3 & 4) 
The perspective and experience of the patient (e.g. perception and 
experience of the disease and the current and past therapies, the influence 
on quality of life, perceptions about side effects and the impact of the 
therapy) is the key point of departure for counseling and supporting patients 
starting or following OACD therapy.  
 An open and trust-based relationship (Chapter 3 & 4) 
An open and trust-based relationship makes most people more comfortable 
to be honest about side effects, their adherence behavior and the difficulties 
they experience during the OACD treatment period. This increases the 
likelihood of finding a balance between survival and quality of life in patients 
taking oral TKIs. In both patients taking AHT and TKIs, this makes the 
burden of the therapy lower.   
Elements contributing to the establishment and maintenance of an open and 
trust-based relationship are: 
- Taking time during appointments to listen to how patients are doing, 
how they experience the therapy and their quality of life 
- Accessibility and continuous availability (e.g. by telephone 
permanence) 
- Having contact with patients on a regular basis, preferable the same 
contact person in order to establish and maintain the trust relationship 
(e.g. pro-active telephone contact on a regular basis between two 
follow-up appointments to ask how patients are doing) 
- Signs of a good multidisciplinary collaboration between HCPs (e.g. 
when it is clear that healthcare professionals exchange information 
with each other and no conflicting advice is provided) 
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- Encouragement to express difficulties and worries 
- Recognition for the patients’ situation and experienced difficulties 
- Not undermining patients’ hope, hope is an important coping strategy 
for patients 
- Interpersonal competence (active listening, caring, empathy, providing 
information and answering questions) 
- Honesty and clarity about side effects and the possible impact of the 
therapy in order not to create false expectations and disappointments 
 Self-management support (Chapter 3 & 4) 
Patients should be supported in adequate self-management. They should be 
guided in making adequate decisions regarding their therapy by: 
- Patient-centered education about (the development of) side-effects to 
set realistic expectations 
- Informing patients as to how medication works and why it is important 
to follow instructions. Different methods can be used in order to inform 
patients adequately (e.g. verbal and written information, a visual 
scheme, e-health). 
- Explain to patients why side effects may occur 
- Discussing the possible ways to incorporate the regimen into daily life 
- Specific interventions to improve self-management (e.g. assist the 
patient in addressing self-identified barriers and help them to deal with 
it). For example: discuss with patients whether they expect instructions 
will be difficult to follow. Search for solutions together that fits the 
patients’ life and needs and do not provide standard tools. For 
example, for some patients a reminder on the mobile phone could be 
very effective to prevent unintentional non-adherence, for others, the 
intake of the OACD could be combined with daily habits. Supporting 
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patients taking OACD requires a high degree of knowledge and 
experience of HCPs, therefore, training of HCPs might be necessary.  
 Social support (Chapter 3, 4 & 6) 
Social support helps patients to deal with the difficulties they encounter and 
makes them feel less alone. Therefore, it is important to involve family 
members and/or friends in the therapy. A knowledge base about the therapy 
and the consequences should also be provided to them. Family members 
should be informed about the ongoing burden of cancer therapy to 
counteract false expectations (such as resuming normal life in the period of 
AHT). Family members could be asked which role would be suitable within 
the informal care and what difficulties they expect. In patients having little 
social support (e.g. older patients), the general practitioner and the home 
nurse could be more involved. The possibility of having contact with peers 
(cancer peer support group) could also be discussed (e.g. in patients 
experiencing difficulties where there is not a direct solution for). However, for 
some patients this might be too confrontational (e.g. the possible 
confrontation with peers suffering a relapse). Patients could also be referred 
to a patients’ association.  
 Self-efficacy (Chapter 2, 3, 4 & 6) 
The patient's belief in his/her ability in succeeding to follow treatment 
instructions to which he/she consented is an important adherence 
influencing factor. However, in usual care, too little attention is paid to self-
efficacy. When patients do not believe to be able to follow certain 
instructions, things that helped the patients in the past could be explored 
and patients could be asked if this could be helpful to them now. 
Furthermore, small and achievable goals could be set in the beginning. 
When patients succeed in these goals, this should be reinforced positively.  
Supporting patients’ self-efficacy requires a high degree of knowledge and 
experience of HCPs, therefore, training of HCPs might be necessary. 
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OACD THERAPY INITIATION 
 The physician may introduce the team and emphasizes the interdisciplinary 
collaboration. Signs of a good interdisciplinary collaboration between 
healthcare professionals increase trust (Chapter 3). The physician may 
introduce the nursing consultations and a nurse practitioner/clinical nurse 
specialist as a point of contact besides the physician. For some patients the 
general practitioner might be an important confidant. Therefore, the 
relationship with the general practitioner should be questioned in the 
beginning of the trajectory and the general practitioner should be involved in 
the trajectory. 
 Knowledge base (chapter 3 & 4): Patients should receive an individualized 
knowledge base about disease, medication, therapy, follow-up, and 
adherence. A good knowledge base is important to support patients’ self-
management, allowing them to make adequate decisions in dealing with 
their therapy. Education (and the amount of information) should be tailored 
to the patients’ needs and level of understanding to increase insightful 
knowledge. Special attention should be paid to e.g. older patients and 
patients with low education. Information should be dosed according to the 
needs of the patient at that specific moment. For example, extensive or 
difficult information should not be provided after patients have received bad 
news.  
 Ask patients about their perceptions of the disease, the therapy and 
their quality of life. 
  Ask if they have already heard of the medication or they know 
people taking this type of OACD and what they expect from the 
OACD. This way, (true/false) perceptions could be detected and the 
patient could be informed adequately.  
 Explain how medication works and why it is important to follow 
instructions (e.g. why it is important to leave a certain time between 
the first and second dose). 
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 Be careful with reporting about treatment options and evaluations. 
Communicating that further treatment with a type of OACD would be 
considered if the OACD showed significant positive results within a 
certain period of time, makes patients fearful and reluctant to report 
side effects. Therefore, HCPs could explain that finding the right 
OACD and the right dose is often the result of a search.   
 Explain what to do in case of (unintentional) deviating from the 
treatment instructions (e.g. in case of forgetting a dose).  
 Explain the importance of finding a balance between the therapeutic 
effect and quality of life. 
 Discuss which side effects could occur (the most important side 
effects could be given in order not to overwhelm patients with 
information – provide patients with additional accessible information 
of all other possible side effects and refer to the continuous 
availability of HCPs by giving a contact card). Being informed about 
side effects is important because it reassures patients that nothing 
else is the matter, such as a progression of their disease. Involve 
family members as described in the general principles (cfr. social 
support).   
 Explain what to do in case of side effects. For example, a simple 
scheme with instructions in case side effects occur could be 
provided so that patients could differentiate harmful from not-harmful 
side effects and know what to do in case of side effects (i.e. what 
they could do themselves, when they should contact the general 
practitioner or the hospital), which is reassuring.  
 Give patients realistic information about the intensity, severity and 
normal course of side effects (i.e. increase or decrease of side 
effects over time). Realistic information is important to prepare 
patients for what to expect (possible impact) of the therapy. This 
way, disappointments could be avoided as this increase the burden 
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of the therapy and affects the relationship with HCPs, which makes 
it more difficult to continue OACD therapy.  
 Make sure the information is provided in a uniform way amongst the 
different HCPs to avoid confusion in patients, which could affect 
their trust in HCPs and the therapy.  
 Explain patients why it is important to be honest about experienced 
side effects, this way patients could be supported in coming to a 
balance between surviving and quality of life. This is particularly 
important for patients who are being confronted with the non-curable 
and life-threatening nature of the disease (greater chance of coming 
to a focus on survival and not reporting side effects). 
 For patients taking multiple medications, reassure them that this is 
being monitored carefully. Here, a pharmacist could have an 
important role. 
 Shared decision making (chapter 5 & 6): ask whether patients want to have 
a role in the decision making process. Discuss which role would be fitting.  
BETWEEN FOLLOW-UP CONSULTATIONS 
 Contact patients (e.g. the nurse practitioner/clinical nurse specialist) by 
phone and ask how they are doing and whether they have any questions 
(create openness and establish trust – see chapter 3 & 4). Contact could be 
intensified at the start of a (new) OACD therapy or when patients 
experience difficulties during the follow-up period. In current practice, this 
requires special attention (chapter 6).  
 Accessibility and continuous availability (e.g. by telephone permanence, e-
mail, e-health platform) (chapter 3 & 4) 
OACD FOLLOW-UP CONSULATIONS 
 Side effects and the impact of the therapy (chapter 2, 3 & 4) 
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 Ask patients how they experience the therapy and how this impacts 
on their quality of life and their roles and stimulate expressions of 
difficulties/worries. Give patients sufficient space to express their 
difficulties, worries and perceptions. Provide recognition for the 
patients’ situation and experienced difficulties.  
 Ask which side effects they experienced, create openness to 
mention side effects and listen  how patients are doing, how they 
experience the therapy and their quality of life. 
 Ask what they tried themselves to reduce side-effects and whether 
this was effective, give positive reinforcement.  Provide them with 
knowledge and tools to reduce side effects. 
 Reassure patients that symptoms are side effects from the OACD 
and not signs of a relapse or a progression of the disease.  
 Give patients answers about side effects, otherwise they might start 
a search on their own, which is often a lonely search and affects the 
relationship with the HCP. Provide patients with reliable information 
and links to websites (e.g. in the patient brochure). 
 Be honest about difficulties where there is not a direct solution for. 
For patients, admitting there is not a direct solution (e.g. in patients 
taking AHT) is often a sign of a human approach, which strengthens 
the relationship.  However, in the case there is not a solution for a 
problem, HCPs could intensify contact (e.g. by telephone or e-mail) 
and follow how patients further deal with this. Establishing contact 
with peers could be useful for some patients. 
 Perspectives and hope (chapter 3 & 4) 
 Ask for the perspectives patients have. Having or creating 
perspectives is of great importance for patients to be able to 
continue therapy.  
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 Patients’ hope may not be undermined by negating hopeful 
reactions or emphasizing medical reality after a hopeful reaction. 
Patients need hope to stand the multitude of uncertain situations 
they are confronted with and to continue therapy while sometimes 
experiencing a low quality of life. Hope is particularly needed to be 
able to continue therapy in patients experiencing a low quality of life 
and intense side effects. When hope is undermined, patients feel 
discouraged. As a result, some patients will no longer report side 
effects and start to experiment themselves with their therapy to 
improve quality of life, which increases the risk of inadequate self-
management and/or non-adherence behavior. 
 Dose reduction/change of OACD (chapter 3) 
 Be aware that patients are often anxious that a dose reduction or 
change of OACD would decrease their survival time. As a result, 
patients with a focus on survival may not report side effects.  
 Consider how patients perceive a dose reduction or change of 
OACD.  
 Explain why a dose reduction or change of OACD is necessary and 
the best solution. Normalize this change and use objective 
parameters such as liver and kidney values to demonstrate that a 
dose reduction is necessary.  
 A follow-up screening could be planned as soon as possible after a 
dose reduction, so the period of uncertainty about the effectiveness 
of the medication, is as short as possible. However, a certain period 
between a dose reduction or change of OACD might be necessary 
to assess effectiveness by screening. Inform patients why it is not 
useful to evaluate earlier.  
 Adherence (chapter 2, 3, 4, 5 & 6) 
 Discussing adherence openly is important. A lot of HCPs state they 
do not know the adherence of their patients nor do they think their 
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patients discuss adherence with them. Supporting and discussing 
patients’ adherence requires a high degree of knowledge and 
experience of HCPs, therefore, training of HCPs might be 
necessary. To be able to talk about adherence, an open and trust-
based relationship and a knowledge base of why it is important to be 
open about adherence behavior is necessary. Be aware that for 
some patients, it is difficult to talk about adherence. To create 
openness, it is important to ask non-threatening questions for 
example:  ‘For some patients it is hard to take every day there 
medication consequently, how is this for you?’ or ‘Could you 
describe how you take your medication and how this goes?’. 
 Feedback mechanisms play an important role in adherence 
behavior. When patients report non-adherence (e.g. forgetting to 
take the OACD), be careful with the feedback that forgetting one 
time is not harmful, this might reinforce non-adherence behavior.  
 Special attention (e.g. intensified follow-up appointments or 
telephonic contacts or support/tools) is required for: 
- patients with other health problems  
- in case of daily routine interruptions (e.g. going on 
holiday) 
- patients experiencing a lot of difficulties 
- patients experiencing difficulties where there is not a 
direct solution for 
- patients taking multiple medications 
- patients having little social support 
- patients longer on OACD therapy 
- patients of whom the contrast with the life before the 
disease is high 
- patients with history of antidepressant use 
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The availability and use of oral anticancer drugs (OACD) in the treatment of 
cancer has steadily increased. The management of adherence and persistence 
to OACD has become a key challenge in modern oncology treatment. 
Adherence and persistence in cancer patients OACD are complex phenomena. 
This doctoral thesis aims to get insight into factors and processes influencing 
(non-)adherence and (non-)persistence in patients taking OACD, explore 
healthcare professionals’ (HCPs) perspectives and usual care in supporting 
adherence to OACD.  
In the first phase of this thesis, a systematic literature review was conducted on 
associated factors of (non-)adherence and (non-)persistence in patients taking 
OACD. Twenty-five studies were included and systematically reviewed. Factors 
positively and negatively associated with adherence and persistence were found 
and structured according to the five categories suggested by the World Health 
Organization (2003): patient-related, therapy-related, disease-related, healthcare 
system-related, and social-economic factors. Older and younger age, and the 
influence of side effects were found to be predominant factors. The systematic 
review suggested that (non-)adherence and (non-)persistence to OACD are 
multi-factorial, complex and interrelated. The need for qualitative studies to 
explore underlying processes influencing adherence and persistence was 
highlighted.  
Second, a qualitative study was conducted to get insight into influencing factors 
and processes underlying (non-)adherence and (non-)persistence in patients 
taking oral tyrosine kinase inhibitors (TKIs). Semi-structured interviews were 
held with 30 patients of different ages and with different types of cancer. A 
grounded theory approach was used. Three foci were found when dealing with 
oral TKIs: (1) a focus on survival, (2) a focus on quality of life, and (3) a balance 
between survival and quality of life. The process of adherence was determined 
by a set of complex and interrelated factors: treatment related side effects, hope, 
anxiety, trust, and feedback mechanisms.  
Third, a qualitative study was conducted to get insight into influencing factors 
and processes underlying (non-)adherence and (non-)persistence in breast 
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cancer patients taking antihormonal therapy (AHT). Semi-structured interviews 
were held with 31 patients. Data collection and analysis were based on a 
grounded theory approach. Expectations regarding the impact of AHT, social 
support from family and friends, and recognition from HCPs were found to 
influence the process of (non-)adherence and (non-)persistence.  
Fourth, a quantitative study was conducted aiming to explore HCPs’ perceptions 
about adherence management (PAMQ) and beliefs towards OACD adherence 
(BMQ), PAMQ influencing factors, and physicians’ shared decision making 
(SDM). A cross-sectional, multi-center observational study among HCPs in 
hemato-oncology settings in Belgium and the Netherlands was conducted. The 
sample consisted of 254 HCPs. A considerable part of HCPs does not know the 
adherence of their patients, nor do they think their patients discuss adherence 
with them. However, they have knowledge of adherence and perceive to be able 
to influence adherence of their patients. Nurses and nurse practitioners/clinical 
nurse specialists had lower necessity concerns differentials than the other 
HCPs. Lower concerns beliefs were associated with a higher total PAMQ-score. 
SDM was considered high among physicians. 
Fifth, within the same quantitative study, usual care in supporting adherence to 
OACD was explored. Two hundred and eight HCPs completed the usual care 
part. The assessment of usual care in the Netherlands and Belgium reveals a 
wide range of care activities provided. Activities in the domain Knowledge and 
Adverse Event Management were reported most frequently whereas activities of 
the domains Self-efficacy and Action Control were reported less.  The reported 
provided care differs between the professions that are involved in OACD 
adherence (with nurse practitioners the most active and pharmacists providing 
the least adherence care) and also by country. There is a strong relationship 
between the perceptions about adherence management and the adherence care 
activities that are provided. 
The results of this PhD study emphasize the importance of the patients’ 
experience to understand (non-)adherence and (non-)persistence to OACD. A 
complex patient tailored intervention informed by our study findings could be 
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developed to support adherence and self-management in cancer patients taking 
OACD. 
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De behandeling van kanker gebeurt in toenemende mate door middel van orale 
antitumorale medicatie (OAM). Therapieontrouw en het vroegtijdig beëindigen 
van de behandeling komen vaak voor. De factoren die therapie(on)trouw bij 
OAM beïnvloeden zijn complex en multifactorieel. Dit doctoraatsonderzoek 
beoogt inzicht te krijgen in beïnvloedende factoren en processen van 
therapie(on)trouw en het vroegtijdige beëindiging van de behandeling met OAM, 
het exploreren van hulpverlenersperspectieven en van de huidige zorg met 
betrekking tot therapietrouw-ondersteuning bij patiënten behandeld met deze 
medicatie. 
In deel één werd een systematische literatuurstudie uitgevoerd naar 
beïnvloedende factoren en processen van therapie(on)trouw en het al dan niet 
vroegtijdig beëindigen van de behandeling met OAM. De review toonde zowel 
positief als negatief beïnvloedende factoren, onder te brengen in de vijf 
categorieën van de WHO (2003): patiënt-gerelateerde, sociale en economisch-
gerelateerde, ziekte-gerelateerde, behandeling-gerelateerde factoren en 
gezondheidszorgsysteem. Oudere en jongere leeftijd, en de invloed van 
bijwerkingen waren vaak voorkomende factoren geassocieerd met 
therapieontrouw en het vroegtijdig beëindigen van de behandeling. De 
systematische literatuurstudie toonde aan dat beïnvloedende factoren van 
therapie(on)trouw en het al dan niet vroegtijdig beëindigen van de behandeling 
met OAM multifactorieel, complex en onderling gerelateerd zijn.  
In het tweede deel werd een kwalitatief onderzoek uitgevoerd om inzicht te 
verkrijgen in beïnvloeden factoren en onderliggende processen van 
therapie(on)trouw in de behandeling met orale tyrosine kinase inhibitoren 
(TKI’s). Door middel van de ‘grounded theory’ benadering werden 30 semi-
gestructureerde interviews met patiënten die orale TKI’s nemen, geanalyseerd. 
De resultaten toonden drie focussen bij patiënten behandeld met orale TKI’s: (1) 
een focus op overleven, (2) een focus op kwaliteit van leven en (3) patiënten die 
tot een evenwicht (proberen) komen tussen overleven en kwaliteit van leven. 
Het onderzoek toonde eveneens een complexe en onderling gerelateerde set 
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aan beïnvloedende factoren: nevenwerkingen, hoop, angst, vertrouwen en 
feedback mechanismen.  
In het derde deel vond een analoog kwalitatief onderzoek plaats om inzicht te 
verkrijgen in beïnvloeden factoren en onderliggende processen van 
therapie(on)trouw en het al dan niet vroegtijdig beëindigen van de behandeling 
met orale antihormonale therapie (AHT), bij 31 patiënten behandeld met AHT. 
Verwachtingen met betrekking tot de impact van de AHT, sociale steun van 
familie en vrienden, en erkenning van hulpverleners werden gevonden als 
beïnvloedende factoren van therapie(on)trouw en het al dan niet vroegtijdig 
beëindigen van de behandeling met AHT. 
Een cross-sectionele multicentrische observationele studie bij 254 hulpverleners 
werkzaam in de hemato-oncologie in België en Nederland, brengt de percepties 
van hulpverleners met betrekking tot het managen van therapietrouw (PAMQ) 
en hun percepties met betrekking tot de noodzaak van en zorgen over OAM 
(BMQ) en gedeelde besluitvorming (SDM) in beeld (deel 4). Een aanzienlijk deel 
van de hulpverleners geeft aan de therapietrouw van hun patiënten niet te 
kennen en denken ook niet dat patiënten therapietrouw met hen bespreken. Wel 
geven ze aan kennis te hebben van therapietrouw en zien ze zichzelf in staat 
om therapietrouw te beïnvloeden. Verpleegkundigen en verpleegkundig 
specialisten vertoonden een lagere differentiaalscore (noodzaak/zorgen) dan 
andere hulpverleners. Minder zorgen met betrekking tot OAM was geassocieerd 
met een hogere PAMQ-totaal score. SDM werd hoog geacht bij artsen.  
Hetzelfde kwantitatief onderzoek exploreerde de gebruikelijke zorg met 
betrekking tot therapietrouw bij OAM bij 208 hulpverleners (deel 5). De 
resultaten toonden een brede range aan zorgactiviteiten in zowel België als 
Nederland. De mate waarin activiteiten werden uitgevoerd verschilde erg 
naargelang het land en de beroepsgroep; verpleegkundig specialisten deden het 
meest aan de therapietrouw zorgactiviteiten, apothekers het minst. De domeinen 
kennis en management van bijwerkingen werden het meest uitgevoerd bij alle 
hulpverleners; eigeneffectiviteit, sociale invloed en action control het minst. De 
resultaten toonden een sterk verband tussen het aantal uitgevoerde 
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zorgactiviteiten en de percepties met betrekking tot het managen van 
therapietrouw.  
De resultaten van dit doctoraatsonderzoek tonen het belang aan van inzicht in 
de beleving van patiënten die orale antitumorale medicatie nemen om 
therapie(on)trouw en het al dan niet vroegtijdig beëindigen van de behandeling 
te begrijpen. Een complexe interventie gebaseerd op onze resultaten en op 
maat van patiënten, kan ontwikkeld worden om therapietrouw en 
zelfmanagement bij patiënten die orale antitumorale medicatie nemen te 
ondersteunen.  
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